Hydroxybupropion analogues for treating drug dependence

ABSTRACT

The invention provides hydroxybupropion analogues capable of inhibiting the reuptake of one or more monoamines and/or acting as antagonists at nicotinic acetylcholine receptors. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin and/or may selectively bind to one or more nicotinic acetylcholine receptor subtypes. Such compounds may be used to treat conditions that are responsive to modification of monoamine levels and/or antagonism of nicotinic acetylcholine receptors, including drug dependency, depression, and obesity.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of PCT InternationalApplication No. PCT/US2011/037312, filed May 20, 2011, which claims thebenefit of U.S. Provisional Application No. 61/347,241, filed May 21,2010. Both of these applications are incorporated by reference herein intheir entireties.

FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with United States Government support undergrant U19 DA019377, awarded by the National Institutes of HealthNational Cooperative Drug Discovery Group. The United States Governmenthas certain rights in the invention.

FIELD OF THE INVENTION

The present application is directed to various compounds and methods ofpreparation of compounds that are capable of functioning as monoaminereuptake inhibitors and/or as antagonists of nicotinic acetylcholinereceptors. The application is also directed to pharmaceuticalcompositions containing one or more of these compounds, which may alsocontain one or more additional therapeutic agents. It is also directedto methods of treatment of various conditions, such as drug dependency,depression, and obesity, which may be responsive to inhibition ofmonoamine reuptake and/or antagonism of nicotinic acetylcholinereceptors.

BACKGROUND OF THE INVENTION

Tobacco use is the leading preventable cause of disease, disability, anddeath in the United States. Cigarette smoking results in more than400,000 premature deaths in the United States each year, accounting forabout 1 in every 5 deaths according to the Centers for Disease Control2008 Smoking and Tobacco Use Fact Sheet. Statistics from the U.S.Department of Health and Human Services show that, on average, adultswho smoke die 14 years earlier than nonsmokers.

Cigarette smoking accounts for about one-third of all cancers, including90% of lung cancer cases. Smoking also causes lung diseases such aschronic bronchitis and emphysema and increases the risk of stroke, heartattack, vascular disease, and aneurysm. In spite of these documentedconnections between tobacco use and disease, a large number of peoplecontinue to use tobacco products. In 2008, 28.6% of the U.S. population12 years of age and older (70.9 million people) had used a tobaccoproduct at least once in the month prior to being interviewed. Thisfigure includes 3.1 million young people aged 12-17 (12.4% of this agegroup).

Nicotine is considered the main psychoactive component in tobacco smokethat causes people to use and continue to use tobacco products. Thepharmacological and behavioral effects result from the activation ofdifferent nicotinic acetylcholine receptor (nAChR) subtypes. Thesubtypes are either homo or hetero pentameric ion channels, consistingof different combinations of genetically distinct subunits, (α1, α2-α10,β1-β4, γ, δ, ε). The predominant nAChR subtypes found in the brain arethought to be heteromeric α4β2 nAChR or homomeric α7-nAChR; however,appreciable amounts of α3β4* and α6β2* nAChRs (where the * indicatesthat other subunits are known or are possible assembly partners withthose specified) are also in the brain regions implicated in reward anddrug dependence.

Nicotine exposure can stimulate activity of somatodendritic nAChRs toalter neuronal electrical activity and neurotransmitter release as aconsequence of neuronal activation. However, by acting at nAChRspositioned on nerve terminals, nicotine can also increaseneurotransmitter release as a consequence of local depolarization of thenerve terminal membrane potential and/or calcium ion mobilization interminals. The integration of these effects is likely to contribute tonicotine's actions, including those that are presumably involved in itsreinforcement of tobacco product use, such as effects in monoaminergicreward pathways.

Even though nicotine dependence has a huge impact on global health,pharmacotherapies for treating tobacco use are limited. Currenttreatments include nicotine-replacement therapies (NRTs), bupropion, andvarenicline. Bupropion [(±)-2-tert-butylamino-3′-chloropropiophenone] isused clinically for the treatment of nicotine addiction as a racemicmixture of its (R)- and (S)-isomers (formulated in a sustained releaseformulation and currently marketed for this purpose as Zyban®).Bupropion is extensively metabolized with less than 1% recovered intactin urine. Major metabolites result from hydroxylation of theN-tert-butyl group by the P450-(CYP)2B6 isoenzyme. The resultinghydroxylated metabolites cyclize to give (2R,3R)- and(2S,3S)-hydroxybupropion. Several studies suggest that(2S,3S)-hydroxybupropion contributes to the antidepressant and smokingcessation efficacy of bupropion. Peak plasma and cerebrospinal fluidconcentrations of (2S,3S)-hydroxybupropion exceed those of bupropion by4- to 7-fold and have a longer elimination half-life than the parentdrug.

The compound (2S,3S)-hydroxybupropion has previously been shown to actas an inhibitor of both dopamine (DA) and norepinephrine (NE) uptake.Furthermore, it has been determined to be a noncompetitive functionalantagonist at α4β2-nAChRs with an IC₅₀ value of 3.3 μM, a concentrationthat is comparable to those needed to inhibit DA and NE uptake. Inaddition, (2S,3S)-hydroxybupropion was demonstrated to be 3-10 timesmore potent than bupropion after acute administration in mice inantagonizing nicotine-induced hypomobility and hypothermia andnicotine-induced analgesia in tail-flick and hot-plate tests. It wasalso equally potent with bupropion in the antidepressant mouseforced-swimming test.

Although bupropion is a successful treatment for nicotine addiction,relatively few chemical analogues have been prepared and evaluated.Since only about one-fifth of smokers are able to maintain long-term (12months) abstinence with any of the present pharmacotherapies, there is aneed in the art for new and improved pharmaceutical compositions fortreating drug addiction.

SUMMARY OF THE INVENTION

The present invention provides compounds useful as monoamine reuptakeinhibitors and methods of synthesis of such compounds. It also providespharmaceutical compositions containing the compounds, which may beuseful in the treatment of various conditions or disorders responsive tothe inhibition of monoamine reuptake by cells and/or the antagonism ofnicotinic acetylcholine receptors. The invention further providesmethods of treating such conditions and disorders, including but notlimited to, addiction, depression, and obesity. For example, in oneaspect, the invention is directed to a method of treating a conditioncomprising administering to a subject in need of treatment of thecondition a pharmaceutical composition comprising a therapeuticallyeffective amount of a compound of the present invention or apharmaceutically acceptable ester, amide, salt, solvate, prodrug, orisomer thereof.

Accordingly, in one aspect, the present invention provides a compoundthat inhibits the reuptake of one or more monoamines and/or acts as anantagonist at α4β2 nAChRs. In some embodiments, the invention provides acompound according to the following structure:

wherein:

R₁ is optionally substituted C1-10 alkyl;

R₂ is H or optionally substituted C1-10 alkyl;

R₃ and R₄ are each independently selected from optionally substitutedC1-10 alkyl; X, Y, and Z are each independently selected from H;optionally substituted C1-10 alkyl; optionally substituted C1-10 alkoxy;optionally substituted C2-10 alkenyl; optionally substituted C2-10alkynyl; optionally substituted C6-C12 aryl; alkaryl; arylalkyl;aryloxy; optionally substituted heteroaryl; optionally substitutedheterocycle; halo; hydroxyl; halogenated alkyl; an amino group offormula NH₂, NR₁₂H, or NR₁₂R₁₃; alkylamino; arylamino; acyl; CN; NO₂;N₃; CH₂OH; CONH₂; CONR₁₂R₁₃; CO₂R₁₂; CH₂OR₁₂; NHCOR₁₂; NHCO₂R₁₂; C1-3alkylthio; sulfate; sulfonic acid; sulfonate ester; phosphonic acid;phosphate; phosphonate; mono-, di-, or triphosphate ester; trityl ormonomethoxytrityl; R₁₂SO; R₁₂SO₂; CF₃S; CF₃SO₂; trialkylsilyl; anddiphenylmethylsilyl; or wherein X and Y or Y and Z form a fused arylring together with the phenyl ring to which X, Y, and Z are attached;and

R₁₂ and R₁₃ are each independently selected from H or optionallysubstituted C1-10 alkyl;

with the proviso that either (a) X is a halo substituent other thanchloro; (b) two or more of X, Y, and Z are halo substituents; (c) one ormore of X, Y, and Z are optionally substituted C6-C12 aryl; (d) X and Yor Y and Z form a fused aryl ring together with the phenyl ring to whichX, Y, and Z are attached; (e) R₁ is an optionally substituted C2-C10alkyl; or any combination of two or more of (a) through (e),

or a pharmaceutically acceptable ester, amide, salt, solvate, prodrug,or isomer thereof.

In certain specific embodiments, the invention provides a compoundhaving the structure:

wherein all substituents are as noted above, or a pharmaceuticallyacceptable ester, amide, salt, solvate, prodrug, or isomer thereof.

In another specific embodiment, the invention provides a compound havingthe structure:

wherein all substituents are as noted above, or a pharmaceuticallyacceptable ester, amide, salt, solvate, prodrug, or isomer thereof.

In certain embodiments, a compound is provided according to the abovestructures,

wherein R₁ is selected from the group consisting of CH₃, CH₂CH₃, andC₃H₇. In some embodiments, a compound is provided according to the abovestructures, wherein X, Y, and Z are independently selected from thegroup consisting of H, Cl, Br, F, optionally substituted C1-10 alkyl,and phenyl. In some embodiments, a compound is provided according to theabove structures, wherein X and Y or Y and Z form a fused aryl ringtogether with the phenyl ring to which X, Y, and Z are attached.

In further embodiments of the invention, a compound is providedaccording to the above structures, wherein R₁ is optionally substitutedmethyl, ethyl, propyl, or butyl, and at least one of X, Y, and Z isoptionally substituted C6-C12 aryl or X and Y or Y and Z form a fusedaryl ring together with the phenyl ring to which X, Y, and Z areattached. In some embodiments, R₁ is optionally substituted C2-C10alkyl, and at least one of X, Y, and Z is optionally substituted C6-C12aryl or halo, or X and Y or Y and Z form a fused aryl ring together withthe phenyl ring to which X, Y, and Z are attached.

Certain compounds that are provided herein include, but are not limitedto, 2-(3-Fluorophenyl)-3,5,5-trimethylmorpholin-2-ol;2-(3-Bromophenyl)-3,5,5-trimethylmorpholin-2-ol;2-Biphenyl-4-yl-3,5,5-trimethylmorpholin-2-ol;2-(3,4-Dichlorophenyl)-3,5,5-trimethylmorpholin-2-ol;2-(Naphthalen-2-yl)-3,5,5-trimethylmorpholin-2-ol;2-(3-Chlorophenyl)-3-ethyl-5,5-dimethylmorpholin-2-ol;2-(3-Chlorophenyl)-5,5-dimethyl-3-propyl-morpholin-2-ol, andpharmaceutically acceptable esters, amides, salts, solvates, prodrugs,or isomers thereof.

Other exemplary compounds that are provided herein include, but are notlimited to, 2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol;2-(3-Methoxyphenyl)-3,5,5-trimethylmorpholin-2-ol;2-(4-Fluorophenyl)-3,5,5-trimethylmorpholin-2-ol;2-(4-Chlorophenyl)-3,5,5-trimethylmorpholin-2-ol;3,5,5-Trimethyl-2-(4-methylphenyl)morpholin-2-ol;2-(4-Methoxyphenyl)-3,5,5-trimethylmorpholin-2-ol;2-(3,4-Difluorophenyl)-3,5,5-trimethylmorpholin-2-ol;(2S,3S)-2-(3,5-Difluorophenyl)-3,5,5-trimethylmorpholin-2-ol;2-(3,5-Dichlorophenyl)-3,5,5-trimethylmorpholin-2-ol;2-(Naphthalen-1-yl)-3,5,5-trimethylmorpholin-2-ol;2-(3-Chlorophenyl)-3,4,5,5-tetramethylmorpholin-2-ol;2-(4-Chlorophenyl)-3,4,5,5-tetramethylmorpholin-2-ol, andpharmaceutically acceptable esters, amides, salts, solvates, prodrugs,or isomers thereof.

In certain embodiments a compound according to the foregoing structuresis provided, wherein the compound comprises an enantiomeric excess of atleast 95% of the (2S-3S) enantiomer.

In another aspect of the present invention is provided a pharmaceuticalcomposition comprising a compound according to any of the foregoingstructures and one or more pharmaceutically acceptable carriers.

In still another aspect is provided a method for treating or delayingthe progression of disorders that are alleviated by inhibiting monoaminereuptake in a patient or antagonizing the nicotinic acetylcholinereceptors, the method comprising administering a therapeuticallyeffective amount of at least one compound according to any one of theforegoing structures. In some embodiments, the disorder is selected fromthe group consisting of addiction, depression, obesity, bipolardisorder, attention deficit disorder (ADD), attentiondeficit/hyperactivity disorder (ADHD), hypoactive sexual desiredisorder, antidepressant-induced sexual dysfunction, orgasmicdysfunction, seasonal affective disorder/winter depression, mania,bulimia and other eating disorders, panic disorders, obsessivecompulsive disorder, schizophrenia, schizo-affective disorder,Parkinson's disease, narcolepsy, anxiety disorders, insomnia, chronicpain, migraine headaches, and restless legs syndrome. In certainembodiments, addiction comprises nicotine addiction.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the effect of phenyl substitution on specific ⁸⁶Rb⁺ effluxon various nAChR sub-types in the presence of a receptorsubtype-specific, EC₈₀-EC₉₀ concentration of the full agonist,carbamylcholine, either alone or in the presence of the indicatedconcentrations of compound; and

FIG. 2 shows the effect of alkyl extensions on specific ⁸⁶Rb⁺ efflux onvarious nAChR sub-types in the presence of a receptor subtype-specific,EC₈₀-EC₉₀ concentration of the full agonist, carbamylcholine, eitheralone or in the presence of the indicated concentrations of compound.

DETAILED DESCRIPTION OF THE INVENTION

The present invention now will be described more fully hereinafter withreference to the accompanying drawings, in which some, but not allembodiments of the inventions are shown.

Indeed, these inventions may be embodied in many different forms andshould not be construed as limited to the embodiments set forth herein;rather, these embodiments are provided so that this disclosure willsatisfy applicable legal requirements. Like numbers refer to likeelements throughout. As used in the specification, and in the appendedclaims, the singular forms “a”, “an”, and “the” include plural referentsunless the context clearly dictates otherwise.

The present invention provides compounds that may function as monoaminereuptake inhibitors or as antagonists of nicotinic acetylcholinereceptors, as well as methods of preparation and pharmaceuticalcompositions thereof. It also provides methods for using such compoundsto treat a variety of disorders that may be responsive to the inhibitionof monoamine reuptake or antagonism of nicotinic acetylcholinereceptors. In particular, the compositions and methods can be used inthe treatment of nicotine addiction and depression. Treatment cancomprise the use of a compound of the present invention as a singleactive agent. In other embodiments, treatment can comprise the use of acompound of the present invention in combination with one or morefurther active agents. The specific pharmaceutical composition (orcompositions) used in the invention, and the methods of treatmentprovided by the invention, are further described below.

DEFINITIONS

The term “alkyl” as used herein means saturated straight, branched, orcyclic hydrocarbon groups (i.e., cycloalkyl groups). In particularembodiments, alkyl refers to groups comprising 1 to 10 carbon atoms(“C1-10 alkyl”). In further embodiments, alkyl refers to groupscomprising 1 to 8 carbon atoms (“C1-8 alkyl”), 1 to 6 carbon atoms(“C1-6 alkyl”), or 1 to 4 carbon atoms (“C1-4 alkyl”). In otherembodiments, alkyl refers to groups comprising 3-10 carbon atoms (“C3-10alkyl”), 3-8 carbon atoms (“C3-8 alkyl”), or 3-6 carbon atoms (“C3-6alkyl”). In specific embodiments, alkyl refers to methyl,trifluoromethyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl,t-butyl, pentyl, cyclopentyl, isopentyl, neopentyl, hexyl, isohexyl,cyclohexyl, cyclohexylmethyl, 3-methylpentyl, 2,2-dimethylbutyl, and2,3-dimethylbutyl.

“Optionally substituted” in reference to a substitutent group refers tosubstituent groups optionally substituted with one or more moietiesselected from the group consisting of halo (e.g., Cl, F, Br, and I);halogenated alkyl (e.g., CF₃, 2-Br-ethyl, CH₂F, CH₂Cl, CH₂CF₃, orCF₂CF₃); hydroxyl; amino; carboxylate; carboxamido; alkylamino;arylamino; alkoxy; aryloxy; nitro; azido; cyano; thio; sulfonic acid;sulfate; phosphonic acid; phosphate; and phosphonate.

The term “alkenyl” as used herein means alkyl moieties wherein at leastone saturated C—C bond is replaced by a double bond. In particularembodiments, alkenyl refers to groups comprising 2 to 10 carbon atoms(“C2-10 alkenyl”). In further embodiments, alkenyl refers to groupscomprising 2 to 8 carbon atoms (“C2-8 alkenyl”), 2 to 6 carbon atoms(“C2-6 alkenyl”), or 2 to 4 carbon atoms (“C2-4 alkenyl”). In specificembodiments, alkenyl can be vinyl, allyl, 1-propenyl, 2-propenyl,1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl,4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, or 5-hexenyl.

The term “alkynyl” as used herein means alkyl moieties wherein at leastone saturated C—C bond is replaced by a triple bond. In particularembodiments, alkynyl refers to groups comprising 2 to 10 carbon atoms(“C2-10 alkynyl”). In further embodiments, alkynyl refers to groupscomprising 2 to 8 carbon atoms (“C2-8 alkynyl”), 2 to 6 carbon atoms(“C2-6 alkynyl”), or 2 to 4 carbon atoms (“C2-4 alkynyl”). In specificembodiments, alkynyl can be ethynyl, 1-propynyl, 2-propynyl, 1-butynyl,2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl,1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, or 5-hexynyl.

The term “alkoxy” as used herein means straight or branched chain alkylgroups linked by an oxygen atom (i.e., —O-alkyl), wherein alkyl is asdescribed above. In particular embodiments, alkoxy refers tooxygen-linked groups comprising 1 to 10 carbon atoms (“C1-10 alkoxy”).In further embodiments, alkoxy refers to oxygen-linked groups comprising1 to 8 carbon atoms (“C1-8 alkoxy”), 1 to 6 carbon atoms (“C1-6alkoxy”), 1 to 4 carbon atoms (“C1-4 alkoxy”) or 1 to 3 carbon atoms(“C1-3 alkoxy”).

The term “halo” or “halogen” as used herein means fluorine, chlorine,bromine, or iodine.

The term “alkylthio” as used herein means a thio group with one or morealkyl substituents, where alkyl is defined as above.

The term “acylamido” refers to an amide group with one or more acylsubstituents, where acyl is as defined below.

The term “acyl” as used herein means a group that can be represented byC(═O)R, in which R is selected from H, alkyl; alkoxy; alkoxyalkylincluding methoxymethyl; aralkyl including optionally substitutedbenzyl; aryloxyalkyl such as phenoxymethyl; aryl including phenyloptionally substituted with halogen, C₁-C₆ alkyl or C₁-C₆ alkoxy;sulfonate esters such as alkyl or aralkyl sulfonyl includingmethanesulfonyl; amino, mono-, di-, or triphosphate ester; trityl ormonomethoxytrityl; trialkylsilyl such as dimethyl-t-butylsilyl ordiphenylmethylsilyl.

The terms “aralkyl” and “arylalkyl” as used herein mean an aryl group asdefined above linked to the molecule through an alkyl group as definedabove.

The terms “alkaryl” and “alkylaryl” as used herein mean an alkyl groupas defined above linked to the molecule through an aryl group as definedabove.

The term “amino” as used herein means a moiety represented by thestructure NR₂, and includes primary amines, and secondary and tertiaryamines substituted by alkyl or aryl (i.e., alkylamino or arylamino,respectively). Thus, R₂ may represent two hydrogen atoms, two alkylmoieties, two aryl moieties, one aryl moiety and one alkyl moiety, onehydrogen atom and one alkyl moiety, or one hydrogen atom and one arylmoiety.

The term “cycloalkyl” means a non-aromatic, monocyclic or polycyclicring comprising carbon and hydrogen atoms.

The term “aryl” as used herein means a stable monocyclic, bicyclic, ortricyclic carbon ring of up to 8 members in each ring, wherein at leastone ring is aromatic as defined by the Hückel 4n+2 rule. Exemplary arylgroups according to the invention include phenyl, naphthyl,tetrahydronaphthyl, and biphenyl.

The term “heteroaryl” as used herein means an aryl group containing fromone or more (particularly one to four) non-carbon atom(s) (particularlyN, O, or S) or a combination thereof, which heteroaryl group isoptionally substituted at one or more carbon or nitrogen atom(s) withalkyl, —CF₃, phenyl, benzyl, or thienyl, or a carbon atom in theheteroaryl group together with an oxygen atom form a carbonyl group, orwhich heteroaryl group is optionally fused with a phenyl ring.Heteroaryl rings may also be fused with one or more cyclic hydrocarbon,heterocyclic, aryl, or heteroaryl rings. Heteroaryl includes, but is notlimited to, 5-membered heteroaryls having one hetero atom (e.g.,thiophenes, pyrroles, furans); 5 membered heteroaryls having twoheteroatoms in 1,2 or 1,3 positions (e.g., oxazoles, pyrazoles,imidazoles, thiazoles, purines); 5-membered heteroaryls having threeheteroatoms (e.g., triazoles, thiadiazoles); 5-membered heteroarylshaving 3 heteroatoms; 6-membered heteroaryls with one heteroatom (e.g.,pyridine, quinoline, isoquinoline, phenanthrine,5,6-cycloheptenopyridine); 6-membered heteroaryls with two heteroatoms(e.g., pyridazines, cinnolines, phthalazines, pyrazines, pyrimidines,quinazolines); 6-membered heretoaryls with three heteroatoms (e.g.,1,3,5-triazine); and 6-membered heteroaryls with four heteroatoms.“Substituted heteroaryl” means a heteroaryl having one or morenon-interfering groups as substituents.

The term “heterocycle” or “heterocyclic” as used herein means one ormore rings of at least 5 atoms, preferably 5, 6, 7, 8, 9, 10, or 11atoms, with or without unsaturation or aromatic character and having atleast one ring atom which is not carbon. Preferred heteroatoms includesulfur, oxygen, and nitrogen. Multiple rings may be fused, as inquinoline or benzofuran. “Substituted heterocycle” means a heterocyclehaving one or more side chains formed from non-interfering substituents.

The term “derivative” as used herein means a compound that is formedfrom a similar, beginning compound by attaching another molecule or atomto the beginning compound. Furthermore, derivatives, according to theinvention, encompass one or more compounds formed from a precursorcompound through addition of one or more atoms or molecules or throughcombining two or more precursor compounds.

The term “prodrug” as used herein means any compound which, whenadministered to a mammal, is converted in whole or in part to a compoundof the invention.

The term “active metabolite” as used herein means a physiologicallyactive compound which results from the metabolism of a compound of theinvention, or a prodrug thereof, when such compound or prodrug isadministered to a mammal

The terms “therapeutically effective amount” or “therapeuticallyeffective dose” as used herein are interchangeable and mean aconcentration of a compound according to the invention, or abiologically active variant thereof, sufficient to elicit the desiredtherapeutic effect according to the methods of treatment describedherein.

The term “pharmaceutically acceptable carrier” as used herein means acarrier that is conventionally used in the art to facilitate thestorage, administration, and/or the healing effect of a biologicallyactive agent.

The term “intermittent administration” as used herein meansadministration of a therapeutically effective dose of a compositionaccording to the invention, followed by a time period of discontinuance,which is then followed by another administration of a therapeuticallyeffective dose, and so forth.

The term “monoamine” as used herein encompasses monoamineneurotransmitters and neuromodulators. In particular, it is used torefer to dopamine, norepinephrine, and serotonin.

Monoamine transporters facilitate the reuptake or reabsorption of thesemonoamines into the presynapses of an individual.

Active Agents

The present invention provides compounds, methods of preparation of thecompounds, pharmaceutical compositions, and methods of treatment ofvarious conditions using such compounds and pharmaceutical compositions.

In some embodiments, compounds according to the following structure areprovided,

wherein:

R₁ is optionally substituted C1-10 alkyl;

R₂ is H or optionally substituted C1-10 alkyl;

R₃ and R₄ are each independently selected from optionally substitutedC1-10 alkyl; X, Y, and Z are each independently selected from H;optionally substituted C1-10 alkyl; optionally substituted C1-10 alkoxy;optionally substituted C2-10 alkenyl; optionally substituted C2-10alkynyl; optionally substituted C6-C12 aryl including, but not limitedto, phenyl and naphthyl; alkaryl; arylalkyl (including optionallysubstituted benzyl); aryloxy; optionally substituted heteroaryl;optionally substituted heterocycle; halo (e.g., Cl, F, Br, and I);hydroxyl; halogenated alkyl (e.g., CF₃, 2-Br-ethyl, CH₂F, CH₂CF₃, andCF₂CF₃); amino (e.g., NH₂, NR₁₂H, and NR₁₂R₁₃); alkylamino; arylamino;acyl; CN; NO₂; N₃; CH₂OH; CONH₂; CONR₁₂R₁₃; CO₂R₁₂; CH₂OR₁₂; NHCOR₁₂;NHCO₂R₁₂; C1-3 alkylthio; sulfate; sulfonic acid; sulfonate esters suchas alkyl or aralkyl sulfonyl, including methanesulfonyl; phosphonicacid; phosphate; phosphonate; mono-, di-, or triphosphate esters; tritylor monomethoxytrityl; R₁₂SO; R₁₂SO₂; CF₃S; and CF₃SO₂; trialkylsilylsuch as dimethyl-t-butylsilyl or diphenylmethylsilyl; or wherein X and Yor Y and Z form a fused aryl ring together with the phenyl ring to whichX, Y, and Z are attached; and

R₁₂ and R₁₃ are each independently selected from H or optionallysubstituted C1-10 alkyl;

with the proviso that either (a) X is a halo substituent other thanchloro (e.g., fluoro or bromo); (b) two or more of X, Y, and Z are halosubstituents; (c) one or more of X, Y, and Z are optionally substitutedC6-C12 aryl (e.g., phenyl); (d) X and Y or Y and Z form a fused arylring together with the phenyl ring to which X, Y, and Z are attached;(e) R₁ is an optionally substituted C2-C10 alkyl (e.g., optionallysubstituted ethyl, propyl, or butyl); or any combination of two or moreof (a) through (e),

or a pharmaceutically acceptable ester, amide, salt, solvate, prodrug,or isomer thereof.

In certain embodiments, the invention provides a compound comprising twoor more of provisos (a) through (e). For example, in some aspects, theinvention provides a compound wherein X is a halo substituent other thanchloro and one or both of Y and Z are halo substituents (combining (a)and (b)). In other aspects, the invention provides a compound wherein Xis a halo substituent other than chloro and one or both of Y and Z isoptionally substituted C6-C12 aryl (combining (a) and (c)). In otheraspects, the invention provides a compound wherein X is a halosubstituent other than chloro and Y and Z form a fused aryl ringtogether with the phenyl ring to which X, Y, and Z are attached(combining (a) and (d)). In other aspects, the invention provides acompound wherein X is a halo substituent other than chloro and R₁ is anoptionally substituted C2-C10 alkyl (combining (a) and (e)). In stillfurther aspects, the invention provides a compound wherein two or moreof X, Y, and Z are halo substituents and one or more of X, Y, and Z areoptionally substituted C6-C12 aryl (combining (b) and (c)). In otheraspects, the invention provides a compound wherein two or more of X, Y,and Z are halo substituents and R₁ is an optionally substituted C2-C10alkyl (combining (b) and (e)). In still further aspects, the inventionprovides a compound wherein one of X and Z is optionally substitutedC6-C12 aryl and Y and the other of X and Z form a fused aryl ringtogether with the phenyl ring to which X, Y, and Z are attached(combining (c) and (d)). In other aspects, the invention provides acompound wherein one or more of X, Y, and Z are optionally substitutedC6-C12 aryl and R₁ is an optionally substituted C2-C10 alkyl (combining(c) and (e)). In other aspects, the invention provides a compoundwherein one or more of X, Y, and Z are optionally substituted C6-C12aryl and R₁ is an optionally substituted C2-C10 alkyl (combining (d) and(e)). Such compounds of the present invention may be capable ofaffecting monoamine uptake efficacy. In particular, in some embodiments,compounds of the present invention may be capable of inhibiting dopamineand/or norepinephrine reuptake. In some embodiments, the compounds ofthe present invention may be capable of acting as antagonists of one ormore nicotinic acetylcholine receptors such as α4β2 nAChRs. Somecompounds may act as noncompetitive functional antagonists at the α4β2nAChRs. In certain embodiments, the compounds of the present inventionmay act both as inhibitors of monoamine reuptake and antagonists of theα4β2 nAChRs.

In some preferred embodiments, a compound of Formula I is provided,wherein R₃ and R₄ are each CH₃. In some preferred embodiments, acompound of Formula I is provided,

wherein X is a halo substituent other than chloro. For example, in somepreferred embodiments, a compound of Formula I is provided, wherein X isfluoro or bromo. In some preferred embodiments, a compound of Formula Iis provided, wherein Y is a halo substituent. For example, in somepreferred embodiments, a compound of Formula I is provided, wherein Y ischloro. In some preferred embodiments, a compound of Formula I isprovided, wherein Y is optionally substituted aryl. For example, in somepreferred embodiments, a compound of Formula I is provided, wherein Y isphenyl. In some preferred embodiments, a compound of Formula I isprovided, wherein X and Y or Y and Z are each halo substituents. Forexample, in some preferred embodiments, a compound of Formula I isprovided, wherein X and Y or Y and Z are both chloro. In some preferredembodiments, a compound of Formula I is provided, wherein X and Z areeach halo substituents. For example, in some preferred embodiments, acompound of Formula I is provided, wherein X and Z are both fluoro. Insome preferred embodiments, a compound of Formula I is provided, whereinX and Y or Y and Z form a fused aryl ring together with the phenyl ringto which X, Y, and Z are attached. For example, in some preferredembodiments, a compound of Formula I is provided, wherein X and Y or Yand Z form a 2-naphthyl ring together with the phenyl ring to which X,Y, and Z are attached. In some preferred embodiments, a compound ofFormula I is provided, wherein R₁ is C1-10 alkyl. For example, in somepreferred embodiments, a compound of Formula I is provided wherein R₁ isCH₃, C₂H₅, or C₃H₇. In other preferred embodiments, a compound ofFormula I is provided wherein R₁ is C₄H₉, C₅H₁₁, C₆H₁₃, C₇H₁₅, C₈H₁₇,C₉H₁₉, or C₁₀H₂₁.

In some preferred embodiments, the compounds of Formula I are racemic.In some preferred embodiments, the compounds of Formula I are specificstereoisomers, with particular stereochemistries at both the carbon towhich the OH and phenyl are attached and the carbon to which R₁ isattached. In particularly preferred embodiments, the compounds ofFormula I are of the (2S-3S) configuration, although as one of skill inthe art is aware, the denotation depends on the identity of thesubstituent represented by R₁. Thus, although such compounds aretypically of the (2S-3S) configuration, it is possible that, dependingon the identity of R₁, a compound may be of the (2S-3R) configuration.In some embodiments therefore, the compound of Formula I may be providedin a composition that is enantiomerically enriched, such as a mixture ofenantiomers in which one enantiomer is present in excess, in particularto the extent of 95% or more, or 98% or more, including 100%. Inpreferred embodiments, a compound of Formula I is provided with the(2S-3S) configuration, with an enantiomeric excess of 95% or more, 96%or more, 97% or more, 98% or more, 99% or more, 99.5% or more, 99.9% ormore, or 100%.

In particular embodiments, compounds according to the followingstructure are provided:

wherein:

R₁ is optionally substituted C1-10 alkyl;

R₂ is H or optionally substituted C1-10 alkyl; X, Y, and Z are eachindependently selected from H; optionally substituted C1-10 alkyl;optionally substituted C1-10 alkoxy; optionally substituted C2-10alkenyl; optionally substituted C2-10 alkynyl; optionally substitutedC6-C12 aryl including, but not limited to, phenyl and naphthyl; alkaryl;arylalkyl (including optionally substituted benzyl); aryloxy; optionallysubstituted heteroaryl; optionally substituted heterocycle; halo (e.g.,Cl, F, Br, and I); hydroxyl; halogenated alkyl (e.g., CF₃, 2-Br-ethyl,CH₂F, CH₂CF₃, and CF₂CF₃); amino (e.g., NH₂, NR₁₂H, and NR₁₂R₁₃);alkylamino; arylamino; acyl; CN; NO₂; N₃; CH₂OH; CONH₂; CONR₁₂R₁₃;CO₂R₁₂; CH₂OR₁₂; NHCOR₁₂; NHCO₂R₁₂; C1-3 alkylthio; sulfate; sulfonicacid; sulfonate esters such as alkyl or aralkyl sulfonyl, includingmethanesulfonyl; phosphonic acid; phosphate; phosphonate; mono-, di-, ortriphosphate esters; trityl or monomethoxytrityl; R₁₂SO; R₁₂SO₂; CF₃S;and CF₃SO₂; trialkylsilyl such as dimethyl-t-butylsilyl ordiphenylmethylsilyl; or wherein X and Y or Y and Z form a fused arylring together with the phenyl ring to which X, Y, and Z are attached;and

R₁₂ and R₁₃ are each independently selected from H or optionallysubstituted C1-10 alkyl;

with the proviso that either (a) X is a halo substituent other thanchloro (e.g., fluoro or bromo); (b) two or more of X, Y, and Z are halosubstituents; (c) one or more of X, Y, and Z are optionally substitutedC6-C12 aryl (e.g., phenyl); (d) X and Y or Y and Z form a fused arylring together with the phenyl ring to which X, Y, and Z are attached;(e) R₁ is an optionally substituted C2-C10 alkyl (e.g., optionallysubstituted ethyl, propyl, or butyl); or any combination of two or moreof (a) through (e),

or a pharmaceutically acceptable ester, amide, salt, solvate, prodrug,or isomer thereof.

In certain embodiments, the invention provides a compound comprising twoor more of provisos (a) through (e). For example, in some aspects, theinvention provides a compound wherein X is a halo substituent other thanchloro and one or both of Y and Z are halo substituents (combining (a)and (b)). In other aspects, the invention provides a compound wherein Xis a halo substituent other than chloro and one or both of Y and Z isoptionally substituted C6-C12 aryl (combining (a) and (c)). In otheraspects, the invention provides a compound wherein X is a halosubstituent other than chloro and Y and Z folio a fused aryl ringtogether with the phenyl ring to which X, Y, and Z are attached(combining (a) and (d)). In other aspects, the invention provides acompound wherein X is a halo substituent other than chloro and R₁ is anoptionally substituted C2-C10 alkyl (combining (a) and (e)). In stillfurther aspects, the invention provides a compound wherein two or moreof X, Y, and Z are halo substituents and one or more of X, Y, and Z areoptionally substituted C6-C12 aryl (combining (b) and (c)). In otheraspects, the invention provides a compound wherein two or more of X, Y,and Z are halo substituents and R₁ is an optionally substituted C2-C10alkyl (combining (b) and (e)). In still further aspects, the inventionprovides a compound wherein one of X and Z is optionally substitutedC6-C12 aryl and Y and the other of X and Z form a fused aryl ringtogether with the phenyl ring to which X, Y, and Z are attached(combining (c) and (d)). In other aspects, the invention provides acompound wherein one or more of X, Y, and Z are optionally substitutedC6-C12 aryl and R₁ is an optionally substituted C2-C10 alkyl (combining(c) and (e)). In other aspects, the invention provides a compoundwherein one or more of X, Y, and Z are optionally substituted C6-C12aryl and R₁ is an optionally substituted C2-C10 alkyl (combining (d) and(e)).

In some embodiments, compounds with one or more chiral centers areprovided. While racemic mixtures of compounds of the invention can beactive, selective, and bioavailable, isolated isomers may be of interestas well.

Although racemic mixtures and all possible stereoisomers are encompassedby this disclosure, in some preferred embodiments, compounds of thefollowing formula are provided:

wherein:

R₁ is optionally substituted C1-10 alkyl;

R₂ is H or optionally substituted C1-10 alkyl;

X, Y, and Z are each independently selected from H; optionallysubstituted C1-10 alkyl; optionally substituted C1-10 alkoxy; optionallysubstituted C2-10 alkenyl; optionally substituted C2-10 alkynyl;optionally substituted C6-C12 aryl including, but not limited to, phenyland naphthyl; alkaryl; arylalkyl (including optionally substitutedbenzyl); aryloxy; optionally substituted heteroaryl; optionallysubstituted heterocycle; halo (e.g., Cl, F, Br, and I); hydroxyl;halogenated alkyl (e.g., CF₃, 2-Br-ethyl, CH₂F, CH₂CF₃, and CF₂CF₃);amino (e.g., NH₂, NR₁₂H, and NR₁₂R₁₃); alkylamino; arylamino; acyl; CN;NO₂; N₃; CH₂OH; CONH₂; CONR₁₂R₁₃; CO₂R₁₂; CH₂OR₁₂; NHCOR₁₂; NHCO₂R₁₂;C1-3 alkylthio; sulfate; sulfonic acid; sulfonate esters such as alkylor aralkyl sulfonyl, including methanesulfonyl; phosphonic acid;phosphate; phosphonate; mono-, di-, or triphosphate esters; trityl ormonomethoxytrityl; R₁₂SO; R₁₂SO₂; CF₃S; and CF₃SO₂; trialkylsilyl suchas dimethyl-t-butylsilyl or diphenylmethylsilyl; or wherein X and Y or Yand Z form a fused aryl ring together with the phenyl ring to which X,Y, and Z are attached; and

R₁₂ and R₁₃ are each independently selected from H or optionallysubstituted C1-10 alkyl;

with the proviso that either (a) X is a halo substituent other thanchloro (e.g., fluoro or bromo); (b) two or more of X, Y, and Z are halosubstituents; (c) one or more of X, Y, and Z are optionally substitutedC6-C12 aryl (e.g., phenyl); (d) X and Y or Y and Z form a fused arylring together with the phenyl ring to which X, Y, and Z are attached;(e) R₁ is an optionally substituted C2-C10 alkyl (e.g., optionallysubstituted ethyl, propyl, or butyl), or any combination of two or moreof (a) through (e),

or a pharmaceutically acceptable ester, amide, salt, solvate, prodrug,or isomer thereof.

In certain embodiments, the invention provides a compound comprising twoor more of provisos (a) through (e). For example, in some aspects, theinvention provides a compound wherein X is a halo substituent other thanchloro and one or both of Y and Z are halo substituents (combining (a)and (b)). In other aspects, the invention provides a compound wherein Xis a halo substituent other than chloro and one or both of Y and Z isoptionally substituted C6-C12 aryl (combining (a) and (c)). In otheraspects, the invention provides a compound wherein X is a halosubstituent other than chloro and Y and Z form a fused aryl ringtogether with the phenyl ring to which X, Y, and Z are attached(combining (a) and (d)). In other aspects, the invention provides acompound wherein X is a halo substituent other than chloro and R₁ is anoptionally substituted C2-C10 alkyl (combining (a) and (e)). In stillfurther aspects, the invention provides a compound wherein two or moreof X, Y, and Z are halo substituents and one or more of X, Y, and Z areoptionally substituted C6-C12 aryl (combining (b) and (c)). In otheraspects, the invention provides a compound wherein two or more of X, Y,and Z are halo substituents and R₁ is an optionally substituted C2-C10alkyl (combining (b) and (e)). In still further aspects, the inventionprovides a compound wherein one of X and Z is optionally substitutedC6-C12 aryl and Y and the other of X and Z form a fused aryl ringtogether with the phenyl ring to which X, Y, and Z are attached(combining (c) and (d)). In other aspects, the invention provides acompound wherein one or more of X, Y, and Z are optionally substitutedC6-C12 aryl and R₁ is an optionally substituted C2-C10 alkyl (combining(c) and (e)). In other aspects, the invention provides a compoundwherein one or more of X, Y, and Z are optionally substituted C6-C12aryl and R₁ is an optionally substituted C2-C10 alkyl (combining (d) and(e)).

Compounds of Formula Ib are typically denoted as being of the (2S-3S)configuration, although as one of skill in the art is aware, thedenotation depends on the identity of the substituent represented by R₁.Thus, although such compounds are typically of the (2S-3S)configuration, it is possible that, depending on the identity of R₁, acompound may be of the (2S-3R) configuration.

As indicated, the compounds disclosed herein as active agents maycontain chiral centers, which may be either of the (R) or (S)configuration, or may comprise a mixture thereof. Accordingly, thepresent invention also includes stereoisomers of the compounds describedherein, where applicable, either individually or admixed in anyproportions. Stereoisomers may include, but are not limited to,enantiomers, diastereomers, racemic mixtures, and combinations thereof.Such stereoisomers can be prepared and separated using conventionaltechniques, either by reacting enantiomeric starting materials, or byseparating isomers of compounds of the present invention. Isomers mayinclude geometric isomers. Examples of geometric isomers include, butare not limited to, cis isomers or trans isomers across a double bond.Other isomers are contemplated among the compounds of the presentinvention. The isomers may be used either in pure form or in admixturewith other isomers of the compounds described herein.

Various methods are known in the art for preparing optically activeforms and determining activity. Such methods include standard testsdescribed herein and other similar tests which are well known in theart. Examples of methods that can be used to obtain optical isomers ofthe compounds according to the present invention include the following:

i) physical separation of crystals whereby macroscopic crystals of theindividual enantiomers are manually separated. This technique mayparticularly be used when crystals of the separate enantiomers exist(i.e., the material is a conglomerate), and the crystals are visuallydistinct;

ii) simultaneous crystallization whereby the individual enantiomers areseparately crystallized from a solution of the racemate, possible onlyif the latter is a conglomerate in the solid state;

iii) enzymatic resolutions whereby partial or complete separation of aracemate by virtue of differing rates of reaction for the enantiomerswith an enzyme;

iv) enzymatic asymmetric synthesis, a synthetic technique whereby atleast one step of the synthesis uses an enzymatic reaction to obtain anenantiomerically pure or enriched synthetic precursor of the desiredenantiomer;

v) chemical asymmetric synthesis whereby the desired enantiomer issynthesized from an achiral precursor under conditions that produceasymmetry (i.e., chirality) in the product, which may be achieved usingchiral catalysts or chiral auxiliaries;

vi) diastereomer separations whereby a racemic compound is reacted withan enantiomerically pure reagent (the chiral auxiliary) that convertsthe individual enantiomers to diastereomers. The resulting diastereomersare then separated by chromatography or crystallization by virtue oftheir now more distinct structural differences and the chiral auxiliarylater removed to obtain the desired enantiomer;

vii) first- and second-order asymmetric transformations wherebydiastereomers from the racemate equilibrate to yield a preponderance insolution of the diastereomer from the desired enantiomer or wherepreferential crystallization of the diastereomer from the desiredenantiomer perturbs the equilibrium such that eventually in principleall the material is converted to the crystalline diastereomer from thedesired enantiomer. The desired enantiomer is then released from thediastereomers;

viii) kinetic resolutions comprising partial or complete resolution of aracemate (or of a further resolution of a partially resolved compound)by virtue of unequal reaction rates of the enantiomers with a chiral,non-racemic reagent or catalyst under kinetic conditions;

ix) enantiospecific synthesis from non-racemic precursors whereby thedesired enantiomer is obtained from non-chiral starting materials andwhere the stereochemical integrity is not or is only minimallycompromised over the course of the synthesis;

x) chiral liquid chromatography whereby the enantiomers of a racemateare separated in a liquid mobile phase by virtue of their differinginteractions with a stationary phase. The stationary phase can be madeof chiral material or the mobile phase can contain an additional chiralmaterial to provoke the differing interactions;

xi) chiral gas chromatography whereby the racemate is volatilized andenantiomers are separated by virtue of their differing interactions inthe gaseous mobile phase with a column containing a fixed non-racemicchiral adsorbent phase;

xii) extraction with chiral solvents whereby the enantiomers areseparated by virtue of preferential dissolution of one enantiomer into aparticular chiral solvent; and

xiii) transport across chiral membranes whereby a racemate is placed incontact with a thin membrane barrier. The barrier typically separatestwo miscible fluids, one containing the racemate, and a driving forcesuch as concentration or pressure differential causes preferentialtransport across the membrane barrier. Separation occurs as a result ofthe non-racemic chiral nature of the membrane which allows only oneenantiomer of the racemate to pass through.

The compound optionally may be provided in a composition that isenantiomerically enriched, such as a mixture of enantiomers in which oneenantiomer is present in excess, in particular to the extent of 95% ormore, or 98% or more, including 100%.

The terms (R), (S), (2R-3R), (2S-3S), (2R-3S) and (2S-3R) as used hereinmean that the composition contains a greater proportion of the namedisomer of the compound in relation to other isomers. In a preferredembodiment these terms indicate that the composition contains at least90% by weight of the named isomer and 10% by weight or less of the oneor more other isomers; or more preferably about 95% by weight of thenamed isomer and 5% or less of the one or more other isomers. Thesepercentages are based on the total amount of the compound of theinvention that is present in the composition.

The compounds of the present invention may be utilized per se or in theform of a pharmaceutically acceptable ester, amide, salt, solvate,prodrug, or isomer. For example, the compound may be provided as apharmaceutically acceptable salt. If used, a salt of the drug compoundshould be both pharmacologically and pharmaceutically acceptable, butnon-pharmaceutically acceptable salts may conveniently be used toprepare the free active compound or pharmaceutically acceptable saltsthereof and are not excluded from the scope of this invention. Suchpharmacologically and pharmaceutically acceptable salts can be preparedby reaction of the drug with an organic or inorganic acid, usingstandard methods detailed in the literature. Examples ofpharmaceutically acceptable salts of the compounds useful according tothe invention include acid addition salts. Salts of non-pharmaceuticallyacceptable acids, however, may be useful, for example, in thepreparation and purification of the compounds. Suitable acid additionsalts according to the present invention include organic and inorganicacids. Preferred salts include those formed from hydrochloric,hydrobromic, sulfuric, phosphoric, citric, tartaric, lactic, pyruvic,acetic, succinic, fumaric, maleic, oxaloacetic, methanesulfonic,ethanesulfonic, p-toluenesulfonic, benzenesulfonic, and isethionicacids. Other useful acid addition salts include propionic acid, glycolicacid, oxalic acid, malic acid, malonic acid, benzoic acid, cinnamicacid, mandelic acid, salicylic acid, and the like. Particular example ofpharmaceutically acceptable salts include, but are not limited to,sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates,monohydrogenphosphates, dihydrogenphosphates, metaphosphates,pyrophosphates, chlorides, bromides, iodides, acetates, propionates,decanoates, caprylates, acrylates, formates, isobutyrates, caproates,heptanoates, propiolates, oxalates, malonates, succinates, suberates,sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates,benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates,hydroxybenzoates, methoxyenzoates, phthalates, sulfonates,xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates,citrates, lactates, γ-hydroxybutyrates, glycolates, tartrates,methanesulfonates, propanesulfonates, naphthalene-1-sulfonates,naphthalene-2-sulfonates, and mandelates.

An acid addition salt may be reconverted to the free base by treatmentwith a suitable base. Preparation of basic salts of acid moieties whichmay be present on a compound useful according to the present inventionmay be prepared in a similar manner using a pharmaceutically acceptablebase, such as sodium hydroxide, potassium hydroxide, ammonium hydroxide,calcium hydroxide, triethylamine, or the like.

Esters of the active agent compounds according to the present inventionmay be prepared through functionalization of hydroxyl and/or carboxylgroups that may be present within the molecular structure of thecompound. Amides and prodrugs may also be prepared using techniquesknown to those skilled in the art. For example, amides may be preparedfrom esters, using suitable amine reactants, or they may be preparedfrom anhydride or an acid chloride by reaction with ammonia or a loweralkyl amine. Moreover, esters and amides of compounds of the inventioncan be made by reaction with a carbonylating agent (e.g., ethyl formate,acetic anhydride, methoxyacetyl chloride, benzoyl chloride, methylisocyanate, ethyl chloroformate, methanesulfonyl chloride) and asuitable base (e.g., 4-dimethylaminopyridine, pyridine, triethylamine,potassium carbonate) in a suitable organic solvent (e.g.,tetrahydrofuran, acetone, methanol, pyridine, N,N-dimethylformamide) ata temperature of 0° C. to 60° C. Prodrugs are typically prepared bycovalent attachment of a moiety, which results in a compound that istherapeutically inactive until modified by an individual's metabolicsystem. Examples of pharmaceutically acceptable solvates include, butare not limited to, compounds according to the invention in combinationwith water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, aceticacid, or ethanolamine. The invention also includes active metabolitesand other derivatives of the compounds of the invention.

In the case of solid compositions, it is understood that the compoundsused in the methods of the invention may exist in different forms. Forexample, the compounds may exist in stable and metastable crystallineforms and isotropic and amorphous forms, all of which are intended to bewithin the scope of the present invention.

If a compound useful as an active agent according to the invention is abase, then the desired salt may be prepared by any suitable method knownto the art, including treatment of the free base with an inorganic acid,such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,phosphoric acid and the like, or with an organic acid, such as aceticacid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonicacid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid,pyranosidyl acids such as glucuronic acid and galacturonic acid,alpha-hydroxy acids such as citric acid and tartaric acid, amino acidssuch as aspartic acid and glutamic acid, aromatic acids such as benzoicacid and cinnamic acid, sulfonic acids such a p-toluenesulfonic acid orethanesulfonic acid, or the like.

If a compound described herein as an active agent is an acid, thedesired salt may be prepared by any suitable method known to the art,including treatment of the free acid with an inorganic or organic base,such as an amine (primary, secondary or tertiary), an alkali metal oralkaline earth metal hydroxide or the like. Illustrative examples ofsuitable salts include organic salts derived from amino acids such asglycine and arginine, ammonia, primary, secondary and tertiary amines,and cyclic amines such as piperidine, morpholine and piperazine, andinorganic salts derived from sodium, calcium, potassium, magnesium,manganese, iron, copper, zinc, aluminum and lithium.

The present invention further includes prodrugs and active metabolitesof the active agent compounds described herein. Any of the compoundsdescribed herein can be administered as a prodrug to increase theactivity, bioavailability, or stability of the compound or to otherwisealter the properties of the compound. Typical examples of prodrugsinclude compounds that have biologically labile protecting groups on afunctional moiety of the active compound. Prodrugs include compoundsthat can be oxidized, reduced, aminated, deaminated, hydroxylated,dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated,acylated, deacylated, phosphorylated, and/or dephosphorylated to producethe active compound.

A number of prodrug ligands are known. In general, alkylation,acylation, or other lipophilic modification of one or more heteroatomsof the compound, such as a free amine or carboxylic acid residue,reduces polarity and allows passage into cells. Examples of substituentgroups that can replace one or more hydrogen atoms on the free amineand/or carboxylic acid moiety include, but are not limited to, thefollowing: aryl; steroids; carbohydrates (including sugars);1,2-diacylglycerol; alcohols; acyl (including lower acyl); alkyl(including lower alkyl); sulfonate ester (including alkyl or arylalkylsulfonyl, such as methanesulfonyl and benzyl, wherein the phenyl groupis optionally substituted with one or more substituents as provided inthe definition of an aryl given herein); optionally substitutedarylsulfonyl; lipids (including phospholipids); phosphotidylcholine;phosphocholine; amino acid residues or derivatives; amino acid acylresidues or derivatives; peptides; cholesterols; or otherpharmaceutically acceptable leaving groups which, when administered invivo, provide the free amine and/or carboxylic acid moiety. Any of thesecan be used in combination with the disclosed active agents to achieve adesired effect.

Particularly preferred compounds of the present invention include thefollowing:

Additional representative, non-limiting compounds of Formula I of thepresent invention, wherein R₁ is CH₃ and the X, Y, and Z substituentsare varied are indicated below in Table 1.

TABLE 1 Representative compounds of Formula I

X Y Z R₁ R₂ R₃ R₄ H H H CH₃ H CH₃ CH₃ Cl H H CH₃ H CH₃ CH₃ H Cl H CH₃ HCH₃ CH₃ Cl Cl H CH₃ H CH₃ CH₃ Cl H Cl CH₃ H CH₃ CH₃ Cl Cl Cl CH₃ H CH₃CH₃ F H H CH₃ H CH₃ CH₃ H F H CH₃ H CH₃ CH₃ F F H CH₃ H CH₃ CH₃ F H FCH₃ H CH₃ CH₃ F F F CH₃ H CH₃ CH₃ Br H H CH₃ H CH₃ CH₃ H Br H CH₃ H CH₃CH₃ Br Br H CH₃ H CH₃ CH₃ Br H Br CH₃ H CH₃ CH₃ Br Br Br CH₃ H CH₃ CH₃CH₃ H H CH₃ H CH₃ CH₃ H CH₃ H CH₃ H CH₃ CH₃ CH₃ CH₃ H CH₃ H CH₃ CH₃ CH₃H CH₃ CH₃ H CH₃ CH₃ CH₃ CH₃ CH₃ CH₃ H CH₃ CH₃ CH₂CH₃ H H CH₃ H CH₃ CH₃ HCH₂CH₃ H CH₃ H CH₃ CH₃ CH₂CH₃ CH₂CH₃ H CH₃ H CH₃ CH₃ CH₂CH₃ H CH₂CH₃ CH₃H CH₃ CH₃ CH₂CH₃ CH₂CH₃ CH₂CH₃ CH₃ H CH₃ CH₃ C₃H₇ H H CH₃ H CH₃ CH₃ HC₃H₇ H CH₃ H CH₃ CH₃ C₃H₇ C₃H₇ H CH₃ H CH₃ CH₃ C₃H₇ H C₃H₇ CH₃ H CH₃ CH₃C₃H₇ C₃H₇ C₃H₇ CH₃ H CH₃ CH₃ Cl CH₃ H CH₃ H CH₃ CH₃ CH₃ Cl H CH₃ H CH₃CH₃ Cl H CH₃ CH₃ H CH₃ CH₃ CH₃ Cl CH₃ CH₃ H CH₃ CH₃ CH₃ CH₃ Cl CH₃ H CH₃CH₃ Cl CH₃ Cl CH₃ H CH₃ CH₃ Cl Cl CH₃ CH₃ H CH₃ CH₃ F CH₃ H CH₃ H CH₃CH₃ CH₃ F H CH₃ H CH₃ CH₃ F H CH₃ CH₃ H CH₃ CH₃ CH₃ F CH₃ CH₃ H CH₃ CH₃CH₃ CH₃ F CH₃ H CH₃ CH₃ F CH₃ F CH₃ H CH₃ CH₃ F F CH₃ CH₃ H CH₃ CH₃ BrCH₃ H CH₃ H CH₃ CH₃ CH₃ Br H CH₃ H CH₃ CH₃ Br H CH₃ CH₃ H CH₃ CH₃ CH₃ BrCH₃ CH₃ H CH₃ CH₃ CH₃ CH₃ Br CH₃ H CH₃ CH₃ Br CH₃ Br CH₃ H CH₃ CH₃ Br BrCH₃ CH₃ H CH₃ CH₃ NO₂ H H CH₃ H CH₃ CH₃ H NO₂ H CH₃ H CH₃ CH₃ NO₂ NO₂ HCH₃ H CH₃ CH₃ NO₂ H NO₂ CH₃ H CH₃ CH₃ NO₂ NO₂ NO₂ CH₃ H CH₃ CH₃ OCH₃ H HCH₃ H CH₃ CH₃ H OCH₃ H CH₃ H CH₃ CH₃ CH₃ OCH₃ H CH₃ H CH₃ CH₃ OCH₃ HOCH₃ CH₃ H CH₃ CH₃ OCH₃ OCH₃ OCH₃ CH₃ H CH₃ CH₃ phenyl H H CH₃ H CH₃ CH₃H phenyl H CH₃ H CH₃ CH₃ phenyl H phenyl CH₃ H CH₃ CH₃ phenyl phenyl HCH₃ H CH₃ CH₃ phenyl phenyl phenyl CH₃ H CH₃ CH₃ Cl CH₂CH₃ H CH₃ H CH₃CH₃ CH₂CH₃ Cl H CH₃ H CH₃ CH₃ Cl H CH₂CH₃ CH₃ H CH₃ CH₃ CH₂CH₃ Cl CH₂CH₃CH₃ H CH₃ CH₃ CH₂CH₃ CH₂CH₃ Cl CH₃ H CH₃ CH₃ Cl CH₂CH₃ Cl CH₃ H CH₃ CH₃Cl Cl CH₂CH₃ CH₃ H CH₃ CH₃ F CH₂CH₃ H CH₃ H CH₃ CH₃ CH₂CH₃ F H CH₃ H CH₃CH₃ F H CH₂CH₃ CH₃ H CH₃ CH₃ CH₂CH₃ F CH₂CH₃ CH₃ H CH₃ CH₃ CH₂CH₃ CH₂CH₃F CH₃ H CH₃ CH₃ F CH₂CH₃ F CH₃ H CH₃ CH₃ F F CH₂CH₃ CH₃ H CH₃ CH₃ BrCH₂CH₃ H CH₃ H CH₃ CH₃ CH₂CH₃ Br H CH₃ H CH₃ CH₃ Br H CH₂CH₃ CH₃ H CH₃CH₃ CH₂CH₃ Br CH₂CH₃ CH₃ H CH₃ CH₃ CH₂CH₃ CH₂CH₃ Br CH₃ H CH₃ CH₃ BrCH₂CH₃ Br CH₃ H CH₃ CH₃ Br Br CH₂CH₃ CH₃ H CH₃ CH₃ Cl C₃H₇ H CH₃ H CH₃CH₃ C₃H₇ Cl H CH₃ H CH₃ CH₃ Cl H C₃H₇ CH₃ H CH₃ CH₃ C₃H₇ Cl C₃H₇ CH₃ HCH₃ CH₃ C₃H₇ C₃H₇ Cl CH₃ H CH₃ CH₃ Cl C₃H₇ Cl CH₃ H CH₃ CH₃ Cl Cl C₃H₇CH₃ H CH₃ CH₃ F C₃H₇ H CH₃ H CH₃ CH₃ C₃H₇ F H CH₃ H CH₃ CH₃ F H C₃H₇ CH₃H CH₃ CH₃ C₃H₇ F C₃H₇ CH₃ H CH₃ CH₃ C₃H₇ C₃H₇ F CH₃ H CH₃ CH₃ F C₃H₇ FCH₃ H CH₃ CH₃ F F C₃H₇ CH₃ H CH₃ CH₃ Br C₃H₇ H CH₃ H CH₃ CH₃ C₃H₇ Br HCH₃ H CH₃ CH₃ Br H C₃H₇ CH₃ H CH₃ CH₃ C₃H₇ Br C₃H₇ CH₃ H CH₃ CH₃ C₃H₇C₃H₇ Br CH₃ H CH₃ CH₃ Br C₃H₇ Br CH₃ H CH₃ CH₃ Br Br C₃H₇ CH₃ H CH₃ CH₃CH₂Cl₃ CH₃ H CH₃ H CH₃ CH₃ CH₃ CH₂CH₃ H CH₃ H CH₃ CH₃ CH₃ H CH₂CH₃ CH₃ HCH₃ CH₃ CH₂CH₃ CH₃ CH₂CH₃ CH₃ H CH₃ CH₃ CH₂CH₃ CH₂CH₃ CH₃ CH₃ H CH₃ CH₃CH₃ CH₂CH₃ CH₃ CH₃ H CH₃ CH₃ CH₃ CH₃ CH₂CH₃ CH₃ H CH₃ CH₃ CH₃ C₃H₇ H CH₃H CH₃ CH₃ C₃H₇ CH₃ H CH₃ H CH₃ CH₃ CH₃ H C₃H₇ CH₃ H CH₃ CH₃ C₃H₇ CH₃C₃H₇ CH₃ H CH₃ CH₃ C₃H₇ C₃H₇ CH₃ CH₃ H CH₃ CH₃ CH₃ C₃H₇ CH₃ CH₃ H CH₃CH₃ CH₃ CH₃ C₃H₇ CH₃ H CH₃ CH₃ CH₂CH₃ C₃H₇ H CH₃ H CH₃ CH₃ C₃H₇ CH₂CH₃ HCH₃ H CH₃ CH₃ CH₂CH₃ H C₃H₇ CH₃ H CH₃ CH₃ C₃H₇ CH₂CH₃ C₃H₇ CH₃ H CH₃ CH₃C₃H₇ C₃H₇ CH₂CH₃ CH₃ H CH₃ CH₃ CH₂CH₃ C₃H₇ CH₂CH₃ CH₃ H CH₃ CH₃ CH₂CH₃CH₂CH₃ C₃H₇ CH₃ H CH₃ CH₃ CH₃ CH₂CH₃ C₃H₇ CH₃ H CH₃ CH₃ CH₃ C₃H₇ CH₂CH₃CH₃ H CH₃ CH₃ CH₂CH₃ CH₃ C₃H₇ CH₃ H CH₃ CH₃ 2-napthyl H CH₃ H CH₃ CH₃2-napthyl Cl CH₃ H CH₃ CH₃ 2-napthyl F CH₃ H CH₃ CH₃ 2-napthyl Br CH₃ HCH₃ CH₃ 2-napthyl CH₃ CH₃ H CH₃ CH₃ 2-napthyl CH₂CH₃ CH₃ H CH₃ CH₃2-napthyl C₃H₇ CH₃ H CH₃ CH₃ 2-napthyl OCH₃ CH₃ H CH₃ CH₃ 2-napthyl NO₂CH₃ H CH₃ CH₃

Additional representative, non-limiting compounds of Formula I of thepresent invention, wherein R₁ is CH₂CH₃ and the X, Y, and Z substituentsare varied are indicated below in Table 2.

TABLE 2 Representative compounds of Formula I

X Y Z R₁ R₂ R₃ R₄ H H H CH₂CH₃ H CH₃ CH₃ Cl H H CH₂CH₃ H CH₃ CH₃ H Cl HCH₂CH₃ H CH₃ CH₃ Cl Cl H CH₂CH₃ H CH₃ CH₃ Cl H Cl CH₂CH₃ H CH₃ CH₃ Cl ClCl CH₂CH₃ H CH₃ CH₃ F H H CH₂CH₃ H CH₃ CH₃ H F H CH₂CH₃ H CH₃ CH₃ F F HCH₂CH₃ H CH₃ CH₃ F H F CH₂CH₃ H CH₃ CH₃ F F F CH₂CH₃ H CH₃ CH₃ Br H HCH₂CH₃ H CH₃ CH₃ H Br H CH₂CH₃ H CH₃ CH₃ Br Br H CH₂CH₃ H CH₃ CH₃ Br HBr CH₂CH₃ H CH₃ CH₃ Br Br Br CH₂CH₃ H CH₃ CH₃ CH₃ H H CH₂CH₃ H CH₃ CH₃ HCH₃ H CH₂CH₃ H CH₃ CH₃ CH₃ CH₃ H CH₂CH₃ H CH₃ CH₃ CH₃ H CH₃ CH₂CH₃ H CH₃CH₃ CH₃ CH₃ CH₃ CH₂CH₃ H CH₃ CH₃ CH₂CH₃ H H CH₂CH₃ H CH₃ CH₃ H CH₂CH₃ HCH₂CH₃ H CH₃ CH₃ CH₂CH₃ CH₂CH₃ H CH₂CH₃ H CH₃ CH₃ CH₂CH₃ H CH₂CH₃ CH₂CH₃H CH₃ CH₃ CH₂CH₃ CH₂CH₃ CH₂CH₃ CH₂CH₃ H CH₃ CH₃ C₃H₇ H H CH₂CH₃ H CH₃CH₃ H C₃H₇ H CH₂CH₃ H CH₃ CH₃ C₃H₇ C₃H₇ H CH₂CH₃ H CH₃ CH₃ C₃H₇ H C₃H₇CH₂CH₃ H CH₃ CH₃ C₃H₇ C₃H₇ C₃H₇ CH₂CH₃ H CH₃ CH₃ Cl CH₃ H CH₂CH₃ H CH₃CH₃ CH₃ Cl H CH₂CH₃ H CH₃ CH₃ Cl H CH₃ CH₂CH₃ H CH₃ CH₃ CH₃ Cl CH₃CH₂CH₃ H CH₃ CH₃ CH₃ CH₃ Cl CH₂CH₃ H CH₃ CH₃ Cl CH₃ Cl CH₂CH₃ H CH₃ CH₃Cl Cl CH₃ CH₂CH₃ H CH₃ CH₃ F CH₃ H CH₂CH₃ H CH₃ CH₃ CH₃ F H CH₂CH₃ H CH₃CH₃ F H CH₃ CH₂CH₃ H CH₃ CH₃ CH₃ F CH₃ CH₂CH₃ H CH₃ CH₃ CH₃ CH₃ F CH₂CH₃H CH₃ CH₃ F CH₃ F CH₂CH₃ H CH₃ CH₃ F F CH₃ CH₂CH₃ H CH₃ CH₃ Br CH₃ HCH₂CH₃ H CH₃ CH₃ CH₃ Br H CH₂CH₃ H CH₃ CH₃ Br H CH₃ CH₂CH₃ H CH₃ CH₃ CH₃Br CH₃ CH₂CH₃ H CH₃ CH₃ CH₃ CH₃ Br CH₂CH₃ H CH₃ CH₃ Br CH₃ Br CH₂CH₃ HCH₃ CH₃ Br Br CH₃ CH₂CH₃ H CH₃ CH₃ NO₂ H H CH₂CH₃ H CH₃ CH₃ H NO₂ HCH₂CH₃ H CH₃ CH₃ NO₂ NO₂ H CH₂CH₃ H CH₃ CH₃ NO₂ H NO₂ CH₂CH₃ H CH₃ CH₃NO₂ NO₂ NO₂ CH₂CH₃ H CH₃ CH₃ OCH₃ H H CH₂CH₃ H CH₃ CH₃ H OCH₃ H CH₂CH₃ HCH₃ CH₃ CH₃ OCH₃ H CH₂CH₃ H CH₃ CH₃ OCH₃ H OCH₃ CH₂CH₃ H CH₃ CH₃ OCH₃OCH₃ OCH₃ CH₂CH₃ H CH₃ CH₃ phenyl H H CH₂CH₃ H CH₃ CH₃ H phenyl H CH₂CH₃H CH₃ CH₃ phenyl H phenyl CH₂CH₃ H CH₃ CH₃ phenyl phenyl H CH₂CH₃ H CH₃CH₃ phenyl phenyl phenyl CH₂CH₃ H CH₃ CH₃ Cl CH₂CH₃ H CH₂CH₃ H CH₃ CH₃CH₂CH₃ Cl H CH₂CH₃ H CH₃ CH₃ Cl H CH₂CH₃ CH₂CH₃ H CH₃ CH₃ CH₂CH₃ ClCH₂CH₃ CH₂CH₃ H CH₃ CH₃ CH₂CH₃ CH₂CH₃ Cl CH₂CH₃ H CH₃ CH₃ Cl CH₂CH₃ ClCH₂CH₃ H CH₃ CH₃ Cl Cl CH₂CH₃ CH₂CH₃ H CH₃ CH₃ F CH₂CH₃ H CH₂CH₃ H CH₃CH₃ CH₂CH₃ F H CH₂CH₃ H CH₃ CH₃ F H CH₂CH₃ CH₂CH₃ H CH₃ CH₃ CH₂CH₃ FCH₂CH₃ CH₂CH₃ H CH₃ CH₃ CH₂CH₃ CH₂CH₃ F CH₂CH₃ H CH₃ CH₃ F CH₂CH₃ FCH₂CH₃ H CH₃ CH₃ F F CH₂CH₃ CH₂CH₃ H CH₃ CH₃ Br CH₂CH₃ H CH₂CH₃ H CH₃CH₃ CH₂CH₃ Br H CH₂CH₃ H CH₃ CH₃ Br H CH₂CH₃ CH₂CH₃ H CH₃ CH₃ CH₂CH₃ BrCH₂CH₃ CH₂CH₃ H CH₃ CH₃ CH₂CH₃ CH₂CH₃ Br CH₂CH₃ H CH₃ CH₃ Br CH₂CH₃ BrCH₂CH₃ H CH₃ CH₃ Br Br CH₂CH₃ CH₂CH₃ H CH₃ CH₃ Cl C₃H₇ H CH₂CH₃ H CH₃CH₃ C₃H₇ Cl H CH₂CH₃ H CH₃ CH₃ Cl H C₃H₇ CH₂CH₃ H CH₃ CH₃ C₃H₇ Cl C₃H₇CH₂CH₃ H CH₃ CH₃ C₃H₇ C₃H₇ Cl CH₂CH₃ H CH₃ CH₃ Cl C₃H₇ Cl CH₂CH₃ H CH₃CH₃ Cl Cl C₃H₇ CH₂CH₃ H CH₃ CH₃ F C₃H₇ H CH₂CH₃ H CH₃ CH₃ C₃H₇ F HCH₂CH₃ H CH₃ CH₃ F H C₃H₇ CH₂CH₃ H CH₃ CH₃ C₃H₇ F C₃H₇ CH₂CH₃ H CH₃ CH₃C₃H₇ C₃H₇ F CH₂CH₃ H CH₃ CH₃ F C₃H₇ F CH₂CH₃ H CH₃ CH₃ F F C₃H₇ CH₂CH₃ HCH₃ CH₃ Br C₃H₇ H CH₂CH₃ H CH₃ CH₃ C₃H₇ Br H CH₂CH₃ H CH₃ CH₃ Br H C₃H₇CH₂CH₃ H CH₃ CH₃ C₃H₇ Br C₃H₇ CH₂CH₃ H CH₃ CH₃ C₃H₇ C₃H₇ Br CH₂CH₃ H CH₃CH₃ Br C₃H₇ Br CH₂CH₃ H CH₃ CH₃ Br Br C₃H₇ CH₂CH₃ H CH₃ CH₃ CH₂Cl₃ CH₃ HCH₂CH₃ H CH₃ CH₃ CH₃ CH₂CH₃ H CH₂CH₃ H CH₃ CH₃ CH₃ H CH₂CH₃ CH₂CH₃ H CH₃CH₃ CH₂CH₃ CH₃ CH₂CH₃ CH₂CH₃ H CH₃ CH₃ CH₂CH₃ CH₂CH₃ CH₃ CH₂CH₃ H CH₃CH₃ CH₃ CH₂CH₃ CH₃ CH₂CH₃ H CH₃ CH₃ CH₃ CH₃ CH₂CH₃ CH₂CH₃ H CH₃ CH₃ CH₃C₃H₇ H CH₂CH₃ H CH₃ CH₃ C₃H₇ CH₃ H CH₂CH₃ H CH₃ CH₃ CH₃ H C₃H₇ CH₂CH₃ HCH₃ CH₃ C₃H₇ CH₃ C₃H₇ CH₂CH₃ H CH₃ CH₃ C₃H₇ C₃H₇ CH₃ CH₂CH₃ H CH₃ CH₃CH₃ C₃H₇ CH₃ CH₂CH₃ H CH₃ CH₃ CH₃ CH₃ C₃H₇ CH₂CH₃ H CH₃ CH₃ CH₂CH₃ C₃H₇H CH₂CH₃ H CH₃ CH₃ C₃H₇ CH₂CH₃ H CH₂CH₃ H CH₃ CH₃ CH₂CH₃ H C₃H₇ CH₂CH₃ HCH₃ CH₃ C₃H₇ CH₂CH₃ C₃H₇ CH₂CH₃ H CH₃ CH₃ C₃H₇ C₃H₇ CH₂CH₃ CH₂CH₃ H CH₃CH₃ CH₂CH₃ C₃H₇ CH₂CH₃ CH₂CH₃ H CH₃ CH₃ CH₂CH₃ CH₂CH₃ C₃H₇ CH₂CH₃ H CH₃CH₃ CH₃ CH₂CH₃ C₃H₇ CH₂CH₃ H CH₃ CH₃ CH₃ C₃H₇ CH₂CH₃ CH₂CH₃ H CH₃ CH₃CH₂CH₃ CH₃ C₃H₇ CH₂CH₃ H CH₃ CH₃ 2-napthyl H CH₂CH₃ CH₂CH₃ CH₃ CH₃2-napthyl Cl CH₂CH₃ H CH₃ CH₃ 2-napthyl F CH₂CH₃ H CH₃ CH₃ 2-napthyl BrCH₂CH₃ H CH₃ CH₃ 2-napthyl CH₃ CH₂CH₃ H CH₃ CH₃ 2-napthyl CH₂CH₃ CH₂CH₃H CH₃ CH₃ 2-napthyl C₃H₇ CH₂CH₃ H CH₃ CH₃ 2-napthyl OCH₃ CH₂CH₃ H CH₃CH₃ 2-napthyl NO₂ CH₂CH₃ H CH₃ CH₃

Additional representative, non-limiting compounds of Formula I of thepresent invention, wherein R₁ is C₃H₇ and the X, Y, and Z substituentsare varied are indicated below in Table 3.

TABLE 3 Representative compounds of Formula I

X Y Z R₁ R₂ R₃ R₄ H H H C₃H₇ H CH₃ CH₃ Cl H H C₃H₇ H CH₃ CH₃ H Cl H C₃H₇H CH₃ CH₃ Cl Cl H C₃H₇ H CH₃ CH₃ Cl H Cl C₃H₇ H CH₃ CH₃ Cl Cl Cl C₃H₇ HCH₃ CH₃ F H H C₃H₇ H CH₃ CH₃ H F H C₃H₇ H CH₃ CH₃ F F H C₃H₇ H CH₃ CH₃ FH F C₃H₇ H CH₃ CH₃ F F F C₃H₇ H CH₃ CH₃ Br H H C₃H₇ H CH₃ CH₃ H Br HC₃H₇ H CH₃ CH₃ Br Br H C₃H₇ H CH₃ CH₃ Br H Br C₃H₇ H CH₃ CH₃ Br Br BrC₃H₇ H CH₃ CH₃ CH₃ H H C₃H₇ H CH₃ CH₃ H CH₃ H C₃H₇ H CH₃ CH₃ CH₃ CH₃ HC₃H₇ H CH₃ CH₃ CH₃ H CH₃ C₃H₇ H CH₃ CH₃ CH₃ CH₃ CH₃ C₃H₇ H CH₃ CH₃CH₂CH₃ H H C₃H₇ H CH₃ CH₃ H CH₂CH₃ H C₃H₇ H CH₃ CH₃ CH₂CH₃ CH₂CH₃ H C₃H₇H CH₃ CH₃ CH₂CH₃ H CH₂CH₃ C₃H₇ H CH₃ CH₃ CH₂CH₃ CH₂CH₃ CH₂CH₃ C₃H₇ H CH₃CH₃ C₃H₇ H H C₃H₇ H CH₃ CH₃ H C₃H₇ H C₃H₇ H CH₃ CH₃ C₃H₇ C₃H₇ H C₃H₇ HCH₃ CH₃ C₃H₇ H C₃H₇ C₃H₇ H CH₃ CH₃ C₃H₇ C₃H₇ C₃H₇ C₃H₇ H CH₃ CH₃ Cl CH₃H C₃H₇ H CH₃ CH₃ CH₃ Cl H C₃H₇ H CH₃ CH₃ Cl H CH₃ C₃H₇ H CH₃ CH₃ CH₃ ClCH₃ C₃H₇ H CH₃ CH₃ CH₃ CH₃ Cl C₃H₇ H CH₃ CH₃ Cl CH₃ Cl C₃H₇ H CH₃ CH₃ ClCl CH₃ C₃H₇ H CH₃ CH₃ F CH₃ H C₃H₇ H CH₃ CH₃ CH₃ F H C₃H₇ H CH₃ CH₃ F HCH₃ C₃H₇ H CH₃ CH₃ CH₃ F CH₃ C₃H₇ H CH₃ CH₃ CH₃ CH₃ F C₃H₇ H CH₃ CH₃ FCH₃ F C₃H₇ H CH₃ CH₃ F F CH₃ C₃H₇ H CH₃ CH₃ Br CH₃ H C₃H₇ H CH₃ CH₃ CH₃Br H C₃H₇ H CH₃ CH₃ Br H CH₃ C₃H₇ H CH₃ CH₃ CH₃ Br CH₃ C₃H₇ H CH₃ CH₃CH₃ CH₃ Br C₃H₇ H CH₃ CH₃ Br CH₃ Br C₃H₇ H CH₃ CH₃ Br Br CH₃ C₃H₇ H CH₃CH₃ NO₂ H H C₃H₇ H CH₃ CH₃ H NO₂ H C₃H₇ H CH₃ CH₃ NO₂ NO₂ H C₃H₇ H CH₃CH₃ NO₂ H NO₂ C₃H₇ H CH₃ CH₃ NO₂ NO₂ NO₂ C₃H₇ H CH₃ CH₃ OCH₃ H H C₃H₇ HCH₃ CH₃ H OCH₃ H C₃H₇ H CH₃ CH₃ CH₃ OCH₃ H C₃H₇ H CH₃ CH₃ OCH₃ H OCH₃C₃H₇ H CH₃ CH₃ OCH₃ OCH₃ OCH₃ C₃H₇ H CH₃ CH₃ phenyl H H C₃H₇ H CH₃ CH₃ Hphenyl H C₃H₇ H CH₃ CH₃ phenyl H phenyl C₃H₇ H CH₃ CH₃ phenyl phenyl HC₃H₇ H CH₃ CH₃ phenyl phenyl phenyl C₃H₇ H CH₃ CH₃ Cl CH₂CH₃ H C₃H₇ HCH₃ CH₃ CH₂CH₃ Cl H C₃H₇ H CH₃ CH₃ Cl H CH₂CH₃ C₃H₇ H CH₃ CH₃ CH₂CH₃ ClCH₂CH₃ C₃H₇ H CH₃ CH₃ CH₂CH₃ CH₂CH₃ Cl C₃H₇ H CH₃ CH₃ Cl CH₂CH₃ Cl C₃H₇H CH₃ CH₃ Cl Cl CH₂CH₃ C₃H₇ H CH₃ CH₃ F CH₂CH₃ H C₃H₇ H CH₃ CH₃ CH₂CH₃ FH C₃H₇ H CH₃ CH₃ F H CH₂CH₃ C₃H₇ H CH₃ CH₃ CH₂CH₃ F CH₂CH₃ C₃H₇ H CH₃CH₃ CH₂CH₃ CH₂CH₃ F C₃H₇ H CH₃ CH₃ F CH₂CH₃ F C₃H₇ H CH₃ CH₃ F F CH₂CH₃C₃H₇ H CH₃ CH₃ Br CH₂CH₃ H C₃H₇ H CH₃ CH₃ CH₂CH₃ Br H C₃H₇ H CH₃ CH₃ BrH CH₂CH₃ C₃H₇ H CH₃ CH₃ CH₂CH₃ Br CH₂CH₃ C₃H₇ H CH₃ CH₃ CH₂CH₃ CH₂CH₃ BrC₃H₇ H CH₃ CH₃ Br CH₂CH₃ Br C₃H₇ H CH₃ CH₃ Br Br CH₂CH₃ C₃H₇ H CH₃ CH₃Cl C₃H₇ H C₃H₇ H CH₃ CH₃ C₃H₇ Cl H C₃H₇ H CH₃ CH₃ Cl H C₃H₇ C₃H₇ H CH₃CH₃ C₃H₇ Cl C₃H₇ C₃H₇ H CH₃ CH₃ C₃H₇ C₃H₇ Cl C₃H₇ H CH₃ CH₃ Cl C₃H₇ ClC₃H₇ H CH₃ CH₃ Cl Cl C₃H₇ C₃H₇ H CH₃ CH₃ F C₃H₇ H C₃H₇ H CH₃ CH₃ C₃H₇ FH C₃H₇ H CH₃ CH₃ F H C₃H₇ C₃H₇ H CH₃ CH₃ C₃H₇ F C₃H₇ C₃H₇ H CH₃ CH₃ C₃H₇C₃H₇ F C₃H₇ H CH₃ CH₃ F C₃H₇ F C₃H₇ H CH₃ CH₃ F F C₃H₇ C₃H₇ H CH₃ CH₃ BrC₃H₇ H C₃H₇ H CH₃ CH₃ C₃H₇ Br H C₃H₇ H CH₃ CH₃ Br H C₃H₇ C₃H₇ H CH₃ CH₃C₃H₇ Br C₃H₇ C₃H₇ H CH₃ CH₃ C₃H₇ C₃H₇ Br C₃H₇ H CH₃ CH₃ Br C₃H₇ Br C₃H₇H CH₃ CH₃ Br Br C₃H₇ C₃H₇ H CH₃ CH₃ CH₂Cl₃ CH₃ H C₃H₇ H CH₃ CH₃ CH₃CH₂CH₃ H C₃H₇ H CH₃ CH₃ CH₃ H CH₂CH₃ C₃H₇ H CH₃ CH₃ CH₂CH₃ CH₃ CH₂CH₃C₃H₇ H CH₃ CH₃ CH₂CH₃ CH₂CH₃ CH₃ C₃H₇ H CH₃ CH₃ CH₃ CH₂CH₃ CH₃ C₃H₇ HCH₃ CH₃ CH₃ CH₃ CH₂CH₃ C₃H₇ H CH₃ CH₃ CH₃ C₃H₇ H C₃H₇ H CH₃ CH₃ C₃H₇ CH₃H C₃H₇ H CH₃ CH₃ CH₃ H C₃H₇ C₃H₇ H CH₃ CH₃ C₃H₇ CH₃ C₃H₇ C₃H₇ H CH₃ CH₃C₃H₇ C₃H₇ CH₃ C₃H₇ H CH₃ CH₃ CH₃ C₃H₇ CH₃ C₃H₇ H CH₃ CH₃ CH₃ CH₃ C₃H₇C₃H₇ H CH₃ CH₃ CH₂CH₃ C₃H₇ H C₃H₇ H CH₃ CH₃ C₃H₇ CH₂CH₃ H C₃H₇ H CH₃ CH₃CH₂CH₃ H C₃H₇ C₃H₇ H CH₃ CH₃ C₃H₇ CH₂CH₃ C₃H₇ C₃H₇ H CH₃ CH₃ C₃H₇ C₃H₇CH₂CH₃ C₃H₇ H CH₃ CH₃ CH₂CH₃ C₃H₇ CH₂CH₃ C₃H₇ H CH₃ CH₃ CH₂CH₃ CH₂CH₃C₃H₇ C₃H₇ H CH₃ CH₃ CH₃ CH₂CH₃ C₃H₇ C₃H₇ H CH₃ CH₃ CH₃ C₃H₇ CH₂CH₃ C₃H₇H CH₃ CH₃ CH₂CH₃ CH₃ C₃H₇ C₃H₇ H CH₃ CH₃ 2-napthyl H C₃H₇ H CH₃ CH₃2-napthyl Cl C₃H₇ H CH₃ CH₃ 2-napthyl F C₃H₇ H CH₃ CH₃ 2-napthyl Br C₃H₇H CH₃ CH₃ 2-napthyl CH₃ C₃H₇ H CH₃ CH₃ 2-napthyl CH₂CH₃ C₃H₇ H CH₃ CH₃2-napthyl C₃H₇ C₃H₇ H CH₃ CH₃ 2-napthyl OCH₃ C₃H₇ H CH₃ CH₃ 2-napthylNO₂ C₃H₇ H CH₃ CH₃

In particular embodiments, the compounds of the present invention arecompounds of Formula I, which include one or more of the following: R₃and R₄ are each CH₃; X is a halo substituent other than chloro (e.g.,fluoro or bromo); Y is a halo substituent (e.g., chloro); Y isoptionally substituted aryl (e.g., phenyl); X and Y or Y and Z are eachhalo substituents (e.g., both chloro); X and Z are each halosubstituents (e.g., both fluoro); X and Y or Y and Z foam a fused arylring together with the phenyl ring to which X, Y, and Z are attached(e.g., a 2-naphthyl ring together with the phenyl ring to which X, Y,and Z are attached); R₁ is C1-10 alkyl (e.g., CH₃, C₂H₅, C₃H₇, C₄H₉,C₅H₁₁, C₆H₁₃, C₇H₁₅, C₈H₁₇, C₉H₁₉, or C₁₀H₂₁).

Such compounds may show enhanced monoamine transporter bindingproperties and may effectively inhibit monoamine uptake and/or may showenhanced activity for nAChR inhibition. In certain embodiments, thecompounds of the present invention display enhanced activity incomparison to bupropion for either or both monoamine uptake inhibitionand/or nAChR inhibition. In some embodiments, the compounds of thepresent invention show enhanced selectivity for one or more monoaminetransporters (dopamine, norepinephrine, and/or serotonin transporters)and/or enhanced selectivity for one or more nAChR subtypes (e.g., α4β2).In certain embodiments, these selectivities may be enhanced incomparison to bupropion for either or both monoamine uptake inhibitionand/or nAChR inhibition.

Methods of Preparation

The present invention also encompasses methods of preparing compoundswith structures encompassed by Formula I, Formula Ia, and/or Formula Ib.One of skill in the art would be able to adapt these methods as requiredto accommodate various functional groups that may affect the chemistryof the synthesis.

Scheme 1 shows a general synthesis used for some compounds representedby Formula I of the present invention, starting with an aryl ketone.Commercially unavailable propiophenones (8) may be synthesized byGrignard additions to commercially available aryl nitriles (7).(Z)-tert-Butyldimethylsilylenol ether formation from thesepropiophenones, using t-butyldimethylsilyl triflate in methylenechloride yields (Z)-enol ethers. The key transformation in this sequenceis a chiral Sharpless hydroxylation reaction of these enol ethers, whichwhen using AD-mix-β, provides (R)-α-hydroxy ketones.

Scheme 2 shows a general synthesis used for some racemic compoundsrepresented by Formula I of the present invention. The appropriatepropiophenones are first synthesized by the addition of ethylmagnesiumbromide to nitriles (7). Simple bromination to form the alpha-bromoketones followed by amination with 2-amino-2-methyl-1-propanol providesthe desired analogues.

In some embodiments, various compounds of the present invention may beprepared by a novel convergent synthetic approach for the preparation of2-substituted morpholinols as outlined in Scheme 3. This approachutilizes a nucleophilic addition of Grignard reagents to(35)-3,5,5-trimethylmorpholin-2-one (15). Treatment of methyl(R)-(+)-lactate (13) with trifluoromethanesulfonic anhydride and2,6-lutidine at 0° C., gives methyl(2R)-2-{[(trifluoromethyl)sulfonyl]oxy}propionate (14) in 77% yield. Thealkylation of 2-amino-2-methyl-1-propanol with triflate 14 at −40° C.for 2 h and overnight at room temperature, and subsequent cyclizationaffords 15. The addition of the appropriate arylmagnesium bromide to 15provides the desired compounds. The C-3 stereocenter of these compoundsis derived from the lactate, rather than created by a synthetictransformation such as the Sharpless hydroxylation used in Scheme 1. Insome embodiments, this center was then leveraged to create the secondC-2 stereocenter. The resulting stereochemistry at C-2 was a result ofeither facial selectivity during the Grignard addition anti to the C-3methyl group and/or a thermodynamic equilibrium of the final product tothe S,S-configuration since the resulting product can ring open andclose. The ring opened form loses its C-2 stereochemistry, forming aketone. This route is more convergent than the Sharpless hydroxylationroute, and in some embodiments, may be more reliable, requiring far lessanalytical work.

Scheme 4 shows a general synthesis used for some N-methylated compoundsof the present invention. These may be synthesized from theirnon-alkylated analogues by reaction with methyl iodide in the presenceof potassium carbonate.

Compositions

While it is possible for the compounds of the present invention to beadministered in the raw chemical form, it is preferred for the compoundsto be delivered as a pharmaceutical formulation. Accordingly, there areprovided by the present invention pharmaceutical compositions comprisingat least one compound capable of inhibiting the reuptake of one or moremonoamines. As such, the formulations of the present invention comprisea compound of Formula I, as described above, or a pharmaceuticallyacceptable ester, amide, salt, or solvate thereof, together with one ormore pharmaceutically acceptable carriers therefore, and optionally,other therapeutic ingredients.

“Pharmaceutically acceptable carrier” denotes a carrier that isconventionally used in the art to facilitate the storage,administration, and/or the healing effect of the agent. The carrier(s)must be pharmaceutically acceptable in the sense of being compatiblewith the other ingredients of the formulation and not unduly deleteriousto the recipient thereof. A carrier may also reduce any undesirable sideeffects of the agent. Such carriers are known in the art. See, Wang etal. (1980) J. Parent. Drug Assn. 34(6):452-462, herein incorporated byreference in its entirety.

Adjuvants or accessory ingredients for use in the formulations of thepresent invention can include any pharmaceutical ingredient commonlydeemed acceptable in the art, such as binders, fillers, lubricants,disintegrants, diluents, surfactants, stabilizers, preservatives,flavoring and coloring agents, and the like. The compositions mayfurther include diluents, buffers, binders, disintegrants, thickeners,lubricants, preservatives (including antioxidants), flavoring agents,taste-masking agents, inorganic salts (e.g., sodium chloride),antimicrobial agents (e.g., benzalkonium chloride), sweeteners,antistatic agents, surfactants (e.g., polysorbates such as “TWEEN 20”and “TWEEN 80”, and pluronics such as F68 and F88, available from BASF),sorbitan esters, lipids (e.g., phospholipids such as lecithin and otherphosphatidylcholines, phosphatidylethanolamines, fatty acids and fattyesters, steroids (e.g., cholesterol)), and chelating agents (e.g., EDTA,zinc and other such suitable cations).

Exemplary pharmaceutical excipients and/or additives suitable for use inthe compositions according to the invention are listed in Remington: TheScience & Practice of Pharmacy,” 21^(st) ed. Lippincott Williams &Wilkins (2006); in the Physician's Desk Reference, 64^(th) ed., ThomsonPDR (2010); and in Handbook of Pharmaceutical Excipients, 6^(th) ed.,Eds. Raymond C. Rowe et al., Pharmaceutical Press (2009), which areincorporated herein by reference.

Binders are generally used to facilitate cohesiveness of the tablet andensure the tablet remains intact after compression. Suitable bindersinclude, but are not limited to: starch, polysaccharides, gelatin,polyethylene glycol, propylene glycol, waxes, and natural and syntheticgums. Acceptable fillers include silicon dioxide, titanium dioxide,alumina, talc, kaolin, powdered cellulose, and microcrystallinecellulose, as well as soluble materials, such as mannitol, urea,sucrose, lactose, dextrose, sodium chloride, and sorbitol. Lubricantsare useful for facilitating tablet manufacture and include vegetableoils, glycerin, magnesium stearate, calcium stearate, and stearic acid.Disintegrants, which are useful for facilitating disintegration of thetablet, generally include starches, clays, celluloses, algins, gums, andcrosslinked polymers. Diluents, which are generally included to providebulk to the tablet, may include dicalcium phosphate, calcium sulfate,lactose, cellulose, kaolin, mannitol, sodium chloride, dry starch, andpowdered sugar. Surfactants suitable for use in the formulationaccording to the present invention may be anionic, cationic, amphoteric,or nonionic surface active agents. Stabilizers may be included in theformulations to inhibit or lessen reactions leading to decomposition ofthe active agent, such as oxidative reactions.

Formulations of the present invention may include short-term,rapid-onset, rapid-offset, controlled release, sustained release,delayed release, and pulsatile release formulations, providing theformulations achieve administration of a compound as described herein.See Remington's Pharmaceutical Sciences (18^(th) ed.; Mack PublishingCompany, Eaton, Pa., 1990), herein incorporated by reference in itsentirety.

Pharmaceutical formulations according to the present invention aresuitable for various modes of delivery, including oral, parenteral(including intravenous, intramuscular, subcutaneous, intradermal, andtransdermal), topical (including dermal, buccal, and sublingual), andrectal administration. The most useful and/or beneficial mode ofadministration can vary, especially depending upon the condition of therecipient and the disorder being treated.

The pharmaceutical formulations may be conveniently made available in aunit dosage form, whereby such formulations may be prepared by any ofthe methods generally known in the pharmaceutical arts. Generallyspeaking, such methods of preparation comprise combining (by variousmethods) an active agent, such as the compounds of Formula I accordingto the present invention (or a pharmaceutically acceptable ester, amide,salt, or solvate thereof) with a suitable carrier or other adjuvant,which may consist of one or more ingredients. The combination of theactive ingredient with the one or more adjuvants is then physicallytreated to present the formulation in a suitable form for delivery(e.g., shaping into a tablet or forming an aqueous suspension).

Pharmaceutical formulations according to the present invention suitableas oral dosage may take various forms, such as tablets, capsules,caplets, and wafers (including rapidly dissolving or effervescing), eachcontaining a predetermined amount of the active agent. The formulationsmay also be in the form of a powder or granules, a solution orsuspension in an aqueous or non-aqueous liquid, and as a liquid emulsion(oil-in-water and water-in-oil). The active agent may also be deliveredas a bolus, electuary, or paste. It is generally understood that methodsof preparations of the above dosage forms are generally known in theart, and any such method would be suitable for the preparation of therespective dosage forms for use in delivery of the compounds accordingto the present invention.

A tablet containing a compound according to the present invention may bemanufactured by any standard process readily known to one of skill inthe art, such as, for example, by compression or molding, optionallywith one or more adjuvant or accessory ingredient. The tablets mayoptionally be coated or scored and may be formulated so as to provideslow or controlled release of the active agent.

Solid dosage forms may be formulated so as to provide a delayed releaseof the active agent, such as by application of a coating. Delayedrelease coatings are known in the art, and dosage forms containing suchmay be prepared by any known suitable method. Such methods generallyinclude that, after preparation of the solid dosage form (e.g., a tabletor caplet), a delayed release coating composition is applied.Application can be by methods, such as airless spraying, fluidized bedcoating, use of a coating pan, or the like. Materials for use as adelayed release coating can be polymeric in nature, such as cellulosicmaterial (e.g., cellulose butyrate phthalate, hydroxypropylmethylcellulose phthalate, and carboxymethyl ethylcellulose), andpolymers and copolymers of acrylic acid, methacrylic acid, and estersthereof.

Solid dosage forms according to the present invention may also besustained release (i.e., releasing the active agent over a prolongedperiod of time), and may or may not also be delayed release. Sustainedrelease formulations are known in the art and are generally prepared bydispersing a drug within a matrix of a gradually degradable orhydrolyzable material, such as an insoluble plastic, a hydrophilicpolymer, or a fatty compound. Alternatively, a solid dosage form may becoated with such a material.

Formulations for parenteral administration include aqueous andnon-aqueous sterile injection solutions, which may further containadditional agents, such as anti-oxidants, buffers, bacteriostats, andsolutes, which render the formulations isotonic with the blood of theintended recipient. The formulations may include aqueous and non-aqueoussterile suspensions, which contain suspending agents and thickeningagents. Such formulations for parenteral administration may be presentedin unit-dose or multi-dose containers, such as, for example, sealedampoules and vials, and may be stores in a freeze-dried (lyophilized)condition requiring only the addition of the sterile liquid carrier, forexample, water (for injection), immediately prior to use. Extemporaneousinjection solutions and suspensions may be prepared from sterilepowders, granules, and tablets of the kind previously described.

The compounds according to the present invention may also beadministered transdermally, wherein the active agent is incorporatedinto a laminated structure (generally referred to as a “patch”) that isadapted to remain in intimate contact with the epidermis of therecipient for a prolonged period of time. Typically, such patches areavailable as single layer “drug-in-adhesive” patches or as multi-layerpatches where the active agent is contained in a layer separate from theadhesive layer. Both types of patches also generally contain a backinglayer and a liner that is removed prior to attachment to the skin of therecipient. Transdermal drug delivery patches may also be comprised of areservoir underlying the backing layer that is separated from the skinof the recipient by a semi-permeable membrane and adhesive layer.Transdermal drug delivery may occur through passive diffusion or may befacilitated using electrotransport or iontophoresis.

Formulations for rectal delivery of the compounds of the presentinvention include rectal suppositories, creams, ointments, and liquids.Suppositories may be presented as the active agent in combination with acarrier generally known in the art, such as polyethylene glycol. Suchdosage forms may be designed to disintegrate rapidly or over an extendedperiod of time, and the time to complete disintegration can range from ashort time, such as about 10 minutes, to an extended period of time,such as about 6 hours.

The compounds of Formula I above may be formulated in compositionsincluding those suitable for oral, buccal, rectal, topical, nasal,ophthalmic, or parenteral (including intraperitoneal, intravenous,subcutaneous, or intramuscular injection) administration. Thecompositions may conveniently be presented in unit dosage form and maybe prepared by any of the methods well known in the art of pharmacy. Allmethods include the step of bringing a compound of Formula I intoassociation with a carrier that constitutes one or more accessoryingredients. In general, the compositions are prepared by bringing acompound of the invention into association with a liquid carrier to forma solution or a suspension, or alternatively, bringing a compound of theinvention into association with formulation components suitable forforming a solid, optionally a particulate product, and then, ifwarranted, shaping the product into a desired delivery form. Solidformulations of the invention, when particulate, will typically compriseparticles with sizes ranging from about 1 nanometer to about 500microns. In general, for solid formulations intended for intravenousadministration, particles will typically range from about 1 nm to about10 microns in diameter.

The amount of the compound of Formula I in the formulation will varydepending on the specific compound selected, dosage form, target patientpopulation, and other considerations, and will be readily determined byone skilled in the art. The amount of the compound of Formula I in theformulation will be that amount necessary to deliver a therapeuticallyeffective amount of the compound to a patient in need thereof to achieveat least one of the therapeutic effects associated with the compounds ofthe invention. In practice, this will vary widely depending upon theparticular compound, its activity, the severity of the condition to betreated, the patient population, the stability of the formulation, andthe like. Compositions will generally contain anywhere from about 1% byweight to about 99% by weight of a compound of the invention, typicallyfrom about 5% to about 70% by weight, and more typically from about 10%to about 50% by weight, and will also depend upon the relative amountsof excipients/additives contained in the composition.

Combinations

In specific embodiments, active agents used in combination withcompounds of the present invention comprise one or more compoundsgenerally recognized as useful for treating the conditions discussedherein. For example, in certain embodiments, the present inventionprovides a method for treating nicotine dependence/addiction.

Thus, in one embodiment, a compound of Formula I is combined with one ormore nicotine substitutes for the treatment of nicotine addiction.Nicotine substitutes (also known as “nicotine replacement therapy” or“NRT”) may make it easier to abstain from tobacco by partially replacingthe nicotine previously obtained from tobacco. Nicotinic replacementtherapies that may be combined with compounds of the present inventioninclude, but are not limited to transdermal nicotine patches (e.g.,Habitrol®, Nicoderm CQ®, and Nicotrol®), nicotine gum (e.g.,Nicorette®), nicotine lozenges (e.g., Commit®), nicotine-containingsublingual tablets (e.g., Nicorette® Microtabs), and nicotine nasalsprays or inhalers.

In certain embodiments, a compound of Formula I may also be combinedwith one or more nicotinic drugs. One particular class of nicotinicdrugs that may be used with compounds of the present inventionencompasses α4-β2 nicotinic receptor partial agonists, includingvarenicline (Chantix®). Another nicotinic drug approved for thetreatment of nicotine dependence is bupropion (Zyban®), which is anα3-β4 nicotinic receptor antagonist, and which can be combined with anyof the compounds provided herein.

In some embodiments, other compounds that have demonstrated off-labelsuccess for smoking cessation may be combined with compounds of FormulaI. Other drug therapies that may be prescribed and used in nicotinedependence in combination with the compounds of the present inventioninclude nortriptyline and doxepin, both tricyclic antidepressants.Additionally, fluoxetine (Prozac®) and buspirone (Buspar®) have beenused to treat nicotine addiction. Clonidine, an α2-noradrenergic agonistused to treat hypertension, has also shown beneficial effects innicotine addiction and studies suggest that mecamylamine may also aid intreatment for nicotine addiction. Immunotherapy may also be used inconjunction with compounds of the present invention, as recent studieshave demonstrated a prototype vaccine against nicotine that may inducethe production of antibodies that bind nicotine in the blood, preventingit from reaching the nicotine receptors.

In some embodiments, compounds of the present invention are used inconjunction with behavioral treatment. For example, psychologicaltreatment (including, but not limited to, psychological counseling,group therapy, and/or behavior therapy), skills training to deal withhigh-risk situations as well as an exercise regimen may prove effectiveat treating nicotine dependence when used in combination with treatmentusing a compound of Formula I.

Combinations of compounds of the present invention with othertherapeutic agents are also included in the present invention, whereinthe condition to be treated is responsive to the inhibition of monoaminereuptake and/or antagonism of nicotinic acetylcholine receptors.

For example, in some embodiments are provided methods for treatingdepression comprising administering a combination of a compound ofFormula I and one or more known antidepressants. Antidepressants usefulaccording to the invention include, but are not limited to, such classesof compounds as selective serotonin reuptake inhibitors (SSRIs),tricyclics, serotonin norepinephrine reuptake inhibitors (5-HT-NE dualreuptake inhibitors), and norepinephrine and dopamine reuptakeinhibitors (NDRIs).

In one embodiment, compounds of Formula I may be combined with one ormore compounds that are serotonin reuptake inhibitors. Serotoninreuptake inhibitors increase the extracellular level of the serotonin byinhibiting its reuptake into the presynaptic cell, which increases thelevel of serotonin available to bind to and stimulate the postsynapticreceptor. A significant percentage of bupropion use currently occurs incombination with one or more antidepressant drugs, most commonly bycombining bupropion with one or more SSRIs. Examples of SSRIs includefluoxetine (PROZAC®) paroxetine (PAXIL®), sertraline (ZOLOFT®),citalopram (CELEXA®), escitalopram (LEXAPRO®), nefazodone (SERZONE®) andfluvoxamine (LUVOX®).

In another embodiment, compounds of Formula I may be combined with oneor more compounds that at least partially inhibit the function ofmonoamine oxidase. Monoamine oxidase inhibitors (MAOIs) comprise a classof compounds understood to act by inhibiting the activity of monoamineoxidase, an enzyme generally found in the brain and liver of the humanbody, which functions to break down monoamine compounds, typicallythrough deamination. There are two isoforms of monoamine oxidaseinhibitors, MAO-A and MAO-B. The MAO-A isofoun preferentially deaminatesmonoamines typically occurring as neurotransmitters (e.g., serotonin,melatonin, epinephrine, norepinephrine, and dopamine). Thus, MAOIs havebeen historically prescribed as antidepressants and for treatment ofother social disorders, such as agoraphobia and social anxiety. TheMAO-β isoform preferentially deaminates phenylethylamine and traceamines. Dopamine is equally deaminated by both isoforms. MAOIs may byreversible or non-reversible and may be selective for a specificisoform. For example, the MAOI moclobemide (also known as Manerix orAurorix) is known to be approximately three times more selective forMAO-A than MAO-B.

Any compound generally recognized as being an MAOI may be usefulaccording to the present invention. Non-limiting examples of MAOIsuseful in combination with compounds of the present invention forpreparing compositions according to the invention include the following:isocarboxazid (MARPLAN®); moclobemide (Aurorix, Manerix, or Moclodura);phenelzine (NARDIL®); tranylcypromine (PARNATE®); selegiline (ELDEPRYL®,EMSAM®, or l-deprenyl); lazabemide; nialamide; iproniazid (marsilid,iprozid, ipronid, rivivol, or propilniazida); iproclozide; toloxatone;harmala; brofaromine (Consonar); benmoxin (Neuralex); and certaintryptamines, such as 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) or5-MeO-AMT (5-methoxy-α-methyltryptamine).

According to still another embodiment of the invention, compounds ofFormula I may be combined with one or more compounds that arenorepinephrine reuptake inhibitors (NRIs). NRIs are also known asnoradrenaline reuptake inhibitors (NARIS) and generally function toelevate the level of norepinephrine in the central nervous system (CNS)by inhibiting reuptake of norepinephrine from the synaptic cleft intothe presynaptic neuronal terminal. Norepinephrine is a catecholamine andphenylethylamine that functions as a neurotransmitter and is known toaffect many conditions. Any compound typically recognized as inhibitingthe reuptake of norepinephrine in the central nervous system can be usedaccording to the present invention. Non-limiting examples of NRIs usefulaccording to the invention comprise atomoxetine (STRATTERA®), reboxetine(EDRONAX®, VESTRA®, or NOREBOX®), viloxazine (EMOVIT®, VIVALAN®,VIVARINT®, or VIVILAN®), maprotiline (DEPRILEPT®, LUDIOMIL®, orPSYMION®), bupropion (WELLBUTRIN® or ZYBAN®), and radafaxine.

Further non-limiting examples of specific antidepressants usefulaccording to the invention include tricyclics such as amitriptyline,nortriptyline, and desipramine; serotonin-norepinephrine reuptakeinhibitors such as venlafaxine (EFFEXOR®), duloxetine (CYMBALTA®), andmilnacipran; tetracyclics such as maprotiline and mirtazapine; and otherclasses of compounds, including triazolopyridines such as trazodone.

The above compounds and classes of compounds are only examples of thetypes of active agents that can be used in combination with a compoundof the present invention for the treatment of disorders that may betreated according to the present invention and are not intended to belimiting of the invention. Other disorders including other types of drugdependence, mood disorders, sleep disorders, anxiety, obesity, orattention deficit disorders may be treated with combination therapiescomprising a compound of Formula I and one or more other treatments.Various further active agents can be combined with one or more compoundsof the present invention according to the invention. For example, anydrug generally recognized as being an antidepressant, antinarcoleptic,or ADHD treatment can be used in combination with one or more compoundsof the present invention. Moreover, it is possible according to theinvention to combine two or more additional active agents with acompound of the present invention for the treatment of the notedconditions.

Non-limiting examples of further active agents that can be combined withcompounds of the present invention include: mood stabilizers (such aslithium, olanzipine, verapamil, quetiapine, lamotrigine, carbamazepine,valproate, oxcarbazepine, risperidone, aripiprazole, and ziprasidone);antipsychotics (such as haloperidol and other butyrophenones,chlorpromazine, fluphenazine, perphenazine, prochlorperazine, and otherphenothiazines, and clozapine); serotonin receptor antagonist (5-HT2 and5-HT3 antagonists) (such as ondansetron, tropisetron, katenserin,methysergide, cyproheptadine, and pizotifen); serotonin receptoragonists (5-HT1A receptor agonists) (such as buspirone); stimulants[such as caffeine, ADDERALL®, methylphenidate (METADATE®, RITALIN®, orCONCERTA®), pemoline (CYLERT®), or modafinil (PROVIGIL®)]; andgamma-hydroxybutyrate (GHB) (XYREM®). Although the above compounds aredescribed in terms of classes of compounds and specific compounds, it isunderstood that there is substantial overlap between certain classes ofcompounds (such as between mood stabilizers, antipsychotics,antidepressants, and serotonin receptor antagonists). Thus, specificcompounds exemplifying a specific class of compounds may also properlybe identified with one or more further classes of compounds.Accordingly, the above classifications should not be viewed as limitingthe scope of the types of compounds useful in combination with compoundsof the present invention for treating the conditions described herein.

The compound of Formula I and the one or more other therapeutic agentsmay be contained within a single composition or alternatively may beadministered concurrently or sequentially (consecutively) in any order.For sequential administration, each of the compound of Formula I and theone or more other therapeutic agents can be formulated in its ownpharmaceutical composition, each of which is to be administeredsequentially, in any order. Alternatively, the compound of Formula I andthe one or more other therapeutic agents can be formulated together. Thecompositions may be formulated for oral, systemic, topical, intravenous,intraparenteral, intravaginal, intraocular, transbuccal, transmucosal,or transdermal administration.

Methods of Use

In a further embodiment, the present invention provides a method fortreating or delaying the progression of disorders that are alleviated byinhibiting monoamine reuptake and/or antagonizing nicotinicacetylcholine receptors in a patient, the method comprisingadministering a therapeutically effective amount of at least onecompound of Formula I to the patient. In particular, the presentinvention relates to the field of treating nicotine dependence inanimals, particularly humans and other mammals, and associated effectsof these conditions. It also may relate to the treatment of otherconditions that may benefit from the inhibition of monoamine reuptakeand/or antagonism of nicotinic acetylcholine receptors. It mayparticularly relate to the treatment of conditions that may benefit fromone or more of dopamine, norepinephrine, and serotonin reuptakeinhibition and/or from selective antagonism of one or more nAChRsubtypes. In some embodiments, the compounds of the present inventionare selective for one or more monoamine transporter. In someembodiments, the compounds show selectivity for inhibition of dopamineand norepinephrine uptake. In some embodiments, the compoundsdemonstrate selectivity for inhibition of dopamine over norepinephrineuptake; in other embodiments, the compounds demonstrate selectivity forinhibition of norepinephrine over dopamine uptake. However, in preferredembodiments, the compounds show greater activity for inhibiting dopamineand norepinephrine reuptake than for inhibiting serotonin reuptake. Inpreferred embodiments, the compounds show selectivity for one or morenAChR subtypes. In some embodiments, compounds show similar activity atboth the α4β2 and α3β4* nAChR subtypes.

In preferred embodiments, compounds are selective for one or both of theα4β2 and α3β4* nAChR subtypes. In particularly preferred embodiments,the compounds are selective for the α4β2 nAChR subtype. Further, in somepreferred embodiments, the compounds may show selectivity for both oneor more monoamine transporter and one or more nAChR subtypes.

Addiction has its common meaning, e.g., the condition that exists whenan individual persists in the use of a substance despite impairment ordistress related to the use of the substance. In preferred embodiments,the compounds of the present invention show a slow onset and longduration of activity. These features make the compounds of the presentinvention particularly suitable for the treatment of addiction to abusedsubstances, which commonly exhibit a fast onset and/or short duration ofactivity. Administration of the compounds of the present invention tosubjects with addiction to one or more substances may be particularlysuited for the treatment of nicotine, cocaine, and methamphetamineaddiction.

The compounds of the present invention may also be applicable totreating depression and depressive conditions. Depression has its commonmeaning, e.g., a common mental disorder that presents with depressedmood, loss of interest or pleasure, feelings of guilt or low self-worth,disturbed sleep or appetite, low energy, and poor concentration or amental state characterized by a pessimistic sense of inadequacy and adespondent lack of activity. Physical changes, such as insomnia,anorexia, weight loss, and decreased energy and libido can also occur asa result of depression. Depression includes dysthymic disorder ordysthymia, defined as a chronic low-grade depression and majordepression as well as other stages or levels of depression. It alsoincludes post-partum depression.

The compounds of the present invention may also be used for otherconditions that may be responsive to inhibition of reuptake of one ormore monoamines. In some embodiments, the compounds may be used to treatpatients for conditions that are responsive to the inhibition ofdopamine, norepinephrine, and/or serotonin For example, in someembodiments, compounds of Formula I may be used to treat patients withbipolar disorder, attention deficit disorder (ADD),attention-deficit/hyperactivity disorder (ADHD), hypoactive sexualdesire disorder, antidepressant-induced sexual dysfunction, orgasmicdysfunction, seasonal affective disorder/winter depression, obesity andfood addiction, mania, bulimia and other eating disorders, panicdisorders, obsessive compulsive disorder, schizophrenia,schizo-affective disorder, Parkinson's disease, narcolepsy, anxietydisorders, insomnia, chronic pain, migraine headaches, and restless legssyndrome.

The method of treatment generally includes administering atherapeutically effective amount of a compound of Formula I, optionallyin a pharmaceutical composition including one or more pharmaceuticallyacceptable carriers. The therapeutically effective amount is preferablysufficient to inhibit the reuptake of one or more monoamines. Thetherapeutically effective amount is further preferably sufficient tocause some relief to the patient in the symptoms of the disorder forwhich the patient is being treated.

For example, in one embodiment, a method of treating nicotine addictionis provided. In such methods, a therapeutically effective amount of acompound of the present invention to treat a patient with nicotineaddiction may be that amount capable of exerting some effect on themonoamine transporters and/or nicotinic acetylcholine receptors.Nicotine is thought to act in part through the activation of differentnAChR subtypes, which may lead to altered neuronal electrical activityand neurotransmitter release.

A therapeutically effective amount of a compound of the presentinvention to treat a patient with depression may be that amount capableof providing some relief from symptoms such as changes in mood, feelingsof intense sadness and despair, mental slowing, loss of concentration,pessimistic worry, agitation, and self-deprecation and/or from physicalchanges such as insomnia, anorexia and weight loss, and decreased energyand libido. The levels of one or more of dopamine, norepinephrine, andserotonin may be low in subjects with depression and thus, inhibition ofthe reuptake of any of these monoamines by the appropriate transportermay be effective to adjust the monoamine levels and treat the symptomsof depression. Some reports also indicate that nAChRs may also beimplicated in patients with depression; therefore, in some embodiments,compounds according to the present invention may provide treatment fordepression by acting as antagonists at one or more of the nAChRsubtypes.

The therapeutically effective dosage amount of any specific formulationwill vary somewhat from drug to drug, patient to patient, and willdepend upon factors such as the condition of the patient and the routeof delivery. When administered conjointly with other pharmaceuticallyactive agents, even less of the compound of the invention may betherapeutically effective. Furthermore, the therapeutically effectiveamount may vary depending on the specific condition to be treated.

The compounds of the invention can be administered once or several timesa day, or according to any other intermittent administration schedule.The daily dose can be administered either by a single dose in the formof an individual dosage unit or several smaller dosage units or bymultiple administration of subdivided dosages at certain intervals.Possible routes of delivery include buccally, subcutaneously,transdermally, intramuscularly, intravenously, orally, or by inhalation.

The compounds of the invention may be used with other types of therapy,including those which are non-drug based. For example, addiction iscommonly treated using one or more therapeutics in combination withbehavior therapy. Thus, in some embodiments, the methods of the presentinvention comprise administering to a subject a compound that that iscapable of functioning as a monoamine reuptake inhibitor and/orantagonist of nAChRs in conjunction with one or more other types ofnon-drug-based therapy.

EXPERIMENTAL SECTION Example 1 Synthesis

Nuclear magnetic resonance (¹H NMR and ¹³C NMR) spectra were recorded ona 300 MHz instrument (Bruker AVANCE 300) unless otherwise noted.Chemical shift data for the proton resonances were reported in parts permillion (δ) relative to internal standard (CH₃)₄Si (δ 0.0). Opticalrotations were measured on an AutoPol III polarimeter, purchased fromRudolf Research. Elemental analyses were performed by Atlantic Microlab,Norcross, Ga. Purity of compounds (>95%) was established by elementalanalyses. Analytical thin-layer chromatography (TLC) was carried out onplates precoated with silica gel GHLF (250 μM thickness). TLCvisualization was accomplished with a UV lamp or in an iodine chamber orvia ninhydrin staining All moisture-sensitive reactions were performedunder a positive pressure of nitrogen maintained by a direct line from anitrogen source. Anhydrous solvents were purchased from Aldrich ChemicalCo.

Certain compounds in the Experimental Section are referred to by number.The compound structure for the numbered compounds can be found, forexample, in Schemes 1-4, Table 4, or in the specific synthesis exampleswhere compound names are given. Methoxypropiophenone,3,4-dichloropropiophenone, 3,5-dichloropropiophenone,1-(pyridin-2-yl)propan-1-one, and 1-(pyridin-3-yl)propan-1-one, weresynthesized, but are now commercially available. 3-Chlorobutyrophenoneand 3-chloropentaphenone were described in an earlier paper on bupropionanalogs (Carroll, F. I.; Blough, B.; Abraham, P.; Mills, A. C.;Holleman, J. A.; Wolckenhauer, S. A.; Decker, A. M.; Landavazo, A.;McElroy, K. T.; Navarro, H. A.; Gatch, M. B.; Foster, M. J., Synthesisand Biological Evaluation of Bupropion Analogues as PotentialPharmacotherapies for Cocaine Addiction. J. Med. Chem. 2009, 52, (21),6768-6781), incorporated herein by reference in its entirety.

Synthesis of Compounds of the Present Invention

In one embodiment, various compounds (e.g., 4a-g and 4q-t) weresynthesized in a fashion similar to that reported in Fang, Q. K.; Han,Z.; Grover, P.; Kessler, D.; Senanayake, C. H.; Wald, S. A.,Tetrahedron: Asymmetry 2000, 11, 3659-3663 for optically active 4astarting with an aryl ketone (Scheme 1). Commercially unavailablepropiophenones (8) were synthesized by Grignard additions tocommercially available aryl nitriles (7).(Z)-tert-Butyldimethylsilylenol ether formation from thesepropiophenones, (e.g., 8a-k), using t-buthyldimethylsilyl triflate inmethylene chloride gave high yields of the (Z)-enol ethers (e.g., 9a-k).The key transformation in this sequence is a chiral Sharplesshydroxylation reaction of these enol ethers, which when using AD-mix-β,provided the (R)-α-hydroxy ketones 10a-k. The products of thesereactions were not checked for optical purity, but were found to beoptically active so optical induction was successful at some level. Dueto possible epimerization throughout the process it was decided toaminate the ketone before establishing optical purity. Initial effortsto reproduce the literature preparation of (2S,3S)-4a by converting(R)-1-(3-chlorophenyl)-2-hydroxypropan-1-one (10a) to the desiredproduct [(2S,3S)-4a] using the literature conditions with2-amino-2-methyl-1-propanol and 2,6-lutidine failed, or was lowyielding. The presence of 2,6-lutidine overwhelmed silica gelchromatography making purification difficult. A modified approach wasdeveloped using proton sponge provided (2S,3S)-4a in good yields.

In some embodiments, various compounds of the present invention (e.g.,4n and 4p, as well as 5 and 6 for comparison) were synthesized asracemic mixtures by following the standard synthesis of bupropionanalogues as outlined in Kelley, J. L.; Musso, D. L.; Boswell, G. E.;Soroko, F. E.; Cooper, B. R., J. Med. Chem. 1996, 39, (2), 347-349,incorporated herein by reference, except substituting2-amino-2-methyl-1-propanol for t-butylamine, shown in Scheme 2. Asillustrated in Scheme 2, the appropriate propiophenones (e.g., 8l-o)were first synthesized by the addition of ethylmagnesium bromide to thenitriles (7), or in the case of the 3-pyridyl analogue was synthesizedby lithium halogen exchange starting with 3-bromopyridine (11) andadding propionitrile. Simple bromination to form the alpha-bromo ketones(e.g., 12a-d) followed by amination with 2-amino-2-methyl-1-propanolprovided the desired analogues in good yield. It should be noted thatthe optically active syntheses of 5 and 6 were attempted using theapproach in Scheme 1, but the Sharpless reaction failed to provide thedesired product.

In some embodiments, various compounds of the present invention (e.g.,4h-m and 4o) were prepared by a novel convergent synthetic approach forthe preparation of 2-substituted morpholinols as outlined in Scheme 3.This new approach utilized a nucleophilic addition of Grignard reagentsto (3S)-3,5,5-trimethylmorpholin-2-one (15). Treatment of methyl(R)-(+)-lactate (13) with trifluoromethanesulfonic anhydride and2,6-lutidine at 0° C., gave methyl(2R)-2-{[(trifluoromethyl)sulfonyl]oxy}propionate (14) in 77% yield. Thealkylation of 2-amino-2-methyl-1-propanol with triflate 14 at −40° C.for 2 h and overnight at room temperature, and subsequent cyclizationafforded 15 in 63% yield. To test the approach, reaction of lactone 15with 3-chlorophenylmagnesium bromide resulted in the formation of(2S,3S)-trimethyl-2-(3′-chlorophenyl)morpholin-2-ol [(2S,3S)-4-a] in 32%yield (98% ee), 16% overall from (R)-(+)-lactate (13). The addition ofthe appropriate arylmagnesium bromide to 15 provided the desiredcompounds (e.g., 4h-m and 4o).

The C-3 stereocenter of these compounds was derived from the lactate,not created by a synthetic transformation such as the Sharplesshydroxylation used in Scheme 1. In some embodiments, this center wasthen leveraged to create the second C-2 stereocenter. The resultingstereochemistry at C-2 was a result of either facial selectivity duringthe Grignard addition anti to the C-3 methyl group and/or athermodynamic equilibrium of the final product to the S,S-configurationsince the resulting product can ring open and close. The ring openedform loses its C-2 stereochemistry, forming a ketone. This route wasmore convergent than the Sharpless hydroxylation route, and was morereliable, requiring far less analytical work.

In some embodiments, N-Methylated compounds (e.g., 4u and 4v) weresynthesized from their non-alkylated analogues (e.g., 4a and 4irespectively) by reaction with methyl iodide in the presence ofpotassium carbonate (Scheme 4).

Note that some of the compounds described herein were prepared andtested for comparison, and do not fall within the genus structure taughtby the present application and thus do not fall within the invention.

Synthesis of (2S,3S)-4a using optically active Sharpless hydroxylationchemistry Step 1:(Z)-tert-Butyl-[1-(3-chlorophenyl)prop-1-enyloxy]dimethylsilane (9a)

In a 250-mL flask 3′-chloropropiophenone (8a, 10 g, 0.059 mol) wasdissolved in 100 mL in CH₂Cl₂ and cooled with an ice water bath. Et₃N(13 mL, 95 mmol) was added to the solution, followed by slow addition ofTBDMSOTf (15 mL, 65 mmol). After stirring overnight at room temperature,the reaction mixture was diluted with CH₂Cl₂ and washed with NaHCO₃. Theorganic layer was separated, dried (Na₂SO₄) and concentrated. The oilyresidue was purified by column chromatography on neutral alumina usinghexanes (a few drops of Et₃N were added) as the eluent to give 16.4 g(98%) of title product as a colorless oil: ¹H NMR (CDCl₃) δ 7.46-7.44(m, 1H), 7.35-7.32 (m, 1H), 7.21-7.20 (m, 2H), 5.23 (q, 1H, J=6.9 Hz),1.73 (d, 3H, J=6.9 Hz), 0.99 (s, 9H), −0.03 (s, 6H). C₁₅H₂₃ClOSi.

Step 2: (R)-1-(3-Chlorophenyl)-2-hydroxypropan-1-one ((R)-10a)

A mixture of AD-mix-β (50.6 g) and CH₃SO₂NH₂ (3.5 g, 0.037 mol) intext-butyl alcohol-water (120 mL/120 mL) was cooled at 0° C. and treatedwith 9a (10 g, 0.036 mol). The reaction mixture was stirred for 16 h at0° C. Sodium sulfite (36 g) was added and the mixture was stirred foranother hour. The mixture was filtered through a Celite pad and washedwith ether. The filtrate was transferred to a separation funnel and thelower dark colored layer was discarded. The upper yellowish phase wasseparated, dried (Na₂SO₄), filtered, and concentrated. The crude productwas purified by column chromatography on silica gel using hexanes-EtOAc(10:1 to 3:1) as the eluent to give 5.8 g (87%) of title product aslight greenish oil: [α]²⁰ _(D) +64.2° (c 1.2, CHCl₃); ¹H NMR (CDCl₃) δ7.91 (s, 1H), 7.80 (d, 1H, J=7.8 Hz), 7.62-7.57 (m, 1H), 7.46 (t, 1H,J=7.8 Hz), 5.15-5.08 (m, 1H), 3.68-3.65 (m, 1H), 1.45 (d, 3H, J=7.1 Hz).C₉H₉ClO₂. Characterization data is similar to that reported in Fang, Q.K. et al., Tetrahedron: Asymmetry 2000, 11: 3659-3663.

Step 3: (2S,3S)-2-(3-Chlorophenyl)-3,5,5-trimethylmorpholin-2-ol[(2S,3S)-4a] Hemi-D-tartrate

A sample of (R)-10a (2.47 g, 0.0134 mol) was added to a 250 mL flask anddissolved in CH₂Cl₂ (40 mL). Proton sponge (3.5 g, 0.016 mol) was addedto the reaction flask, and the reaction mixture was cooled to −50° C.Triflic anhydride (2.47 mL, 14.7 mmol) was slowly added to the reactionflask, the temperature was allowed to rise to 0° C. and stirred for anadditional hour. The resulting orange slurry was transferred by syringeto another flask containing a solution of 2-amino-2-methyl-1-propanol(2.6 g, 0.029 mol) in CH₃CN (40 mL) at −10° C. After stirring for 4 h at0° C., the precipitate was removed by filtration and the filtrate wasconcentrated. The residue was extracted with ether and solid was removedby filtration and discarded. The filtrate was concentrated to an oil.Purification of the residue by chromatography on silica gel using EtOAcwith 1% NH₄OH as the eluent gave 1.39 g (41%) of (2S,3S)-4a as a whitesolid. Characterization data is similar to data reported in Fang, Q. K.;Han, Z.; Grover, P.; Kessler, D.; Senanayake, C. H.; Wald, S. A.,Tetrahedron: Asymmetry 2000, 11, 3659-3663.

The product freebase (1.2 g, 0.0047 mol) was dissolved in 20 mL of MeOHand treated with a solution of D-tartaric acid (350 mg, 2.30 mmol) inMeOH (3 mL). After stirring for 5 min at room temperature, the reactionmixture was concentrated, the sample dissolved in CH₂Cl₂ (30 mL) andMeOH was added until the solution was clear. Next, ether was addedslowly until it became cloudy or small crystals started to form. Afterkeeping the mixture at 0° C. for 1 h, the white solid was collected byfiltration and recrystallized to give 0.7 g of (2S,3S)-4a.0.5D-tartrateas a white solid (ee 98.4%): mp 128-131° C.; [α]²³ _(D) +13.7° (c 0.76,CH₃OH); Anal. (C₁₅H₂₁ClNO₅.0.5H₂O) calcd: C, 53.02; H, 6.53; N, 4.12.found: C, 53.12; H, 6.65; N, 4.00.

Synthesis of (2R,3R)-2-(3-Chlorophenyl)-3,5,5-trimethylmorpholin-2-ol((2R,3R)-4a)

Following the procedure described for (2S,3S)-4a, a sample of(S)-1-(3-Chlorophenyl)-2-hydroxypropan-1-one ((S)-10a, 4.5 g, 0.024mol), was dissolved in CH₂Cl₂ (75 mL) and treated with Proton sponge(6.3 g) and cooled to −50° C. Next, triflic anhydride (4.5 mL, 32 mmol)was added slowly, and the reaction mixture was stirred at 0° C. for anadditional hour. The resulting orange slurry was transferred by syringeto another flask containing a solution of 2-amino-2-methyl-1-propanol,(4.7 g, 0.052 mol) in CH₃CN. After purification, 3.3 g (78%) of the(2R,3R)-4a was isolated and converted to 2.7 g of the Hemi-L-tartratesalt (>99% ee): mp 128-131° C.; [α]²³ _(D) −13.0° (c 0.79, CH₃OH).Characterization data is similar to data reported in Fang, Q. K. et al.,Tetrahedron: Asymmetry 2000, 11, 3659-3663.

Synthesis of (2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol (4b)

Compound 4b was synthesized by a procedure similar to that described for(2S,3S)-4a using (R)-1-phenyl-2-hydroxypropan-1-one (10b, 3.49 g, 0.0233mol), Proton sponge (5.9 g), triflic anhydride (4.2 mL, 26 mmol), and2-amino-2-methyl-1-propanol (4.6 g, 0.052 mol) in CH₂Cl₂ (50 mL). Afterpurification by chromatography on silica gel, 3.52 g (68%) of the freebase 4b was isolated, and converted to 1.19 g of the hemi-D-tartratesalt, which had >99% ee: mp 112-113° C.; [α]²⁰ _(D) +15.8° (c 1.1,CH₃OH); ¹H NMR (methanol-d₄) δ 7.61-7.59 (m, 2H), 7.44-7.36 (m, 3H),4.32 (s, 1H), 4.24 (d, 1H, J=12.3 Hz), 3.58-3.48 (m, 2H), 1.64 (s, 3H),1.39 (s, 3H), 1.09 (d, 3H, J=6.6 Hz); ¹³C NMR (methanol-d₄) δ 179.1,142.4, 130.3, 129.6 (2C), 127.9 (2C), 97.3, 75.4, 67.4, 55.47, 55.27,24.1, 21.3, 14.3; LCMS (ESI) m/z 222.4 (M-tartrate)⁺; Anal.(C₁₅H₂₂NO₅.0.5H₂O) calcd: C, 59.00; H, 7.59; N, 4.59. found: C, 58.77;H, 7.46; N, 4.64.

Synthesis of (2S,3S)-2-(3-Fluorophenyl)-3,5,5-trimethylmorpholin-2-ol(4c)

Compound 4c was synthesized by a procedure similar to that described for(2S,3S)-4a using (R)-1-(3-fluorophenyl)-2-hydroxypropan-1-one (10c, 3.94g, 0.024 mol), Proton sponge (6.0 g), triflic anhydride (4.6 mL, 25.8mmol), and 2-amino-2-methyl-1-propanol (4.6 g, 0.052 mol) inacetonitrile (50 mL). After purification, 2.2 g (39%) of the free base4c was isolated and converted to the hemi-D-tartrate salt, whichhad >99% ee: mp 131-132° C.; [α]²⁰ _(D) +20.4° (c 1.0, CH₃OH); ¹H NMR(methanol-d₄) δ 7.45-7.41 (m, 2H), 7.35-7.31 (m, 1H), 7.11-7.09 (m, 1H),4.33 (s, 1H), 4.26 (d, 1H, J=12.0 Hz), 3.56-3.45 (m, 2H), 1.59 (s, 3H),1.34 (s, 3H), 1.06 (d, 3H, J=6.6 Hz); ¹³C NMR (methanol-d₄) δ 178.1,165.4, 162.1, 144.8, 130.8, 123.2, 116.3 (d), 114.3 (d), 96.2, 74.5,67.0, 54.3, 23.6, 20.8, 13.7; LCMS (ESI) m/z 240.0 [(M-tartrate)⁺,M=C₁₅H₂₁FNO₅]; Anal. (C₁₅H₂₁FNO₅.0.5H₂O) calcd: C, 55.72; H, 6.86; N,4.33. found: C, 55.61; H, 6.89; N, 4.33.

Synthesis of (2S,3S)-2-(3-Bromophenyl)-3,5,5-trimethylmorpholin-2-ol(4d)

Compound 4d was synthesized by a procedure similar to that described for(2S,3S)-4a using (R)-1-(3-bromophenyl)-2-hydroxypropan-1-one (10d, 4.0g, 0.018 mol), Proton sponge (4.5 g, 0.021 mol), triflic anhydride (3.2mL, 192 mmol), and 2-amino-2-methyl-1-propanol (3.4 g, 0.038 mol) inacetonitrile (50 mL). After purification, 2.04 g (39%) of the free base4d was isolated and converted to 1.6 g of the hemi-D-tartrate salt,which had >99% ee: mp 129-130° C.; [α]²⁰ _(D) +9.6° (c 1.0, CH₃OH); ¹HNMR (methanol-d₄) δ 7.77-7.76 (m, 1H), 7.63-7.53 (m, 2H), 7.38-7.32 (m,1H), 4.37 (s, 1H), 4.14 (d, 1H, J=12.0 Hz), 3.58-3.39 (m, 2H), 1.57 (s,3H), 1.32 (s, 3H), 1.07-1.02 (m, 3H); ¹³C NMR (methanol-d₄) δ 178.8,145.1, 133.3, 131.1, 126.9, 123.6, 96.7, 75.2, 67.7, 55.0, 24.4, 21.5,14.4; LCMS (ESI) m/z 300.6 [(M-tartrate)⁺, M=C₁₅H₂₁BrNO₅]; Anal.(C₁₅H₂₁BrNO₅.0.25H₂O) calcd: C, 47.44; H 5.71; N, 3.69. found: C, 47.33;H, 5.84; N, 3.63.

Synthesis of (2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol (4e)

Compound 4e was synthesized by a procedure similar to that described for(2S,3S)-4a using (R)-1-(3-methylphenyl)-2-hydroxypropan-1-one (10e, 4.2g, 0.026 mol), Proton sponge (6.5 g, 0.030 mol), triflic anhydride (4.60mL, 282 mmol), and 2-amino-2-methyl-1-propanol (5.0 g, 0.056 mol) inacetonitrile (55 mL). After purification, 4.0 g (66%) of the free base4e was isolated and converted to 3.6 g of the hemi-D-tartrate salt,which had 94% ee: mp 104-105° C.; [α]²⁰ _(D) +11.9° (c 0.85, CH₃OH); ¹HNMR (methanol-d₄) δ 7.43-7.38 (m, 2H), 7.28 (t, 1H, J=7.8 Hz), 7.21-7.18(m, 1H), 4.33 (s, 1H), 4.20 (d, 1H, J=12.0 Hz), 3.52-3.45 (m, 2H), 2.38(s, 3H), 1.61 (s, 3H), 1.36 (s, 3H), 1.06 (d, 3H, J=6.6 Hz); ¹³C NMR(methanol-d₄) δ 179.0, 142.3, 139.4, 130.9, 129.5, 128.4, 125.0, 97.2,75.3, 67.4, 55.2, 24.2, 21.9, 21.4, 14.4; LCMS (ESI) m/z 236.2[(M-tartrate)⁺, M=C₁₆H₂₄NO₅]; Anal. (C₁₆H₂₄NO₅.0.75H₂O) calcd: C, 59.33;H, 7.94; N, 4.32. found: C, 59.20; H, 7.88; N, 4.34.

Synthesis of (2S,3S)-2-(3-Methoxyphenyl)-3,5,5-trimethylmorpholin-2-ol(4f)

Compound 4f was synthesized by a procedure similar to that described for(2S,3S)-4a using (R)-1-(3-methoxyphenyl)-2-hydroxypropan-1-one (10f, 4.2g, 0.023 mol), Proton sponge (5.9 g, 0.028 mol), triflic anhydride (4.2mL, 257 mmol), and 2-amino-2-methyl-1-propanol (4.5 g, 0.051 mol) inCH₂Cl₂ (50 mL). After purification, 4.16 g (71%) of the free base 4f wasisolated and converted to 1.24 g the hemi-D-tartrate salt, which had 91%ee: mp 99-100° C.; [α]²⁰ _(D) +7.9° (c 1.1, CH₃OH); ¹H NMR (methanol-d₄)δ 7.32 (t, 1H, J=7.8 Hz), 7.19-7.14 (m, 2H), 6.96-6.92 (m, 1H), 4.33 (s,1H), 4.18 (d, 1H, J=12.3 Hz), 3.81 (s, 3H), 3.52 (d, 1H, J=12.3 Hz),3.48-3.45 (m, 1H), 1.59 (s, 3H), 1.34 (s, 3H), 1.06 (d, 3H, J=6.6 Hz).¹³C NMR (methanol-d₄) δ 178.8, 161.4, 144.1, 130.7, 120.1, 115.4, 113.8,97.1, 75.2, 67.6, 56.1, 55.2, 24.4, 21.5, 14.5; LCMS (ESI) m/z 252.3[(M-tartrate)⁺, % M=C₁₆H₂₄NO₆]; Anal. (C₁₆H₂₄NO₆.0.5H₂O) calcd: C,57.30; H, 7.51; N, 4.18. found: C, 57.33; H, 7.55; N, 4.14.

Synthesis of (2S,3S)-2-(3-Nitrophenyl)-3,5,5-trimethylmorpholin-2-ol(4g)

Compound 4g was synthesized by a procedure similar to that described for(2S,3S)-4a using (R)-1-(3-nitrophenyl)-2-hydroxypropan-1-one (10g, 4.0g, 0.021 mol), Proton sponge (5.2 g, 0.0246 mol), triflic anhydride (3.7mL, 0.023 mol), and 2-amino-2-methyl-1-propanol (4.0 g, 0.045 mol) inacetonitrile (45 mL). After purification, 1.0 g (18%) of the free base4g was isolated and converted to the hemi-D-tartrate salt, which had 94%ee: mp 192-193° C.; [α]²⁰ _(D) +6.5° (c 1.0, CH₃OH); ¹H NMR(methanol-d₄) δ 8.47-8.25 (m, 1H), 8.31-8.26 (m, 1H), 8.05-8.01 (m, 1H),7.73-7.66 (m, 1H), 4.34 (s, 1H), 4.18 (d, 1H, J=12.1 Hz), 3.59 (d, 1H,J=6.6 Hz), 3.50 (q, 1H, J=6.6 Hz), 1.60 (s, 3H), 1.35 (s, 3H), 1.07 (d,3H, J=6.6 Hz); ¹³C NMR (methanol-d₄) δ 178.3, 149.9, 145.3, 134.4,131.0, 125.0, 123.0, 96.8, 75.0, 68.1, 54.8, 24.7, 21.7, 14.6; LCMS(ESI) m/z 267.3 [(M-tartrate)', M=C₁₅H₂₁N₂O₇]; Anal.(C₁₅H₂₁N₂O₇.0.25H₂O) calcd: C, 52.09; H, 6.27; N, 8.10. found: C, 52.13;H, 6.22; N, 8.06.

Synthesis of (2S,3S)-2-(4-Fluorophenyl)-3,5,5-trimethylmorpholin-2-ol(4h)

A solution of 15 (166 mg, 1.16 mmol) in dry THF (1.2 mL, 1M) under an N₂atmosphere was cooled to −78° C. and treated with4-fluorophenylmagnesium bromide (1.3 equiv., 1.5 mmol, 1.9 mL, 0.8 Msolution in THF). The reaction mixture was stirred at −78° C. for 3 h. Asaturated aqueous solution of NH₄Cl was added to the reaction vessel,and the mixture was allowed to warm to room temperature. EtOAc (5 mL)was added to the reaction vessel and the organic layer was separated.The aqueous phase was extracted with EtOAc (three times). The combinedorganic extracts were washed (water, brine), dried (Na₂SO₄) andconcentrated. The residue was purified by column chromatography onsilica gel using CH₂Cl₂ to CH₂Cl₂-MeOH (90:10) as the eluent to afford80 mg of 4h as a white solid: [α]²² _(D) +31.2° (c 0.5, CHCl₃); ¹H NMR(CDCl₃) δ 7.60-7.55 (m, 2H), δ 7.08-7.00 (m, 2H), 3.83 (d, 1H, J=11.3Hz), 3.40 (d, 1H, J=11.3 Hz), 3.17 (q, 1H, J=6.4 Hz), 1.38 (s, 3H), 1.08(s, 3H), 0.78 (d, 3H, J=6.4 Hz); ¹³C NMR (CDCl₃) δ 128.0, 127.9, 114.87,114.58, 103.2, 98.4, 96.8, 69.5, 53.5, 27.3, 22.8, 16.4; LCMS (ESI) m/z240.0 [(M+H)⁺, M=C₁₃C₁₈FNO₂].

A sample of 4h (56.0 mg, 0.234 mmol) in ether (2 mL) was treated with asolution of fumaric acid (30.0 mg, 0.258 mmol) in MeOH (0.6 mL). Themixture was stirred at room temperature overnight. Filtration andwashing of the filter cake with ether, followed by recrystallization ofthe solid from MeOH-ether gave 45 mg (54%) of 4h.0.5 fumarate: mp178-182° C.; [α]²² _(D) +29° (c 0.6, MeOH); ¹H NMR (methanol-d₄) δ7.65-7.59 (m, 2H), 7.15-7.08 (m, 2H), 6.66 (s, 1H), 4.15 (d, 1H, J=12.2Hz), 3.52 (d, 1H, J=12.2 Hz), 3.41-3.33 (m, 1H), 1.56 (s, 3H), 1.32 (s,3H), 1.03 (d, 3H, J=6.6 Hz); ¹³C NMR (methanol-d₁) δ 136.7, 129.75,129.64, 115.92, 115.63, 67.5, 54.8, 54.1, 24.3, 21.3, 14.3; LCMS (ESI)m/z 240.3 [(M-fumaric)⁺, M=C₁₃H₁₈FNO₂.0.5C₄H₄O₄]; Anal. (C₁₅H₂₀FNO₄.H₂O)calcd: C, 57.13; H, 7.03; N, 4.44. found: C, 57.57; H, 6.90; N, 4.46.

Synthesis of (2S,3S)-2-(4-Chlorophenyl)-3,5,5-trimethylmorpholin-2-ol(4i)

A solution of 15 (357 mg, 2.50 mmol) in dry THF (2.5 mL, 1M) under an N₂atmosphere was cooled to −78° C. and treated with4-chlorophenylmagnesium bromide (2 equiv., 5.00 mmol, 5.00 mL, 1Msolution in ether). The reaction mixture was stirred at −78° C. for 2 h.A saturated aqueous solution of NH₄Cl was added to the reaction vessel,and the mixture was allowed to warm to room temperature. EtOAc was addedand the organic layer was separated and the aqueous phase was extractedwith EtOAc (trice). The combined organic extracts were washed (water,brine), dried (Na₂SO₄) and concentrated. The residue was purified bycolumn chromatography on silica gel using CH₂Cl₂ to CH₂Cl₂-MeOH (90:10)as the eluent to afford 180 mg (29%) of 4i as a white solid: [α]²³ _(D)+33° (c 0.4, CHCl₃): ¹H NMR (CDCl₃) δ 7.54 (d, 2H, J=8.5 Hz), 7.32 (d,2H, J=8.5 Hz), 3.83 (d, 1H, J=11.3 Hz), 3.40 (d, 1H, J=11.3 Hz), 3.18(q, 1H, J=6.5 Hz), 1.38 (s, 3H), 1.08 (s, 3H), 0.78 (d, 3H, J=6.5 Hz);¹³C NMR (CDCl₃) δ 128.5, 128.1, 127.6, 127.2, 101.6, 95.9, 69.5, 53.4,49.7, 27.3, 22.8, 16.4; LCMS (ESI) m/z 256.3 [(M+H)⁺, M=C₁₃H₁₈ClNO₂].

A sample of 4i (161 mg, 0.629 mmol) in ether (3 mL) was treated with asolution of fumaric acid (73.0 mg, 0.629 mmol) in MeOH (1.2 mL). Themixture was stirred at room temperature overnight. Filtration andwashing of the filter cake with ether, followed by recrystallizationfrom MeOH-ether gave 123 mg (53%) of 4i.0.5 fumarate as a white solid;mp 187-190° C.; [α]²² _(D)+22° (c 0.75, MeOH); ¹H NMR (methanol-d₄) δ7.58 (d, 2H, J=8.6 Hz), 7.41 (d, 1H, J=8.6 Hz), 6.67 (s, 1H), 4.11 (d,1H, J=12.0 Hz), 3.51 (d, 1H, J=12.0 Hz), 3.38-3.36 (m, 1H), 1.53 (s,3H), 1.28 (s, 3H), 1.00 (d, 3H, J=6.6 Hz); ¹³C NMR (methanol-d₁) δ172.9, 141.1, 136.7, 135.8, 129.3, 96.6, 67.4, 54.68, 54.37, 24.1, 21.2,14.1; LCMS (ESI) m/z 256.6 [(M-fumaric)⁺, M=C₁₃H₁₈ClNO₂.0.5C₄H₄O₄];Anal. (C₁₅H₂₀ClNO₄.0.5H₂O) calcd: C, 55.81; H, 6.56; N, 4.34. found: C,55.84; H, 6.58; N, 4.13.

Synthesis of (2S,3S)-3,5,5-Trimethyl-2-(4-methylphenyl)morpholin-2-ol(4j)

A solution of morpholin-2-one 15 (270 mg, 1.88 mmol) in anhydrous THF(1.9 mL) was cooled to −78° C. and treated with p-tolylmagnesium bromide(1.2 equiv., 2.26 mmol, 2.26 mL, 1 M solution in THF) under an N₂atmosphere. After stirring the reaction mixture at −78° C. for 1.5 h,saturated aqueous solution of NH₄Cl (30 mL) was added to the reactionvessel, and the mixture was allowed to warm to room temperature. Ether(30 mL) was added to the reaction flask, the organic layer wasseparated. The aqueous phase was extracted with ether (twice). Thecombined organic extracts were washed (water, brine), dried (Na₂SO₄) andconcentrated. The residue was purified by column chromatography onsilica gel using CH₂Cl₂ to CH₂Cl₂-MeOH (90:10) as the eluent to give 271mg (41%) of 4j as a yellow foam: [α]²² _(D) +21.2° (c 0.9, CHCl₃); ¹HNMR (CDCl₃) δ 7.47 (d, 2H, J=8.2 Hz), 7.16 (d, 2H, J=8.0 Hz), 3.85 (d,1H, J=11.3 Hz), 3.40 (d, 1H, J=11.2 Hz), 3.20-3.07 (m, 1H), 2.35 (s,3H), 1.39 (s, 3H), 1.08 (s, 3H), 0.81 (d, 3H, J=6.5 Hz); ¹³C NMR (CDCl₃)δ 129.6, 128.60, 128.49, 125.9, 103.2, 96.2, 69.4, 53.9, 53.4, 49.6,27.3, 22.8, 16.5; LCMS (ESI) m/z 236.3 [(M+H)⁺, M=C₁₄H₂₁NO₂].

A sample of 4j (240 mg, 0.683 mmol) in ether (3 mL) was treated with asolution of fumaric acid (87.0 mg, 0.751 mmol) in MeOH (2 mL) andstirred at room temperature overnight. Ether was added to the reactionmixture. The solid was recrystallized from MeOH-ether to give 140 mg(67%) of 4j.0.5 fumarate as a white solid: mp 178-182° C.; [α]²² _(D)+19° (c 0.6, MeOH); ¹H NMR (methanol-d₄) δ 7.47 (d, 2H, J=8.2 Hz), 7.21(d, 2H, J=8.0 Hz), 6.65 (s, 1H), 4.18 (d, 1H, J=12.2 Hz), 3.51 (d, 1H,J=12.2 Hz), 3.46 (q, 1H, J=6.6 Hz), 2.35 (s, 3H), 1.58 (s, 3H), 1.34 (s,3H), 1.04 (d, 1H, J=6.6 Hz); ¹³C NMR (methanol-d₄) δ 139.9, 139.2,136.9, 129.8, 127.4, 96.8, 67.2, 54.9, 54.6, 24.1, 21.1, 14.1; LCMS(ESI) m/z 236.2 [(M-fumaric)⁺ C₁₄H₂₁NO₂.0.5C₄H₄O₄]; Anal.(C₁₆H₂₃NO₄.0.25H₂O) calcd: C, 64.52; H, 7.95; N, 4.70. found: C, 64.56;H, 7.76; N 4.65.

Synthesis of (2S,3S)-2-(4-Methoxyphenyl)-3,5,5-trimethylmorpholin-2-ol(4k)

A solution of 15 (434 mg, 3.03 mmol) in anhydrous THF (3 mL, 1M) wascooled to −78° C. and treated with 4-methoxyphenylmagnesium bromide (1.3equiv., 3.93 mmol, 3.9 mL of 1 M solution in THF). The reaction mixturewas stirred at −78° C. and under an N₂ atmosphere for 1.5 h. A saturatedaqueous solution of NH₄Cl (30 mL) was added to the reaction vessel, andthe mixture was allowed to warm to room temperature. The mixture wasextracted with ether (three times). The combined ether extracts werewashed (water, brine), dried (Na₂SO₄) and concentrated. The residue waspurified by column chromatography on silica gel using CH₂Cl₂ toCH₂Cl₂-MeOH—NH₄OH (90:9:1) as the eluent to give 380 mg of a yellowsolid.

The sample (379 mg, 0.783 mmol) in ether (5 mL) was treated with HCl(1.00 mmol, 0.250 mL, 4 M solution in dioxane). The mixture was stirredat room temperature overnight. Ether was added to the reaction mixture.The suspension was sonicated, centrifuged, and decanted three times toafford a solid pellet. The solid material was recrystallized fromMeOH-ether to give 215 mg (95%) of 4k.HCl as a pale yellow solid: mp170-172° C.; [α]²⁰ _(D) +19.6° (c 1.0, MeOH). ¹H NMR (methanol-d₄) δ7.52 (d, 2H, J=8.9 Hz), 6.95 (d, 2H, J=8.9 Hz), 4.22 (d, 1H, J=12.4 Hz),3.81 (s, 3H), 3.58-3.45 (m, 2H), 1.62 (s, 3H), 1.39 (s, 3H), 1.10 (d,3H, J=6.6 Hz); ¹³C NMR (methanol-d₄) δ 161.8, 133.5, 132.8, 128.8,114.6, 96.7, 66.6, 55.80, 55.7, 55.2, 23.4, 20.8, 13.7; LCMS (ESI) m/z286.4 (M−H)⁺, M=C₁₄H₂₁NO₃.HCl]; Anal. (C₁₄H₂₂ClNO₃) calcd: C, 58.43; H,7.71; N, 4.87. found: C, 58.42; H, 7.83; N, 4.81.

Synthesis of (2S,3S)-2-Biphenyl-4-yl-3,5,5-trimethylmorpholin-2-ol (4l)

A solution of 15 (394 mg, 2.75 mmol) in anhydrous THF (2.75 mL, 1M) wascooled to −78° C. and treated with 4-biphenylmagnesium bromide (1.2equiv., 3.30 mmol, 6.60 mL, 0.5 M solution in THF) under an N₂atmosphere. After stirring at −78° C. for 1.5 h, the reaction mixturewas treated with saturated aqueous solution of NH₄Cl (40 mL) and EtOAcwas added (30 mL). The organic layer was separated. The aqueous phasewas extracted with EtOAc trice. The combined organic extracts werewashed (water, brine), dried (Na₂SO₄) and concentrated. Purification ofthe residue by column chromatography on silica gel using CH₂Cl₂ toCH₂Cl₂-MeOH (90:10) as the eluent afforded 300 mg (37%) of 4l as a whitesolid: [α]²³ _(D) +15.2° (c 0.3, CHCl₃); ¹H NMR (CDCl₃) δ 7.70-7.33 (m,9H), 3.88 (d, 1H, J=11.3 Hz), 3.44 (d, 1H, J=11.3 Hz), 3.29-3.25 (m,1H), 1.42 (s, 3H), 1.10 (s, 3H), 0.86 (d, 3H, J=6.5 Hz); ¹³C NMR (CDCl₃)δ 140.9, 129.0, 128.97, 128.74, 128.4, 127.54, 127.30, 127.13, 126.7,126.5, 96.2, 69.5, 53.4, 51.4, 49.6, 27.4, 22.8, 16.6; LCMS (ESI) m/z298.4, 280.3 [(M+H)⁺, M=C₁₉H₂₃NO₂].

A sample of 4l (379 mg, 1.27 mmol) in CH₂Cl₂ (4 mL) was treated with asolution of fumaric acid (148 mg, 1.27 mmol) in MeOH (4 mL) The mixturewas stirred at room temperature overnight. Filtration and washing of thefilter cake with ether, followed by recrystallization from MeOH-ethergave 130 mg (25%) of 4l.0.5 fumarate as a white solid: mp 197-202° C.;[α]²² _(D) +18° (c 1.6, MeOH); ¹H NMR (methanol-d₄) δ 7.70-7.63 (m, 6H),7.49-7.35 (m, 3H), 6.69 (s, 1H), 4.20 (d, 1H, J=12.1 Hz), 3.55 (d, 1H,J=12.1 Hz), 3.47 (q, 1H, J=6.7 Hz), 1.60 (s, 3H), 1.34 (s, 3H), 1.08 (d,3H, J=6.6 Hz); ¹³C NMR (methanol-d₄) δ 142.9, 141.8, 141.4, 136.7,129.9, 128.6, 128.04, 128.02, 127.7, 96.9, 67.5, 54.8, 54.1, 30.7, 24.4,21.3, 14.4; LCMS (ESI) m/z 298.6, 280.3 [(M-fumaric)⁺,M=C₁₉H₂₃NO₂.0.5C4H₄O₄]; Anal (C₂₁H₂₅NO₄.0.75H₂O) calcd: C, 68.36; H,7.24; N, 3.80. found: C, 68.59; H, 7.22; N, 3.76.

Synthesis of(2S,3S)-2-(3,4-Difluorophenyl)-3,5,5-trimethylmorpholin-2-ol (4m)

A solution of morpholin-2-one 15 (410 mg, 2.86 mmol) in anhydrous THF(2.9 mL, 1M) was cooled to −78° C. and treated with3,4-difluorophenylmagnesium bromide (1.2 equiv., 3.43 mmol, 6.90 mL, 0.5M solution in THF) under an N₂ atmosphere. After stirring the reactionmixture at −78° C. under an inert atmosphere for 1.5 h, saturatedaqueous solution of NH₄Cl was added to the reaction vessel. The reactionmixture was allowed to warm to room temperature and extracted with ether(three times). The combined organic extracts were washed (water, brine),dried (Na₂SO₄) and concentrated. Purification of the residue by columnchromatography on silica gel using CH₂Cl₂ to CH₂Cl₂-MeOH—NH₄OH (90:9:1)as the eluent gave 190 mg (25%) of 4m as a yellow solid: [α]²² _(D)+18.2° (c 1.0, CHCl₃); ¹H NMR (CDCl₃) δ 7.45-7.39 (m, 1H), 7.34-7.32 (m,1H), 7.18-7.10 (m, 1H), 3.82 (d, 1H, J=11.3 Hz), 3.40 (d, 1H, J=11.3Hz), 3.18 (q, 1H, J=6.5 Hz), 1.38 (s, 3H), 1.08 (s, 3H), 0.78 (d, 3H,J=6.5 Hz); ¹³C NMR (CDCl₃) δ 122.40, 122.31 116.74, 116.51, 115.8,115.6, 96.5, 69.6, 53.4, 49.8, 27.3, 22.8, 16.5; LCMS (ESI) m/z 258.6,[(M+H)⁺, M=C₁₃H₁₇F₂NO₂].

A sample of 4m (180 mg, 0.699 mmol) in ether (3 mL) was treated with asolution of fumaric acid (80.0 mg, 0.689 mmol) in MeOH (2.5 mL). Themixture was stirred at room temperature overnight. Ether was added tothe reaction mixture. The suspension was sonicated, centrifuged, anddecanted to afford a solid pellet that was recrystallization fromMeOH-ether. The suspension was sonicated, centrifuged, and decantedthree times to afford 119 mg (53%) of 4m.0.5 fumarate as a white solid:mp 187-189° C.; [α]²² _(D) +29 (c 0.5, MeOH); ¹H NMR (methanol-d₄) δ7.52-7.41 (m, 2H), 7.38-7.22 (m, 1H), 6.65 (s, 1H), 4.34 (s, 1H), 4.15(d, 1H, J=12.2 Hz), 3.54 (d, 1H, J=12.2 Hz), 3.46 (q, 1H, J=6.6 Hz),1.57 (s, 3H), 1.33 (s, 3H), 1.06 (d, 3H, J=6.6 Hz); ¹³C NMR(methanol-d₄) δ 136.7, 124.4, 118.1, 117.8, 117.1, 116.9, 98.2, 67.5,54.58, 54.36, 24.1, 21.2, 14.1; LCMS (ESI) m/z 258.6, [(M-fumaric)⁺M=C₁₃H₁₇F₂NO₂.0.5C₄H₄O₄]; Anal. (C₁₅H₁₉F₂NO₄.0.5H₂O) calcd: C, 55.55; H,6.22; N, 4.32. found: C, 55.72; H, 6.07; N, 4.25.

Synthesis of 2-(3,4-Dichlorophenyl)-3,5,5-trimethylmorpholin-2-ol[(±)-4n]

To a solution of 3′,4′-dichloropropiophenone (81, 5.02 g, 0.247 mol) inCH₂Cl₂ (100 mL) was added ten drops of bromine. After stirring at roomtemperature under nitrogen for several min, the characteristic red colorof bromine disappeared indicating initiation of the reaction. Theremainder of the bromine (1.27 mL, 24.7 mmol) was added dropwise and thereaction solution was allowed to stir at room temperature under nitrogenatmosphere for 1.75 h. Analysis by TLC (silica, 2:1 hexane:CH₂Cl₂)indicated consumption of starting material. The reaction solution wasquenched and brought to a pH of 9 with a saturated aqueous solution ofNaHCO₃ and concentrated NH₄OH. The solution was extracted with CH₂Cl₂,dried (Na₂SO₄), filtered, concentrated, and dried to give 7.14 g (100%)of 2-bromo-(3′,4′-dichlorophenyl)propan-1-one as a white solid.Characterization data is similar with data reported in Anderson, W. K.;Jones, A. N., J. Med. Chem. 1984, 27, (12), 1559-1565.

2-Bromo-(3′,4′-dichlorophenyl)propan-1-one (6.97 g, 0.025 mol) in aminimal amount of CH₂Cl₂ was transferred to a sealable reaction tube.Most of the CH₂Cl₂ was removed via positive nitrogen flow.2-Amino-2-methyl-1-propanol (23.6 mL, 247 mmol) was added in oneportion, and the tube was sealed and placed in an oil bath heated to 75°C. After stirring at 75° C. overnight, analysis by TLC (silica, 9:1:20ether-Et₃N-hexane) showed only a trace amount of starting materialremaining and the reaction was allowed to cool to room temperature. Thereaction mixture was quenched and brought to a pH of 10 with a saturatedaqueous solution of NaHCO₃ and the product was extracted with CH₂Cl₂.The organic layer was separated, dried (Na₂SO₄), filtered, concentrated,and dried to give 11.29 g of a yellow oil. The residue was purified bycolumn chromatography on silica gel using ether-Et₃N-hexane (9:1:50) aseluent to give 3.50 g (49%) of 4n as a white solid: ¹H NMR (250 MHz,DMSO-d₆) δ 7.70-7.67 (m, 1H), 7.47-7.39 (m, 2H), 3.81 (d, 1H), 3.40 (d,1H), 3.22-3.14 (m, 1H), 1.38 (s, 3H), 1.08 (s, 3H), 0.78 (d, 3H).

A solution of (±)-4n (3.34 g, 0.012 mol) in methanol was treated withfumaric acid (1.34 g, 0.012 mol). The mixture was allowed to stir for 15min and a white solid precipitated out of solution, which was collectedby vacuum filtration to afford 2.23 g (53%) of 4n.0.5 fumarate as awhite solid: mp 188-189° C.; ¹H NMR (250 MHz, DMSO-d₆) δ 7.68-7.62 (m,2H), 7.52-7.48 (m, 1H), 3.77 (d, 1H), 3.36 (d, 1H), 3.13-3.07 (q, 1H),1.33 (s, 3H), 1.07 (s, 3H), 0.76 (d, 3H); Anal. (C₁₅H₁₉Cl₂NO₄) calcd: C,51.74; H, 5.50; N, 4.02. found: C, 51.48; H, 5.55; N, 3.95.

Synthesis of(2S,3S)-2-(3,5-Difluorophenyl)-3,5,5-trimethylmorpholin-2-ol (4o)

A solution of 15 (448 mg, 3.13 mmol) in anhydrous THF (3 mL, 1M) wascooled to −78° C. and treated with 3,5-dipfluorophenylmagnesium bromide(1.2 equiv., 3.75 mmol, 7.5 mL, 0.5 M solution in THF). The reactionmixture was stirred at −78° C. and under an N₂ atmosphere for 1.5 h.Saturated aqueous solution of NH₄Cl was added to the reaction vessel,and the mixture was allowed to warm to room temperature. The reactionmixture was extracted with ether (three times). The combined etherextracts were washed (water, brine), dried (Na₂SO₄) and concentrated.Purification of the residue by column chromatography on silica gel usingCH₂Cl₂ to CH₂Cl₂-MeOH—NH₄OH (90:9:1) as the eluent gave 105 mg (13%) of4o as a yellow solid: [α]²² _(D) +19.5° (c 0.8, CHCl₃); ¹H NMR (CDCl₃) δ7.16-7.10 (m, 2H), 6.82-6.67 (m, 1H), 3.81 (d, 1H, J=12.0 Hz), 3.40 (d,1H, J=12.0 Hz), 3.18 (q, 1H, J=6.0 Hz), 1.39 (s, 3H), 1.12 (s, 3H), 0.83(d, 3H, J=6.5 Hz); ¹³C NMR (CDCl₃) δ 109.63, 109.40, 103.9, 103.5,103.2, 95.8, 69.2, 53.3, 50.1, 49.6, 26.9, 22.5, 15.2; LCMS (ESI) m/z258.8 [(M+H)⁺, M=C₁₃H₁₇F₂NO₂].

A sample of 4o (71.0 mg, 0.275 mmol) in CH₂Cl₂ (1.5 mL) was treated withHCl (0.386 mmol, 0.100 mL solution 4M in dioxane). The mixture wasstirred at room temperature overnight and ether was added to thereaction mixture. The suspension was sonicated, centrifuged, anddecanted to afford a solid pellet; this procedure was repeated threetimes. The solid material was recrystallized from methanol-ether. Thesuspension was sonicated, centrifuged, decanted and dried to give 60 mg(74%) of 4o.HCl as a pale yellow solid: mp 199-204° C.; [α]²² _(D)+21.5° (c 1.0, MeOH); ¹H NMR (methanol-d₄) δ 7.23-7.18 (m, 2H),7.03-6.92 (m, 1H), 4.19 (d, 1H, J=12.0 Hz), 3.65-3.54 (m, 2H), 1.62 (s,3H), 1.39 (s, 3H), 1.12 (d, 3H, J=6.0 Hz); ¹³C NMR (methanol-d₄) δ166.1, 162.8, 111.1, 110.9, 105.6, 105.2, 104.9, 66.9, 55.6, 54.5, 23.5,20.9, 13.7; LCMS (ESI) m/z 258.5 [(M-HCl)⁺, M=C₁₃H₁₇F₂NO₂.HCl]; Anal.(C₁₃H₁₈ClF₂NO₂) calcd: C, 53.16; H, 6.18; N, 4.77. found: C, 53.09; H,6.18; N, 4.71.

Synthesis of 2-(3,5-Dichlorophenyl)-3,5,5-trimethylmorpholin-2-ol[(±)-4p]

To a stirred solution of 3,5-dichloropropiophenone (8m, 3.81 g, 0.0188mol) in CH₂Cl₂ (28 mL) was added bromine (0.986 mL, 19.1 mmol) dropwise.The bromine was immediately consumed upon addition of each drop untilthe end of addition when it had a consistent brownish color, indicativeof excess bromine. The reaction was immediately quenched with saturatedaqueous NaHCO₃, extracted three times with CH₂Cl₂. The organic layer wasseparated, combined and concentrated under reduced pressure, withoutdrying to afford a yellow oil. The oil was dissolved in anhydrousdiethyl ether (50 mL) and 2-amino-2-methyl-1-propanol (6.7 g, 0.075 mol)was added. The reaction mixture was stirred overnight and quenched withsaturated aqueous NaHCO₃. The aqueous layer was extracted three timeswith CH₂Cl₂, and the organic layers concentrated to afford anotheryellow oil. Purification by column chromatography on silica gel afforded2.51 g (46%) of the title compound. The hemi-fumarate salt was preparedby dissolving the free base in methanol and adding 1.0 g of fumaric acidto form the title compound: mp 188-190° C.; ¹H NMR (DMSO-d₆) δ 7.58-7.57(m, 1H), 7.47 (m, 2H), 6.67 (s, 0.5H), 4.09 (d, 1H, J=11.9 Hz), 3.53 (d,1H, J=12.0 Hz), 3.41-3.37 (m, 1H), 1.53 (s, 3H), 1.28 (s, 3H), 1.02 (d,3H, 6.6 Hz); ¹³C NMR (DMSO-d₆) δ 134.9, 133.6, 127.7, 125.2, 94.7, 67.2,52.5, 50.1, 25.0, 21.6, 14.6; Anal. (C₁₅H₁₉Cl₂NO₄.0.25H₂O) calcd: C,51.08; H, 5.57; N, 3.97. found: C, 51.13; H, 5.64; N, 3.90.

Synthesis of (2S,3S)-2-(Naphthalen-1-yl)-3,5,5-trimethylmorpholin-2-ol(4q)

Compound 4q was synthesized by a procedure similar to that described for(2S,3S)-4a employing (R)-2-hydroxy-1-(naphthalen-1-yl)propan-1-one (10h,1.15 g, 0.058 mol), Proton sponge (1.5 g, 0.070 mol), triflic anhydride(1.1 mL, 64 mmol), and 2-amino-2-methyl-1-propanol (1.1 g, 0.012 mol) inCH₃CN (45 mL). After purification, 1.35 g (86%) of the free base 4q wasisolated and converted to the D-tartrate salt, which was recrystallizedfrom H₂O-MeOH-Et₂O solvent system: mp 115-116+C.; [α]²⁰ _(D) −9.5° (c0.74, CH₃OH); ¹H NMR (methanol-d₄) δ 8.89 (d, 1H, J=8.4 Hz), 7.97-7.89(m, 3H), 7.54-7.50 (m, 3H), 4.33 (s, 1H), 3.70 (d, 1H, J=12.2 Hz), 3.48(q, 1H, J=7.0 Hx), 1.77 (s, 3H), 1.41 (s, 3H), 0.96 (d, 3H, J=6.6 Hz);¹³C NMR (methanol-d₄) δ 136.5, 132.3, 131.9, 130.5, 130.2, 128.1, 127.4,127.0, 126.1, 99.0, 75.1, 68.1, 67.3, 53.9, 24.8, 22.9, 15.8, 15.2; LCMS(ESI) m/z 272.3 [(M-tartrate)⁺, M=C₁₉H₂₄NO₅]; Anal. (C₁₉H₂₄NO₅.0.75H₂O)calcd: C, 63.41; H, 7.14; N, 3.89. found: C, 63.63; H, 7.44; N, 3.70.

Synthesis of (2S,3S)-2-(Naphthalen-2-yl)-3,5,5-trimethylmorpholin-2-ol(4r)

Compound 4r was synthesized by a procedure similar to that described for(2S,3S)-4a using (R)-2-hydroxy-1-(naphthalen-2-yl)propan-1-one (10i, 2.5g, 0.013 mol), Proton sponge (3.24 g, 0.0151 mol), triflic anhydride(2.4 mL, 137 mmol), and 2-amino-2-methyl-1-propanol (2.4 g, 0.027 mol)in acetonitrile (40 mL). After purification, 2.2 g (65%) of the freebase 4r was isolated and converted to the hemi-D-tartrate salt: mp179-180° C.; [α]²⁰ _(D) −1.5° (c 0.55, CH₃OH); ¹H NMR (methanol-d₄) δ8.13-8.12 (m, 1H), 7.95-7.88 (m, 3H), 7.75-7.71 (m, 1H), 7.57-7.50 (m,2H), 4.33 (s, 1H), 4.25 (d, 1H, J=11.9 Hz), 3.66-3.57 (m, 2H), 1.65 (s,3H), 1.37 (s, 3H), 1.09 (d, 3H, J=6.6 Hz); ¹³C NMR (methanol-d₄) δ178.7, 139.9, 135.3, 134.6, 129.8, 129.33, 129.00, 128.0, 127.8, 127.4,125.4, 97.4, 75.2, 67.7, 55.1, 24.5, 21.6, 14.6; LCMS (ESI) m/z 272.5[(M-tartrate)⁺, M=C₁₉H₂₄NO₅]; Anal. (C₁₉H₂₄NO₅.0.5H₂O) calcd: C, 65.88;H, 6.98; N, 4.04. found: C, 65.75; H, 7.03; N, 4.06.

Synthesis of(2S,3S)-2-(3-Chlorophenyl)-3-ethyl-5,5-dimethylmorpholin-2-ol (4s)

Compound 4s was synthesized by a procedure similar to that described for(2S,3S)-4a using (R)-1-(3-chlorophenyl)-2-hydroxybutan-1-one (10j, 1.13g, 0.0568 mol), Proton sponge (1.43 g, 0.0667 mol), triflic anhydride(1.0 g, 0.063 mol), and 2-amino-2-methyl-1-propanol (1.09 g, 0.0122 mol)in CH₂Cl₂ (13 mL). After purification, the free base 4r was converted to0.230 g of its D-tartrate salt: mp 160-161° C.; [α]²⁰ _(D) +5.6° (c 0.8,CH₃OH); ¹H NMR (methanol-d₄) δ 7.49-7.46 (m, 1H), 7.41-7.35 (m, 3H),4.37-4.34 (m, 1H), 4.30-4.24 (m, 1H), 3.81-3.62 (m, 2H), 1.57 (s, 3H),1.47-1.36 (m, 2H), 1.33 (s, 3H), 0.81-0.71 (m, 3H); ¹³C NMR(methanol-d₄) δ 178.5, 145.2, 135.6, 131.2, 130.3, 128.2, 126.5, 97.1,75.0, 67.8, 61.1, 55.0; LCMS (ESI) m/z 270.4 [(M-tartrate)⁺,M=C₁₆H₂₃ClNO₅); Anal. (C₁₆H₂₃ClNO₅.0.25H₂O) calcd: C, 55.01; H, 6.78; N,4.01. found: C, 54.99; H, 6.85; N, 4.08.

Synthesis of(2S,3S)-2-(3-Chlorophenyl)-5,5-dimethyl-3-propyl-morpholin-2-ol (4t)

Compound 4t was synthesized by a procedure similar to that described for(2S,3S)-4a using (R)-1-(3-chlorophenyl)-2-hydroxypent-1-one (10k, 1.5 g,0.0704 mol), Proton sponge (1.8 g, 0.0840 mol), triflic anhydride (1.29g, 0.081 mol), and 2-amino-2-methyl-1-propanol (1.42 g, 0.0159 mol) inCH₂Cl₂ (7 mL). After purification, 790 mg (40%) of the free base 4t wasisolated and converted to the hemi-D-tartrate salt, which had 99% ee: mp151-152° C., [α]²⁰ _(D) −10.1° (c 0.77, CH₃OH); ¹H NMR (methanol-d₄) δ7.50-7.47 (m, 1H), 7.43-7.36 (m, 3H), 4.38 (s, 1H), 4.32 (d, 1H, J=10.0Hz), 3.81-3.66 (m, 1H), 1.58 (s, 3H), 1.49-1.38 (m, 2H), 1.35 (s, 3H),1.34-1.27 (m, 1H), 1.02-0.92 (m, 1H), 0.77 (t, 3H, J=7.0 Hz); ¹³C NMR(methanol-d₄) δ 176.1, 142.9, 133.3, 128.9, 128.0, 125.9, 124.2, 94.8,72.7, 65.4, 57.0, 52.7, 29.9, 22.0, 19.3, 18.2, 12.1; Anal.(C₁₇H₂₅ClNO₅) calcd: C, 56.90; H, 7.02; N, 3.90. found: C, 56.46; H,7.01; N, 3.79.

Synthesis of(2S,3S)-2-(3-Chlorophenyl)-3,4,5,5-tetramethylmorpholin-2-ol (4u)

A sample of (2S,3S)-2-(3-Chlorophenyl)-3,5,5-trimethylmorpholin-2-ol(4i, 107 mg, 0.42 mmol) in DMF (2.0 mL) was treated with K₂CO₃ (174 mg,1.26 mmol). After stirring the reaction mixture at room temperatureunder an inert atmosphere for 1.5 h, CH₃I (19.0 μL, 0.3 mmol) was addedto the reaction flask and the reaction mixture was stirred at 70° C. for24 h. The reaction mixture was cooled to 0° C. water added, followed byextraction with ether (thee times). The combined organic extracts werewashed (water, brine), dried (Na₂SO₄) and concentrated to a pale yellowoil. Purification of the residue by column chromatography gave a 72 mg(63%) of 4u as a white solid. The compound 4u was converted to thecorresponding di-p-tolyl-L-tartrate salt: mp 128-129° C.; [α]²⁰ _(D)−50.0° (c 0.83, CH₃OH); ¹H NMR (DMSO-d₆) δ 7.85 (d, 4H, J=7.8 Hz),7.50-7.40 (m, 4H), 7.32 (d, 4H, J=7.8 Hz), 5.6 (s, 2H), 4.07 (d, 1H,J=12.4 Hz), 3.50-3.40 (m, 1H), 2.56 (s, 3H), 2.36 (s, 6H), 1.40 (s, 3H),1.21 (s, 3H), 0.90 (d, 3H, J=6.2 Hz); ¹³C NMR (DMSO-d₆) δ 168.2, 164.9,143.9, 132.7, 129.9, 129.3 (d), 128.6, 126.67, 126.31, 125.3, 96.4,72.2, 66.2, 60.4, 59.2, 33.3, 21.1, 15.9, 11.5; Anal.(C₃₄H₃₈ClNO₁₀.2H₂O) calcd: C, 59.00; H, 6.12; N, 2.02. found: C, 58.89;H, 6.01; N, 2.00.

Synthesis of(2S,3S)-2-(4-Chlorophenyl)-3,4,5,5-tetramethylmorpholin-2-ol (4v)

A sample of (4i) (144 mg, 0.563 mmol) in anhydrous THF (1.9 mL) wastreated with K₂CO₃ (4 folds, 311 mg, 2.25 mmol). After stirring thereaction mixture at room temperature under inert atmosphere for 1 h,CH₃I (1.3 equiv., 46.0 μL, 0.731 mmol) was added to the reaction flask.The reaction mixture was stirred at room temperature for 24 h, cooled to0° C. and water added, followed by extraction with ether (thee times).The combined organic extracts were washed (water, brine), dried (Na₂SO₄)and concentrated to a pale yellow oil. Purification of the residue bycolumn chromatography on silica gel and CH₂Cl₂-MeOH—NH₄OH (90:9:1) asthe eluent gave 93.0 mg (61%) of a white solid: mp=75-78° C.; [α]²² _(D)+28.0° (c 1.0, CHCl₃); ¹H NMR δ 7.58-7.53 (m, 2H), 7.34-7.31 (m, 2H),4.52-4.49 (br, 1H), 3.90 (d, 1H, J=11.6 Hz), 3.32 (d, 1H, J=11.6 Hz),2.85 (q, 1H, J=6.5 Hz), 2.20 (s, 3H), 1.19 (s, 3H), 1.07 (s, 3H), 0.76(d, 3H, J=6.5 Hz); ¹³C NMR δ 133.9, 128.59, 128.36, 128.05, 127.7, 97.5,70.4, 59.3, 53.8, 32.3, 25.5, 14.4, 13.1; MS (ESI) m/z 270.4 [(M+H)⁺M=C₁₄H₂₀ClNO₂].

A sample of 4v (90 mg, 0.33 mmol) in ether (1.5 mL) was treated with asolution of fumaric acid (38 mg, 0.33 mmol) in MeOH (1 mL) The mixturewas stirred at room temperature overnight. Ether was added to thereaction mixture. The suspension was sonicated, centrifuged, anddecanted to afford a solid pellet; this procedure was repeated threetimes. Recrystallization from MeOH/ether afforded the title product aswhite solid 101 mg (77%): mp=167-169° C.; [α]²² _(D) +44.3° (c 1.0,MeOH); ¹H NMR (methanol-d₄) δ 7.60 (d, 2H, J=8.6 Hz), 7.43 (d, 2H, J=8.6Hz), 6.68 (s, 2H), 4.35 (d, 1H, J=12.8 Hz), 3.64-3.54 (m, 2H), 2.79 (s,3H), 1.60 (s, 3H), 1.41 (s, 3H), 1.14 (d, 3H, J=6.5 Hz); ¹³C NMR(methanol-d₄) δ 171.4, 140.9, 136.3, 129.4, 98.1, 67.6, 63.4, 62.5,34.3, 21.8, 20.8, 16.9, 12.3; MS (ESI) m/z 270.4 [(M-fumaric)⁺,M=C₁₄H₂₀ClNO₂.C₄H₄O₄]; Anal. (C₁₈H₂₄ClNO₆.0.5H₂O) calcd: C, 54.75; H,6.38; N, 3.55. found: C, 54.53; H, 6.27; N, 3.58.

Synthesis of 3,5,5-Trimethyl-2-(pyridin-3-yl)morpholin-2-ol (5)

A sample of 1-(pyridin-3-yl)propan-1-one (8o, 685 mg, 5.00 mmol) wasdissolved in CCl₄ (20 mL). Bromine (0.26 mL, 5 mmol) was added to thereaction flask, and the reaction mixture was gently refluxed for 1 h.The solvent was decanted. The deep red solid at the bottom of flask waswashed with ether, dried, suspended in CH₃CN (40 mL), and treated with2-amino-2-methyl-1-propanol (0.89 g, 0.01 mol). The reaction mixture wasstirred for 8 h. The precipitate was removed by filtration and thefiltrate was extracted with EtOAc. The organic layer was washed withaqueous NaHCO₃, dried (Na₂SO₄) and concentrated to a deep red oilresidue. The oily residue was purified by column chromatography onsilica gel and CH₂Cl₂-MeOH (20:1 to 5:1) with 1% NH₄OH) to give 56 mgfree base that was converted to 5.tartrate as a yellow solid: mp115-116° C.; ¹H NMR (CDCl₃) δ 8.85-8.83 (m, 1H), 8.54 (dd, 1H, J=4.7,1.7 Hz), 7.91 (tt, 1H, J=8.0, 2.0 Hz), 7.31-7.25 (m, 1H), 3.85-3.82 (m,1H), 3.42 (d, 1H, J=11.2 Hz), 3.21 (q, 1H, J=6.5 Hz), 1.40 (s, 3H), 1.10(s, 3H), 0.81 (d, 3H, J=6.5 Hz); ¹³C NMR (CDCl₃) δ 149.4, 148.1, 137.2,134.1, 122.8, 95.4, 69.4, 53.55, 49.8, 27.4, 22.8, 16.4; LCMS (ESI) m/z223.3 [(M-tartrate)⁺, M=C₁₆H₂₄N₂O₈]; Anal. (C₁₆H₂₄N₂O₈.0.75H₂O) calcd:C, 48.90; H, 6.66; N, 7.26. found: C, 49.92; H, 6.51; N, 6.87.

Synthesis of 3,5,5-Trimethyl-2-(pyridin-2-yl)morpholin-2-ol (6)

1-(Pyridin-2-yl)propan-1-one (8n, 1.71 g, 0.013 mol) was dissolved inCCl₄ (50 mL). Bromine (0.66 mL, 12.7 mmol) was added and gently refluxedfor 1 h. The solvent was decanted. The orange solid at the bottom offlask was washed with ether, vacuum dried, and then suspend in CH₃CN (40mL), followed by the addition of 2-amino-2-methyl-1-propanol (2.30 g,0.0254 mol). The reaction mixture was stirred for 24 h. The precipitatewas separated by filtration and was extracted with EtOAc. The organiclayer was washed with aqueous NaHCO₃ and dried (Na₂SO₄) and concentratedto give a orange oil. The residue was purified by column chromatographyon silica gel using, CH₂Cl₂-MeOH (50:1 to 20:1) with 1% NH₄OH) to give0.94 g (33%) of free base that was converted to the correspondingtartrate salt: ¹H NMR (CDCl₃) δ 8.55-8.51 (m, 1H), 7.84-7.59 (m, 1H),7.63-7.57 (m, 1H), 7.34-7.26 (m, 1H), 6.00 (s, 1H), 3.97-3.91 (m, 1H),3.47-3.37 (m, 2H), 1.42 (s, 3H), 1.10 (s, 3H), 0.74 (d, 3H, J=6.5 Hz);¹³C NMR (CDCl₃) δ 158.6, 147.2, 137.5, 123.6, 120.5, 94.2, 70.0, 52.1,48.9, 27.1, 22.9, 16.2; LCMS (ESI) m/z 223.4 [(M-tartrate)⁺,M=C₁₆H₂₄N₂O₈]; Anal (C₁₆H₂₄N₂O₈.0.5H₂O) calcd: C, 50.39; H, 6.61; N,7.35. found: C, 50.44; H, 6.80; N, 7.09.

Synthesis of 1-Naphthalen-1-ylpropan-1-one (8 q)

A sample of 1-cyanonaphthylene (7a, 5.0 g, 0.0327 mol) in dry diethylether (200 mL) was treated with ethyl magnesium bromide (49.2 mol, 16.4mL 3 M solution in ether) under nitrogen atmosphere at room temperature.The solution was stirred overnight at 25° C. and then cooled to 0° C.The reaction was quenched slowly with 1 N aqueous HCl and allowed towarm to room temperature over 1 h with stirring. The aqueous layer wasextracted with ether. The combined organic layers were washed withaqueous NaHCO₃, water and brine, and dried (Na₂SO₄). The organic layerswere concentrated and the resulting yellow oil was purified by columnchromatography on silica gel using hexane-EtOAc (20:1) to (10:1) as theeluent afforded 3.55 g (60%) of the title product: ¹H NMR (CDCl₃) δ8.59-8.52 (m, 1H), 8.00-7.94 (m, 1H), 7.90-7.81 (m, 2H), 7.62-7.45 (m,3H), 3.08 (q, 2H, J=7.3 Hz), 1.29 (t, 3H, J=7.3 Hz). C₁₃H₁₂O.

Synthesis of 1-Naphthalen-2-ylpropan-1-one (8r)

Compound 8r was synthesized by a procedure similar to that described for8q using identical amounts, except commercially available2-cyanonaphthylene (7b) was used in place of 1-cyanonaphthylene.Purification by column chromatography on silica gel using hexane-EtOAc(20:1) to (10:1) afforded 4g (66%) of the title product as a whitesolid: ¹H NMR (CDCl₃) δ 8.48 (s, 1H), 8.05 (d, 1H, J=7.5 Hz), 8.00-7.94(m, 1H), 7.93-7.85 (m, 2H), 7.64-7.51 (m, 2H). 3.15 (q, 2H, J=7.2 Hz),1.29 (t, 3H, J=7.2 Hz); ¹³C NMR (CDCl₃) δ 129.9, 128.8 (d), 128.2,127.1, 124.3, 32.3, 8.8. C₁₃H₁₂O.

Synthesis of (Z)-tert-Butyl(1-phenylprop-1-enyloxy)dimethylsilane (9b)

Compound 9b was synthesized by a procedure similar to 9a usingcommercially available propiophenone (8b, 5.0 g, 0.037 mol), TBDMSOTf(9.4 mL, 41.0 mmol), and of Et₃N (8.3 mL) in CH₂Cl₂ (50 mL). Afterpurification, 7.32 g (79%) of 9b was isolated as colorless oil: ¹H NMR(CDCl₃) δ 7.50-7.40 (m, 2H), 7.35-7.22 (m, 3H), 5.23 (q, 1H, J=6.9 Hz),1.77 (d, 3H, J=6.9 Hz), 1.03 (s, 9H), −0.04 (s, 6H); ¹³C NMR (CDCl₃) δ150.4, 140.0, 128.0, 127.4, 125.9, 105.9, 25.9, 18.5, 11.9, −3.9;C₁₅H₂₄OSi.

Synthesis of(Z)-tert-Butyl(1-(3-fluorophenyl)prop-1-enyloxy)dimethylsilane (9c)

Compound 9c was synthesized by a procedure similar to that described for9a using commercially available 3-fluoropropiophenone (8c, 5.0 g, 0.033mol), TBDMSOTf (8.3 mL, 36.1 mmol), and Et₃N (7.3 mL) in CH₂Cl₂ (50 mL).After purification, 8.1 g (93%) of 9c was isolated as colorless oil: ¹HNMR (CDCl₃) δ 7.38-7.10 (m, 2H), 7.00-6.87 (m, 1H), 5.26 (q, 1H, J=6.9Hz), 1.75 (d, 3H, J=6.9 Hz), 1.00 (s, 9H), −0.02 (s, 6H); ¹³C NMR(CDCl₃) δ 164.5, 161.2, 149.2, 142.4, 129.4, 121.4, 114.3, 114.0, 112.8,112.5, 107.1, 105.9, 26.0, 18.5, 11.9, −3.9. C₁₅H₂₃FOSi.

Synthesis of(Z)-tert-Butyl(1-(3-bromophenyl)prop-1-enyloxy)dimethylsilane (9d)

Compound 9d was synthesized by a procedure similar to that described for9a using commercially available 3-bromopropiophenone (8d, 1.0 g, 0.0047mol), TBDMSOTf (1.4 mL, 5.1 mmol), and Et₃N (1.1 mL) in CH₂Cl₂ (10 mL).After workup, 1.15 g (75%) of crude 9d was isolated as colorless oilwith a Z-E ratio of 94:6: ¹H NMR (CDCl₃) δ 7.64-7.58 (m, 1H), 7.41-7.34(m, 2H), 7.17 (t, 1H, J=8.04 Hz), 5.25 (q, 1H, J=6.9 Hz), 1.75 (d, 3H,J=6.9 Hz), 1.02 (s, 9H), −0.03 (s, 6H); ¹³C NMR (CDCl₃) δ 148.8, 141.9,130.2, 129.5, 128.7, 124.1, 122.1, 25.8, 18.3, 11.8, −4.0. C₁₅H₂₃BrOSi.

Synthesis of (Z)-tert-Butyl(1-(m-tolyl)prop-1-enyloxy)dimethylsilane(9e)

Compound 9e was synthesized by a procedure similar to that described for9a using commercially available 3-methylpropiophenone (8e, 5.0 g, 0.033mol), TBDMSOTf (8.5 mL, 36.1 mmol), and Et₃N (7.5 mL) in CH₂Cl₂ (50 mL).After purification by column chromatography on silica gel, 7.45 g (84%)of 9e was isolated as colorless oil: ¹H NMR (CDCl₃) δ 7.31-7.24 (m, 2H),7.23-7.17 (m, 1H), 7.10-7.05 (m, 1H), 5.22 (q, 1H, J=6.9 Hz), 2.37 (s,3H), 1.76 (d, 3H, J=6.9 Hz), 1.03 (s, 9H), −0.03 (s, 6H); ¹³C NMR(CDCl₃) δ 150.7, 140.1, 137.7, 128.4, 127.9, 126.8, 123.2, 105.9, 26.3,21.8, 18.7, 12.1, −3.6. C₁₆H₂₆OSi.

Synthesis of(Z)-tert-Butyl-(1-(3-methoxyphenyl)prop-1-enyloxy)dimethylsilane (91)

Compound 9f was synthesized by a procedure similar to that described for9a using 3-methoxypropiophenone (8f, 6.00 g, 0.0366 mol), TBDMSOTf (9.2mL, 40.2 mmol), and Et₃N (8.1 mL) in CH₂Cl₂ (60 mL). After purificationon alumina, 8.14 g (80%) of 9f was isolated as colorless oil: ¹H NMR(CDCl₃) δ 7.24-7.16 (m, 1H), 7.07-6.98 (m, 2H), 6.84-6.76 (m, 1H), 5.23(q, 1H, J=6.9 Hz), 3.81 (s, 3H), 1.75 (d, 3H, J=6.9 Hz), 1.01 (s, 9H),−0.01 (s, 6H); ¹³C NMR (CDCl₃) δ 159.4, 150.1, 141.5, 129.0, 118.4,113.3, 111.2, 106.1, 55.3, 26.0, 18.5, 11.9, −3.9. C₁₆H₂₆O₂Si.

Synthesis of(Z)-tert-Butyl-(1-(3-nitrophenyl)prop-1-enyloxy)dimethylsilane (9g)

Compound 9g was synthesized by a procedure similar to that described for9a using commercially available 3-nitropropiophenone (8g, 5.0 g, 0.028mol), TBDMSOTf (7.1 mL, 30.7 mmol), and Et₃N (6.2 mL) in CH₂Cl₂ (50 mL).After purification on alumina, 8.0 g (98%) of 9g was isolated ascolorless oil: ¹H NMR (CDCl₃) δ 8.34-8.30 (m, 1H), 8.12-8.06 (m, 1H),7.80-7.75 (m, 1H), 7.52-7.42 (m, 1H), 5.40 (q, 1H, J=6.9 Hz), 1.78 (d,3H, J=6.9 Hz), 1.02 (s, 9H), −0.02 (s, 6H); ¹³C NMR (CDCl₃) δ 148.8,141.6, 131.3, 129.0, 122.1, 120.5, 108.6, 106.8, 25.9, 18.4, 12.0, −3.8.C₁₅H₂₃NO₃Si.

Synthesis of(Z)-tert-Butyldimethyl-(1-(naphthalen-1-yl)prop-1-enyloxy)silane (9q)

Compound 9q was synthesized by a procedure similar to that described for9a using 1-naphthalen-1-ylpropan-1-one (8h, 3.5 g, 0.019 mol), TBDMSOTf(4.8 mL, 0.021 mol), and Et₃N (4.3 mL) in CH₂Cl₂ (26 mL). Afterpurification, 4.58 g (81%) of title product was isolated as colorlessoil: ¹H NMR (CDCl₃) δ 8.27-8.24 (m, 1H), 7.83-7.75 (m, 2H), 7.48-7.38(m, 4H), 5.04 (q, 1H, J=6.0 Hz), 1.83 (d, 3H, J=6.0 Hz), 0.87 (s, 9H),−0.29 (s, 6H); ¹³C NMR (CDCl₃) δ 150.0, 138.3, 133.6, 131.6, 128.1,128.0, 126.8, 126.2, 125.7, 125.1, 108.4, 26.3, 25.7, 18.2, −4.6.C₁₉H₂₆OSi.

Synthesis of(Z)-tert-Butyldimethyl-(1-(naphthalen-2-yl)prop-1-enyloxy)silane (9r)

Compound 9r was synthesized by a procedure similar to that described for9a using 1-naphthalen-2-ylpropan-1-one (8i, 4.0 g, 0.0217 mol, TBDMSOTf(5.5 mL, 23.9 mmol), and Et₃N (4.9 mL) in CH₂Cl₂ (26 mL). Afterpurification, 4.7 g (73%) of the title product was isolated as colorlessoil: ¹H NMR (CDCl₃) δ 7.86-7.74 (m, 1H), 7.86-7.74 (m, 3H), 7.59 (dd,1H, J=8.6, 1.7 Hz), 7.51-7.41 (m, 2H), 5.38 (q, 1H, J=6.9 Hz), 1.81 (d,3H, J=6.9 Hz), 1.04 (s, 9H), 0.02 (s, 6H); ¹³C NMR (CDCl₃) δ 150.5,137.5, 133.5, 133.2, 128.5, 127.9, 127.8, 126.4, 126.0, 107.0, 105.9,26.3, 26.1, 18.8, −3.6. C₁₉H₂₆OSi.

Synthesis of(Z)-tert-Butyl(1-(3-chlorophenyl)but-1-enyloxy)dimethylsilane (9s)

Compound 9s was synthesized by a procedure similar to that described for9a using 3-chlorobutyrophenone (8j, 3.1 g, 0.0169 mol), TBDMSOTf (4.3mL, 18.6 mmol), and Et₃N (3.8 mL) in CH₂Cl₂ (30 mL). After purification,3.7 g (74%) of the title product was isolated as colorless oil: ¹H NMR(CDCl₃) δ 7.48-7.44 (m, 1H), 7.38-7.32 (m, 1H), 7.31-7.29 (m, 2H), 5.16(t, 1H, J=7.1 Hz), 2.30-2.19 (m, 2H), 1.09-1.03 (m, 3H), 1.01 (s, 9H),−0.04 (s, 6H); ¹³C NMR (CDCl₃) δ 147.5, 141.7, 133.9, 129.2, 127.3,125.9, 123.8, 114.9, 25.8, 19.5, 14.1, 0.0, −4.1. C₁₆H₂₅ClOSi.

Synthesis of(Z)-tert-Butyl(1-(3-chlorophenyl)pent-1-enyloxy)dimethylsilane (9t)

Compound 9t was synthesized by a procedure similar to that described for9a using 3-chloropentaphenone (8k, 2.7 g, 0.014 mol), TBDMSOTf (3.5 mL,15 mmol), and Et₃N (3.1 mL) in CH₂Cl₂ (25 mL). After purification, 4.18g (96%) of the title product was isolated as colorless oil: ¹H NMR(CDCl₃) δ 7.47-7.44 (m, 1H), 7.38-7.32 (m, 1H), 7.30-7.28 (m, 1H),7.25-7.22 (m, 1H), 5.18 (t, 1H, J=7.2 Hz), 2.20 (q, 2H, J=7.5 Hz),1.54-1.38 (m, 2H), 1.02 (s, 9H), 1.00-0.90 (m, 3H), −0.05 (s, 6H); ¹³CNMR (CDCl₃) δ 148.0, 141.8, 133.9, 129.2, 127.6, 125.9, 123.9, 113.0,28.3, 25.8, 22.8, 14.0, 0.0, −4.01. C₁₇H₂₇ClOSi.

Synthesis of (S)-1-(3-Chlorophenyl)-2-hydroxypropan-1-one [(S)-10a]

Compound (S)-10a was synthesized by a procedure similar to thatdescribed for (R)-10a using(Z)-tert-butyl(1-(3-chlorophenyl)prop-1-enyloxy)dimethylsilane (9a, 8.8g, 0.031 mol), AD-mix-α (43.5 g), and CH₃SO₂NH₂ (3a, 3 g, 0.032 mol) intert-butyl alcohol-water (120 mL:120 mL). The reaction mixture wasquenched with sodium sulfite (31.1 g). After purification, 4.51 g (78%)of the (S)-10a was isolated. Characterization data is similar with datareported in Fang, Q. K.; Han, Z.; Grover, P.; Kessler, D.; Senanayake,C. H.; Wald, S. A., Tetrahedron: Asymmetry 2000, 11, 3659-3663.

Synthesis of (R)-1-Phenyl-2-hydroxypropan-1-one (10b)

Compound 10b was synthesized by a procedure similar to that describedfor (R)-10a using (Z)-tert-butyl(1-phenprop-1-enyloxy)dimethylsilane(9b, 7.2 g, 0.029 mol), AD-mix-β (40.7 g), and CH₃SO₂NH₂ (2.8 g, 0.0294mol) in tert-butyl alcohol-water (110 mL:110 mL) The reaction wasquenched with sodium sulfite (29.1 g). After purification, 2.49 g (80%)of the title product was isolated: [α]²⁰ _(D) +84.9° (c 1.6, CHCl₃); ¹HNMR (CDCl₃) δ 7.96-7.90 (m, 2H), 7.66-7.58 (m, 1H), 7.54-7.47 (m, 2H),5.23-5.12 (m, 1H), 3.84 (d, 1H, J=6.3 Hz), 1.45 (d, 3H, J=7.05 Hz); ¹³CNMR (CDCl₃) δ 202.4, 134.0, 133.4, 128.9, 128.7, 69.3, 22.3. C₉H₁₀O₂.

Synthesis of (R)-1-(3-Fluorophenyl)-2-hydroxypropan-1-one (10c)

Compound 10c was synthesized by a procedure similar to that describedfor (R)-10a using(Z)-tert-butyl(1-(3-fluorophenyl)prop-1-enyloxy)dimethylsilane, (9c, 8.0g, 0.030 mol), AD-mix-β (42.1 g), and CH₃SO₂NH₂ (2.90 g, 0.0301 mol) intert-butyl alcohol-water (120 mL:120 mL). The reaction was quenched withsodium sulfite (30.1 g). After purification, 4.4 g (87%) of the desiredproduct 10c was isolated: [α]²⁰ _(D) +58.1° (c 3.2, CHCl₃); ¹H NMR(CDCl₃) δ 7.74-7.59 (m, 2H), 7.54-7.45 (m, 1H), 7.37-7.28 (m, 1H),5.19-5.07 (m, 1H), 1.76 (d, 1H, J=6.3 Hz), 1.46 (d, 3H, J=6.9 Hz); ¹³CNMR (CDCl₃) δ 201.6, 164.9, 131.0, (d), 124.7, 121.3 (d), 115.8 (d),69.9, 22.4. C₉H₉FO₂.

Synthesis of (R)-1-(3-Bromophenyl)-2-hydroxypropan-1-one (10d)

Compound 10d was synthesized by a procedure similar to that describedfor (R)-10a using(Z)-tert-butyl(1-(3-bromophenyl)prop-1-enyloxy)dimethylsilane, (9d, 1.15g, 0.0035 mol), AD-mix-β (4.9 g), and CH₃SO₂NH₂ (334 mg, 3.5 mmol) intert-butyl alcohol-water (17.5 mL. 17.5 mL). The reaction was quenchedwith sodium sulfite (3.5 g). After purification by column chromatographyon silica gel, 0.700 g (88%) of the desired product was isolated: [α]²⁰_(D) +61.1° (c 1.3, CHCl₃); ¹H NMR (CDCl₃) δ 8.09-8.04 (m, 1H),7.87-7.81 (m, 1H), 7.78-7.72 (m, 1H), 7.39 (t, 1H, J=8.0 Hz), 5.18-5.05(m, 1H), 3.66 (d, 1H, J=6.4 Hz), 1.45 (d, 3H, J=7.2 Hz); ¹³C NMR (CDCl₃)δ 201.2, 136.8, 135.2, 131.6, 130.4, 127.1, 123.3, 69.5, 22.1. C₉H₉BrO₂.

Synthesis of (R)-1-(m-Tolyl)-2-hydroxypropan-1-one (10e)

Compound 10e was synthesized by a procedure similar to that describedfor (R)-10a using

(Z)-tert-butyl(1-(3-methylphenyl)prop-1-enyloxy)dimethylsilane, (9e, 7.4g, 0.028 mol), AD-mix-β (39.5 g), and CH₃SO₂NH₂ (2.73 g, 0.029 mol) intert-butyl alcohol-water (110 mL:110 mL). The reaction was quenched withsodium sulfite (28.3 g). After purification, 4.2 g (85%) of the desired10e was isolated: [α]²⁰ _(D) +83.9° (c 2.0, CHCl₃); ¹H NMR (CDCl₃) δ7.78-7.67 (m, 2H), 7.46-7.33 (m, 2H), 5.20-5.09 (m, 1H), 3.86 (d, 1H,J=6.3 Hz), 2.42 (s, 3H), 1.44 (d, 311, J=7.0 Hz); ¹³C NMR (CDCl₃) δ202.6, 138.8, 134.8, 133.5, 129.1, 128.7, 125.9, 69.4, 22.3, 21.4.C₁₀H₁₂O₂.

Synthesis of (R)-1-(3-Methoxyphenyl)-2-hydroxypropan-1-one (10f)

Compound 10f was synthesized by a procedure similar to that describedfor (R)-10a using(Z)-tert-butyl(1-(3-methoxyphenyl)prop-1-enyloxy)dimethylsilane, (9f,8.1 g, 0.029 mol), AD-mix-β (40.7 g), and CH₃SO₂NH₂ (2.8 g, 0.0294 mol)in tert-butyl alcohol-water (110 mL:110 mL) The reaction was quenchedwith sodium sulfite (29.1 g). After purification, 4.2 g (80%) of thedesired 10f was isolated: [α]²⁰ _(D) +71.1° (c 1.1, CHCl₃); ¹H NMR(CDCl₃) δ 7.51-7.45 (m, 2H), 7.44-7.37 (m, 1H), 7.19-7.13 (m, 1H),5.19-5.09 (m, 1H), 3.87 (s, 3H), 3.76 (d, 1H, J=6.5 Hz), 1.45 (d, 3H,J=7.1 Hz); ¹³C NMR (CDCl₃) δ 202.3, 160.0, 134.7, 129.9, 121.1, 120.3,113.1, 69.4, 55.5, 22.4. C₁₀H₁₂O₃.

Synthesis of (R)-1-(3-Nitrophenyl)-2-hydroxypropan-1-one (10g)

Compound 10g was synthesized by a procedure similar to that describedfor (R)-10a using(Z)-tert-butyl(1-(3-nitrophenyl)prop-1-enyloxy)dimethylsilane, (9g, 8.0g, 0.027 mol), AD-mix-β (38 g), and CH₃SO₂NH₂ (2.64 g, 0.0277 mol) intert-butyl alcohol-water (110 mL:110 mL). The reaction was quenched withsodium sulfite (27.4 g). After purification by column chromatography onsilica gel, 4.0 g (75%) of the desired product was isolated: [α]²⁰ _(D)+63.8° (c 1.3, CHCl₃); ¹H NMR (CDCl₃) δ 8.80-8.74 (m, 1H), 8.52-8.44 (m,1H), 8.31-8.24 (m, 1H), 7.83-7.68 (m, 1H), 5.27-5.13 (m, 1H), 3.59 (d,1H, J=6.5 Hz), 1.49 (d, 3H, J=7.08 Hz); ¹³C NMR (CDCl₃) δ 200.4, 148.6,134.9, 134.1, 130.2, 128.1, 121.6, 69.8, 21.9; C₉H₉NO₄.

Synthesis of (R)-2-Hydroxy-1-(naphthalen-1-yl)propan-1-one (10h)

Compound 10h was synthesized by a procedure similar to that describedfor (R)-10a using(Z)-tert-butyl(1-(naphthalen-1-yl)prop-1-enyloxy)dimethylsilane, (9h,4.58 g, 0.015 mol), AD-mix-β (21.4 g), and CH₃SO₂NH₂ (1.5 g, 0.0158 mol)in tert-butyl alcohol-water (60 mL:60 mL). The reaction was quenchedwith sodium sulfite (15.3 g). After purification by columnchromatography on silica gel, 1.15 g (38%) of the title product wasisolated plus 2.1 g of starting olefin was recovered, raising theeffective yield to 70%: [α]²⁰ _(D) +140.2° (c 3.2, CHCl₃); ¹H NMR(CDCl₃) δ 8.51-8.46 (m, 1H), 8.04 (d, 1H, J=8.3 Hz), 7.93-7.87 (m, 1H),7.80-7.75 (m, 1H), 7.66-7.48 (m, 3H), 5.30-5.17 (m, 1H), 3.96 (d, 111,J=5.8 Hz), 1.36 (d, 3H, J=7.1 Hz); ¹³C NMR (CDCl₃) δ 205.7, 134.1,133.5, 132.5, 130.7, 128.7, 128.4, 127.7, 126.9, 125.5, 124.4, 71.2,21.3; LCMS (ESI) m/z 201.2 [(M+H)⁺, M=C₁₃H₁₂O₂].

Synthesis of (R)-2-Hydroxy-1-(naphthalen-2-yl)propan-1-one (10i)

Compound 10i was synthesized by a procedure similar to that describedfor (R)-10a using(Z)-tert-butyl(1-(naphthalen-2-yl)prop-1-enyloxy)dimethylsilane, (9i,4.7 g, 0.016 mol), AD-mix-β (22.0 g), and CH₃SO₂NH₂ (1.55 g, 0.016 mol)in tert-butyl alcohol-water (60 mL:60 mL). The reaction was quenchedwith sodium sulfite (15.7 g). After purification by columnchromatography on silica gel, 2.5 g (80%) of the desired product wasisolated: [α]²⁰ _(D) +115° (c 0.7, CHCl₃); ¹H NMR (CDCl₃) δ 8.44 (s,1H), 8.01-7.86-8.00 (m, 4H), 7.69-7.54 (m, 2H), 5.37-5.27 (m, 1H), 3.86(d, 1H, J=6.5 Hz), 1.52 (d, 3H, J=7.0 Hz); ¹³C NMR (CDCl₃) δ 202.3,136.0, 132.4, 130.7, 130.5, 129.7, 129.0, 128.8, 127.9, 127.1, 124.0,69.4, 22.5. C₁₃H₁₂O₂.

Synthesis of (R)-1-(3-Chlorophenyl)-2-hydroxybutan-1-one (10j)

Compound 10j was synthesized by a procedure similar to that describedfor (R)-10a using(Z)-tert-butyl(1-(3-chlorophenyl)but-1-enyloxy)dimethylsilane (9j, 3.7g, 0.013 mol), AD-mix-β (17.5 g), and CH₃SO₂NH₂ (1.2 g, 0.0126 mol) intert-butyl alcohol-water (45 mL:45 mL). The reaction was quenched withsodium sulfite (12.5 g). After purification by column chromatography onsilica gel, 2.2 g (79%) of the title product was isolated: [α]²⁰ _(D)+31.4° (c 1.0, CHCl₃); ¹H NMR (CDCl₃) δ 7.91-7.88 (m, 1H), 7.81-7.75 (m,1H), 7.62-7.56 (m, 1H), 7.45 (t, 1H, J=7.8 Hz), 5.06-4.98 (m, 1H), 3.60(d, 1H, J=6.5 Hz), 2.04-1.87 (m, 1H), 1.70-1.51 (m, 1H), 0.94 (t, 3H,J=7.4 Hz); ¹³C NMR (CDCl₃) δ 201.4, 135.8, 135.7, 134.2, 130.6, 128.9,126.9, 74.5, 29.1, 9.2. C₁₀H₁₁ClO₂.

Synthesis of (R)-1-(3-Chlorophenyl)-2-hydroxypentan-1-one (10k)

Compound 10k was synthesized by a procedure similar to that describedfor (R)-10a using(Z)-tert-butyl(1-(3-chlorophenyl)pent-1-enyloxy)dimethylsilane (9k, 4.1g, 0.013 mol), AD-mix-β (18.5 g), and CH₃SO₂NH₂ (1.3 g, 0.014 mol) intert-butyl alcohol-water (50 mL:50 mL). The reaction was quenched withsodium sulfite (13.2 g). After purification, 2.4 g (77%) of the desiredproduct was isolated: [α]²⁰ _(D) +33.3° (c 1.1, CHCl₃); ¹H NMR (CDCl₃) δ7.91-7.87 (m, 1H), 7.80-7.75 (m, 1H), 7.63-7.17 (m, 1H), 7.45 (t, 1H,J=7.6 Hz), 5.08-5.00 (m, 1H), 3.58 (d, 1H, J=6.5 Hz), 1.89-1.75 (m, 1H),1.61-1.35 (m, 3H), 0.93 (t, 3H, J=7.2 Hz); ¹³C NMR (CDCl₃) δ 201.1,135.4, 133.8, 130.2, 128.6, 126.5, 73.2, 37.8, 18.2, 13.8. C₁₁H₁₃ClO₂.

Synthesis of Methyl (2R)-2-[(trifluoromethyl)sulfonyl]oxypropionate)(14)

Following a procedure reported in Damaj, M. I.; Fei-Yin, M.; Dukat, M.;Glassco, W.; Glennon, R. A.; Martin, B. R., J. Pharmacol. Exp. Ther.1998, 284, 1058-1065 with modification, a solution of methyl-(R)-lactate(13) (5.20 g, 0.05 mol) in anhydrous CH₂Cl₂ (200 mL, 0.25 M) was cooledto 0° C. and was treated with trifluoromethane sulfonic anhydride (8.8mL, 52.5 mmol) and 2,6-lutidine (6.10 mL, 52.5 mmol) under an N₂atmosphere. After stirring for 20 min at 0° C., the reaction mixture wasconcentrated to a pink oil residue. Column chromatography on silica gelusing CH₂Cl₂ as the eluent afforded 9.15 g (77%) of 14 as a light pinkoil with characterization data as previously reported:³¹ [α]²⁵ _(D)+40.5° (c 1.0, CHCl₃); ¹H NMR (CDCl₃) δ 5.27 (q, 1H, J=6.9 Hz), 3.85 (s,3H), 1.71 (d, 3H, J=6.9 Hz); ¹³C NMR (CDCl₃) δ 167.8, 79.9, 53.3, 18.0;LCMS (ESI) m/z 240.1 [(M+4H)⁺, M=C₅H₇F₃O₅S].

Synthesis of (3S)-3,5,5-Trimethylmorpholin-2-one (15)

A solution of triflate 14 (5.00 g, 0.021 mol) in anhydrous CH₂Cl₂ (80mL) under an N₂ atmosphere, was cooled to −40° C. and was treated with asolution of 2-amino-2-methyl-1-propanol (2.5 folds, 4.68 g, 0.0525 mol)in anhydrous CH₂Cl₂ (10 mL). After stirring for 2 h at −40° C., thereaction mixture was warmed slowly to 0° C. then to room temperature andstirred overnight. The reaction mixture was treated with saturatedaqueous NaHCO₃ solution (100 mL). The organic phase was washed (water,brine), separated, and dried (Na₂SO₄). The aqueous layer was extractedwith EtOAc (twice). The organic layer was separated, washed (water,brine) and dried (Na₂SO₄). The organic extracts were combined andconcentrated to give a yellow oil. Column chromatography on silica gelusing hexanes-EtOAc (1:2) to EtOAc gave 1.88 g (63%) of 15 as a lightyellow oil: [α]²³ _(D) −75° (c 1.0, CHCl₃); ¹H NMR (CDCl₃) δ 4.11 (s,2H), 3.71 (q, 1H, J=6.8), 1.39 (d, 3H, J=6.8 Hz), 1.26 (s, 3H), 1.18 (s,3H); ¹³C NMR (CDCl₃) δ 229.2, 77.6, 49.5, 49.3, 27.2, 24.2, 18.4; LCMS(APCI) m/z 144.3 [(M+H)⁺, M=C₇H₁₃NO₂]; Anal. (C₇H₁₃NO₂) calcd: C, 58.72;H, 9.15; N, 9.78. found: C, 58.60; H, 9.35; N, 9.79. Note: ¹H NMR datais similar with the data reported in the literature for the racemiccompound (Koch, T. H.; Olesen, J. A.; DeNiro, J., J. Am. Chem. Soc.1975, 97, (25), 7285-7288).

Example 2 Biological Studies a) In Vitro Studies

Cell Lines and Culture:

Human embryonic kidney (HEK-293) cells stably expressing human DAT, NETor SERT were maintained as previously described in Eshleman, A. J.;Carmolli, M.; Cumbay, M.; Martens, C. R.; Neve, K. A.; Janowsky, A., J.Pharmacol. Exp. Ther. 1999, 289, (2), 877-885. Use was made of severalhuman cell lines that naturally or heterologously express specific,functional, human nAChR subtypes. Cells of the TE671/RD line naturallyexpresses muscle-type nAChR (a1β1γδ- or α1*-nAChR), and SH-SY5Yneuroblastoma cells naturally expresses autonomic α3β4*-nAChRs(containing α3, β4, probably α5, and sometimes β2 subunits). Differentclones of SH-EP1 epithelial cell lines have been engineered toheterologously express either α4β2-nAChR, which are thought to be themost abundant, high affinity nicotine-binding nAChR in mammalian brain,or α4β4-nAChR, another possible brain nAChR subtype (SH-EP1-hα4β2 orα4β4 cells, respectively). These cells were maintained as low passagenumber (1-26 from our frozen stocks) cultures to ensure stableexpression of native or heterologously-expressed nAChR as previouslydescribed (see Lukas, R. J.; Fryer, J. D.; Eaton, J. B.; L., G. C., Somemethods for studies of nicotinic acetylcholine receptor pharmacology, inNicotinic receptors and the Nervous System, Levine, E. D., Ed. CRCPress: Boca Raton, 2002; pp 3-27, incorporated herein by reference inits entirety). Cells were passaged once weekly by splittingjust-confluent cultures 1/300 (TE671/RD), 1/5 (SH-SY5Y), or 1/20(transfected SH-EP1) in serum-supplemented medium to maintain log-phasegrowth.

Transporter Assays:

The (2S,3S)-4a analogues 4b-4v and comparison compounds 5 and 6 wereevaluated for their ability to inhibit uptake of [³H]dopamine ([³H]DA),[³H]serotonin ([³H]5HT), and [³H]norepinephrine ([³H]NE) into HEK293cells stably expressing human DA transporters [(h)DAT], 5HT transporters[(h)SERT], or NE transporters [h(NET)] using methods similar to thosepreviously reported. See, for example, Damaj, M. I.; Carroll, F. I.;Eaton, J. B.; Navarro, H. A.; Blough, B. E.; Mirza, S.; Lukas, R. J.;Martin, B. R., Mol. Pharmacol. 2004, 66, (3), 675-682 and Eshleman, A.J.; Carmolli, M.; Cumbay, M.; Martens, C. R.; Neve, K. A.; Janowsky, A.,J. Pharmacol. Exp. Ther. 1999, 289, (2), 877-885, both incorporated byreference herein in their entireties. The results are given in Table 4.

Compound 2 (bupropion) inhibits dopamine reuptake (IC₅₀=660 nM), whichwould increase synaptic levels of dopamine and presumed reward. Compound(2S,3S)-4a (IC₅₀=630 nM), but not (2R,3R)-4a (IC₅₀>10 μM), is aseffective as 2 in inhibiting DA uptake inhibition. Compound 2 alsoinhibits norepinephrine reuptake (IC₅₀=1850 nM), which increasessynaptic levels of norepinephrine. Interestingly, (2S,3S)-4a (IC₅₀=241nM), but not (2R,3R)-4a (IC₅₀=9900 nM), is 7.7-times more potent than 2in inhibiting NE uptake. Neither 2 nor its hydroxymetabolites are active(IC₅₀>10 μM) as inhibitors of serotonin (5HT) uptake.

Among the new hydroxybupropion analogues tested, the propyl extendedchain form 4t and the (±)-3′,4′-dichlorophenyl derivative (±)-4n form of(2S,3S)-4a with IC₅₀ values of 30 and 70 nM, respectively, the ethylextended chain form 4s (IC₅₀=204 nM), the 4-chlorophenyl analogue 4i(IC₅₀=285 nM), and the 2-napthyl derivative 4r (IC₅₀=453 nM) have higherpotency than (2S,3S)-4a (IC₅₀=630 nM) as inhibitors of DA uptake.

In terms of activity for NE uptake inhibition, the ethyl and propylextended chain fours, 4s and 4t (IC₅₀ values of 43 nM and 31 nM,respectively), the (±)-3′-,4′-dichlorophenyl derivative (±)-4n (IC₅₀=114nM) and the 3′,5′-difluoro analogue 4o (IC₅₀=151 nM) are more potentthan (2S,3S)-4a (IC₅₀=241 nM).

The only analogues that had sub-micromolar IC₅₀ values for inhibition of5HT uptake were the (±)-3′,4′-dichlorophenyl analogue (±)-4n (IC₅₀=360nM) and the 2-napthyl analogue 4r (IC₅₀=334 nM). (2S,3S)-4a, (2R,3R)-4aand 16 of the analogues were inactive at the SERT. The remaininganalogues had IC₅₀ values greater than 1560 nM.

Compound 2 has ˜3-fold selectivity for inhibition at DA over NE uptakeand is inactive at inhibition of 5HT uptake. Neither (2R,3R)-4a nor(2S,3S)-4a shows activity for 5HT uptake. Compound (2R,3R)-4a's pooractivity overall precludes comments about its transporter selectivity.On the other hand, (2S,3S)-4a has the opposite DA/NE inhibition ofuptake selectivity relative to 2, exhibiting ˜3-fold selectivity forinhibition of uptake of NE over DA. Only the 2-napthyl analogue 4r showsselectivity for the SERT (IC₅₀=334 nM) compared to 453 and 1570 nM forDA and NE uptake inhibition. Analogues 4b-4g, 4l-4m, 4o-4q, 4s, and4u-4v share with (2S,3S)-4a selectivity for inhibition of NE over DAuptake with selectivity for inhibition of NE over DA uptake beinghighest for the 3′-methoxyphenyl analogue 4f, the ethyl extendedanalogue 4s and N-methyl-4′-chorophenyl analogue 4v (5-fold each), the3′,5′-difluoro analogue 4o and N-methyl analogue 4u (7-8-fold) and the3′-nitrophenyl 4g (10-fold) and the naphthyl analogue 4q (24-fold).However, relative to (2S,3S)-4a, only 4s and 4o have a combination ofhigher potency in NE uptake inhibition and selectivity for NE over DAuptake inhibition. The propyl-extended chain analogue, 4t, has muchhigher potency than (2S,3S)- or (2R,3R)-4a at each of the monoaminetransporter targets, but it is essentially equipotent for NE and DAuptake inhibition (IC₅₀=31 and 30 nM). The only analogues tested withselectivity for inhibition of DA over NE uptake [discounting the smallpreference for DA over NE and 5HT inhibition shown by(±)-3′,4′-dichlorophenyl analogue (±)-4n] are the 4′-chlorophenylanalogue 4i or 4′-methylphenyl analogues 4j and 2-napthyl analogue (4r)(3-5-fold). However, by contrast to 4r, the structurally related1-napthyl analogue (4q) has 24-fold selectivity for inhibition of NEover DA uptake. Thus, alkyl extension as well as phenyl substitution canimpact inhibitory potency and selectivity of the hydroxybupropionanalogues for monoamine transporters.

nAChR Functional Assays:

Compound (2S,3S)-4a and analogues 4b-4v and 5 and 6 also were evaluatedfor their ability to antagonize functional responses of α3β4*-, α4β2-,α4β4-, and α1*-nAChR using previously reported methods (see Damaj, M.I.; Carroll, F. I.; Eaton, J. B.; Navarro, H. A.; Blough, B. E.; Mirza,S.; Lukas, R. J.; Martin, B. R., Mol. Pharmacol. 2004, 66, (3),675-682), modified as described below. Effects of hydroxybupropionanalogues 4b-4v and 5 and 6 on function of diverse, human nAChR subtypesnaturally or heterologously expressed by human cell lines were assessedusing ⁸⁶Rb⁺ efflux assays that are specific only for nAChR function inthe cells used.

Cells were harvested at confluence from 100-mm plates by mildtrypsinization (Irvine Scientific, Santa Ana, Calif.) and trituration or(for SH-SY5Y cells) by trituration alone before being suspended incomplete medium and evenly seeded at a density of 1.25-2 confluent100-mm plates per 24-well plate (Falcon; ˜100-125 μg of total cellprotein per well in a 500 μL volume). After cells had adhered (generallyovernight, but no sooner than 4 h later), the medium was removed andreplaced with 250 μL per well of complete medium supplemented with˜350,000 cpm of ⁸⁶Rb⁺ (PerkinElmer Life and Analytical Sciences, Boston,Mass.) and counted at 40% efficiency using Cerenkov counting (TriCarb1900 liquid scintillation analyzer, 59% efficiency; PerkinElmer LifeSciences).

After at least 4 h and typically overnight, ⁸⁶Rb⁺ efflux was measuredusing the “flip-plate” technique. See Lukas, R. J.; Fryer, J. D.; Eaton,J. B.; L., G. C., Some methods for studies of nicotinic acetylcholinereceptor pharmacology, in Nicotinic receptors and the Nervous System,Levine, E. D., Ed. CRC Press: Boca Raton, 2002; pp 3-27, incorporatedherein by reference in its entirety). Briefly, after aspiration of thebulk of ⁸⁶Rb⁺ loading medium from each well of the “cell plate,” eachwell containing cells was rinsed 3× with 2 mL of fresh ⁸⁶Rb⁺ effluxbuffer (130 mM NaCl, 5.4 mM KCl, 2 mM CaCl₂, 5 mM glucose, 50 mM HEPES,pH 7.4) to remove extracellular ⁸⁶Rb⁺. Following removal of residualrinse buffer by aspiration, the flip-plate technique was used again tosimultaneously introduce 1.5 mL of fresh efflux buffer containing drugsof choice at indicated final concentrations from a 24-well “efflux/drugplate” into the wells of the cell plate. After a 5 min incubation, thesolution was “flipped” back into the efflux/drug plate, and anyremaining buffer in the cell plate was removed by aspiration. Cellsremaining in the cell plate were lysed and suspended by addition of 1.5mL of 0.1 M NaOH, 0.1% sodium dodecyl sulfate to each well. Suspensionsin each well were then subjected to Cerenkov counting (Wallac MicobetaTrilux 1450; 25% efficiency) after placement of inserts (Wallac1450-109) into each well to minimize cross-talk between wells.

For quality control and normalization purposes, the sum of ⁸⁶Rb⁺ in cellplates and efflux/drug plates was defined to confirm material balance(i.e., that the sum of ⁸⁶Rb⁺ released into the efflux/drug plates and⁸⁶Rb⁺ remaining in the cell plate were the same for each well). Thisassured that ⁸⁶Rb⁺ efflux was the same whether measured in absoluteterms or as a percentage of loaded ⁸⁶Rb⁺. Similarly, the sum of ⁸⁶Rb⁺ incell plates and efflux/drug plates also determined the efficiency of⁸⁶Rb⁺ loading (the percentage of applied ⁸⁶Rb⁺ actually loaded intocells).

Control, total ⁸⁶Rb⁺ efflux was assessed in the presence of only a fullyefficacious concentration of carbamylcholine (1 mM for SH-EP1-hα4β2,SH-EP1-hα4β4 cells or TE671/RD cells; 3 mM for SH-SY5Y cells). Control,non-specific ⁸⁶Rb⁺ efflux was measured either in the presence of thefully efficacious concentration of carbamylcholine plus 100 μMmecamylamine, which gave full block of agonist-induced and spontaneousnAChR-mediated ion flux, or in the presence of efflux buffer alone.Either determination of non-specific efflux was equivalent. Specificefflux was then taken as the difference in control samples between totaland non-specific ⁸⁶Rb⁺ efflux. Any intrinsic agonist activity of testdrugs was ascertained using samples containing test drug only atdifferent concentrations and was normalized, after subtraction ofnon-specific efflux, to specific efflux in test drug-free, controlsamples. Antagonism of carbamylcholine-evoked ⁸⁶Rb⁺ efflux was assessedin samples containing the full agonist at a concentration where itstimulates 80-90% of maximal function (i.e., its EC₈₀-EC₉₀ value) whenexposed alone to a given nAChR subtype (i.e., 460 μM for TE671/RD cells,2 mM for SH-SY5Y cells; 200 μM for SH-EP1-hα4β2 or -α4β4 cells) and testdrugs at the concentrations shown. After subtraction of non-specificefflux, results were normalized to specific ion flux in control samples.For studies of mechanism of antagonism, concentration-response curveswere obtained using samples containing the full agonist,carbamylcholine, at the indicated concentrations alone or in thepresence of a concentration of the test ligand close to its IC₅₀ valuefor inhibition of nAChR function. In other studies, cells werepre-exposed to analogues for 1 h (over the last hour of ⁸⁶Rb⁺ loading)or 1 day (with ⁸⁶Rb⁺ loading occurring during the final 4 h of drugpretreatment) before effects on nAChR function were assessed afteranalogue was removed (during extracellular ⁸⁶Rb⁺ removal) or in thecontinued presence of drug.

Ion flux assay results were fit using Prism (GraphPad) to the Hillequation, F=F_(max)/(1+(X/Z)^(n)), where F is the test sample specificion flux as a percentage of control, F_(max) is specific ion flux in theabsence of test drug (i.e., for control samples), X is the test ligandconcentration, Z is the EC₅₀ (n>0 for agonists) or IC₅₀ (n<0 forantagonists), and n is the Hill coefficient. All concentration-ion fluxresponse curves were simple and fit well allowing maximum and minimumion flux values to be determined by curve fitting, but in cases whereantagonists had weak functional potency, minimum ion flux was set at 0%of control. Note that because agonist concentrations used for testligand antagonism assessments were EC₈₀-EC₉₀ values, not all of thedata, even at the lowest concentrations of test antagonist, approaches100% of specific efflux as separately determined in sister samplesexposed to fully efficacious concentrations of agonist. Results aregiven in Table 4 below.

Relative to 2 (IC₅₀=7.9 nM), (2R,3R)-4a has comparable activity atα1*-nAChR (IC₅₀=7.6 nM), but (2R,3R)-4a is weaker in its interactions atα4β2- and a4β4-nAChR, although it retains 2's selectivity for action ata3β4*-nAChR. As was previously noted, (2S,3S)-4a has an altered nAChRfunctional inhibitory profile relative to 2, showing higher potency atα4β2-nAChR (IC₅₀=3.3 μM compared to 12 μM for 2) and higher selectivityfor α4β2- over other nAChR fold).

Relative to (2R,3R)-4a and (2S,3S)-4a (IC₅₀ values of 6.5 and 11 μM,respectively), the 3′-deschlorophenyl-analogue 4b, and the3′-methylphenyl and 4′-methylphenyl-analogues 4e and 4j have comparableinhibitory potencies at α3β4*-nAChR (IC₅₀=8.5-8.9 μM). By contrast,there is slightly higher potency at α3β4*-nAChR for the 3′-bromophenyl4d, 3′-chlorophenyl-4-(N-methyl) 4u, ethyl and propyl chain extendedanalogues 4s and 4t, 4′-chloro 4i, 3′,5′-dichlorophenyl 4p, 1-naphthyl4q, and 4′-chloro-4-(N-methyl) 4v analogues (IC₅₀=3.2-6.5 μM). Havingslightly higher antagonist potencies at α3β4*-nAChR are the(±)-3′,4′-dichlorophenyl analogue, (±)-4n and the 2-naphthyl analogue 4r(IC₅₀ values of 2.6 and 2.0 μM, respectively, but the only analogue withhigher potency than 2 (1.8 μM IC₅₀) at a3β4*-nAChR is the biphenylanalogue 4l (IC₅₀=1.3 μM). For these analogues, IC₅₀ values forinhibition of α1*-nAChR function are higher (>33 μM for 4b, 4e, 4u, and4v) or are in the range (5.9-19 μM for 4d, 4i-4j, 4l, (±)-4n, 4p-4t) ofIC₅₀ values for inhibition of α1*-nAChR by (2S,3S)-4a or (2R,3R)-4a (28or 7.6 μM, respectively).

In absolute terms, the 3′-bromophenyl-(4d), 3′-fluorophenyl-(4c),biphenyl 4l, and ethyl extended chain analogue 4s have higher inhibitorypotency at α4β2-nAChR than (2S,3S)-4a (IC₅₀ values of 0.55, 1.3, 1.8 and2.9 relative to 3.3 μM, respectively).

Of the analogues tested, 4i-4l, (±)-4n, 4p-4q, 4t, and 4v and the2-napthyl derivative 4r have selectivity as does 2 for a3β4*-nAChR overthe other nAChR subtypes (but never more than 4-fold, except for 4vhaving-9-fold selectivity). (2R,3R)-4a is barely selective fora3β4*-nAChR over α1*-nAChR, but about 5-fold selective for α3β4*- overα4β2-nAChR. Of all the analogues tested, 4b-4e, 4g-4h, 4o and 4s haveselectivity for α4β2-nAChR over other nAChR subtypes. Compounds 4f, 4mand 4u are about equipotent at α4β2- and α3β4*-nAChR. From anotherperspective, only the racemic 3′,4′-dicholoro (±)-4n (˜8-fold) and4′-chloro-4-(N-methyl) 4v (˜9-fold) have higher selectivity for α3β4*-over α4β2-nAChR than (2R,3R)-4a (˜5-fold) or 2 (˜6.7-fold). The3′-fluorophenyl 4c (˜12-fold), 3′-bromophenyl 4d (˜6-fold), and3′-nitrophenyl 4g (˜3-fold) analogues have selectivity for α4β2-nAChRover other nAChR subtypes better than or comparable to that for(2S,3S)-4a (˜3-fold).

None of the analogues has activity as agonist at α1*-, α3β4*-, α4β2-, ora4β4-nAChR, because ⁸⁶Rb⁺ efflux in the presence of these ligands aloneat concentrations from −5 nM to 100 μM (data not shown here) wasindistinguishable from responses in cells exposed only to efflux buffer.

We compared inhibitory potencies across transporters and nAChR relativeto (2S,3S)-4a, which has-3-fold selectivity for inhibition of NE over DAuptake inhibition and ˜14-fold selectivity for inhibition of NE uptakeinhibition over α4β2-nAChR function. Interestingly, there is a change toabsolute selectivity for inhibition of α4β2-nAChR over NE uptakeinhibition (˜1.7-fold) or over DA uptake inhibition (˜6-fold) (and˜3.6-fold selectivity for inhibition of NE over DA uptake) for3′-bromophenyl 4d. There is an even more striking increase inselectivity for inhibition of α4β2-nAChR function for biphenyl analogue4l (>5-fold over DA uptake inhibition and 6-fold over NE uptakeinhibition), which, however, is slightly selective for inhibition ofα3β4*-nAChR over α4β2-nAChR.

Selectivity for inhibition of NE uptake inhibition over α4β2-nAChRfunction also is reduced for analogues 4c (˜1.7-fold), 4h (˜3-fold), 4f(˜3.3-fold), 4g and 4r (˜4-fold), 4e (˜5.3-fold), and 4b (˜12-fold), andfor analogue 4p (˜4.5-fold). Conversely, there is an increase inselectivity for inhibition of NE uptake over α4β2-nAChR function for 4t(˜240-fold), (±)-4n (˜175-fold), 4v (80-fold), 4s (˜67-fold), and 4o(42-fold), although selectivity for inhibition of NE uptake overinhibition of α3β4*- instead of α4β2-nAChR function is less for 4t,(±)-4-n, and 4v (˜154-, 23-, and 9-fold, respectively; recall that 4thas comparable activity for DA and NE uptake inhibition). Although itsselectivity for inhibition of DA over NE uptake is marginal, (±)-4n has˜37-fold selectivity for inhibition of DA uptake over α3β4*-nAChRand >285-fold selectivity for inhibition of DA uptake over α4β2-nAChR.For 4r and 4p, selectivity for inhibition of NE uptake over a3β4*-nAChRfunction is marginal (1.3- and 1.6-fold, respectively), but biphenyl 4lhas 7.9-fold selectivity for inhibition of a3β4*-nAChR over inhibitionof NE uptake, surpassing selectivity seen for (2R,3R)-4a (˜1.5-fold).

TABLE 4 Inhibition of monoamine uptake and nAChR function forhydroxybupropion analogs

monoamine uptake inhibition^(a) IC50 (nM) Cmpd^(c) R₁ R₂ X Y Z [³H]DA[³H]NE [³H]5HT 2 — —   660 ± 178   1850 ± 300 IA (2R,3R)-4a CH₃ H Cl H HIA   9900 ± 1400 IA (2S,3S)-4a CH₃ H Cl H H   630 ± 50   241 ± 60 IA 4bCH₃ H H H H   1065 ± 30   550 ± 90 IA 4c CH₃ H F H H   1380 ± 360   740± 150 IA 4d CH₃ H Br H H   3340 ± 680   920 ± 300 IA 4e CH₃ H CH₃ H H  2600 ± 400   1130 ± 20 IA 4f CH₃ H CH₃O H H 16,000 ± 2000   3000 ± 900IA 4g CH₃ H NO₂ H H 12,000 ± 4000   1210 ± 340 IA 4h CH₃ H H F H   4200± 700   3800 ± 600 IA 4i CH₃ H H Cl H   285 ± 70   830 ± 90 4600 ± 9004j CH₃ H H CH₃ H   832 ± 260   1680 ± 330 IA 4k CH₃ H H CH₃O H IA IA IA4l CH₃ H H C₆H₅ H IA 10,300 ± 1500 IA 4m CH₃ H F F H   2140 ± 180   740± 110 IA 4n^(c) CH₃ H Cl Cl H    70 ± 20   114 ± 30  360 ± 40 4o CH₃ H FH F   1020 ± 190   151 ± 43 IA 4p^(c) CH₃ H Cl H Cl   8250 ± 720   2440± 730 IA 4q CH₃ H 1-napthyl 10,000 ± 4000   411 ± 53 1565 ± 215 4r CH₃ H2-napthyl   453 ± 4   1570 ± 430  334 ± 42 4s C₂H₅ H Cl H H   204 ± 23  43.4 ± 72 2500 ± 540 4t C₃H₇ H Cl H H    30 ± 4    31 ± 10 4130 ± 7704u CH₃ CH₃ Cl H H   3400 ± 600   415 ± 9 IA 4v CH₃ CH₃ H Cl H   2870 ±820   527 ± 104 6480 ± 1280 5^(c) IA IA IA 6^(c) IA   7950 ± 1800 IAnAChR inhibition^(b) IC₅₀ (μM) Cmpd^(c) R₁ R₂ X Y Z α3β4^(±) α4β2 α4β4α1*β1 2  1.8 (1.15) 12 (1.15) 12 (1.07)  7.9 (1.12) (2R,3R)-4a CH₃ H ClH H  6.5 (1.20) 31 (1.12) 41 (1.07)  7.6 (1.12) (2S,3S)-4a CH₃ H Cl H H11 (1.48)  3.3 (1.07) 30 (1.10) 28 (1.45) 4b CH₃ H H H H  8.9 (1.23) 6.4 (1.23) 92 (1.29) IA 4c CH₃ H F H H 15 (1.12)  1.3 (1.17) IA IA 4dCH₃ H Br H H  3.2 (1.12)  0.55 (1.23) 30 (1.07) 18 (1.07) 4e CH₃ H CH₃ HH  8.6 (1.12)  6.0 (1.20) 64 (1.20) 33 (1.07) 4f CH₃ H CH₃O H H 11(1.07) 10 (1.26) IA 49 (1.07) 4g CH₃ H NO₂ H H 14 (1.10)  4.8 (1.26) 80(1.10) 96 (1.10) 4h CH₃ H H F H 20 (1.15) 12 (1.10) IA 69 (1.17) 4i CH₃H H Cl H  5.1 (1.07)  9.2 (1.17) 33 (0.05) 19 (1.15) 4j CH₃ H H CH₃ H 8.6 (1.07) 12 (1.12) 62 (1.10) 20 (1.15) 4k CH₃ H H CH₃O H 11 (1.10) 27(1.23) 72 (1.12) 25 (1.10) 4l CH₃ H H C₆H₅ H  1.3 (1.12)  1.8 (1.12) 8.1 (1.07)  5.9 (1.15) 4m CH₃ H F F H 11.9 (1.15) 12 (1.07) IA 36 (1.2)4n^(c) CH₃ H Cl Cl H  2.6 (1.10) 20 (1.07) 14 (1.17)  7.2 (1.12) 4o CH₃H F H F 11 (1.15)  6.3 (1.51) 62 (1.07) 23 (1.12) 4p^(c) CH₃ H Cl H Cl 3.9 (1.07) 11 (1.05) 18 (1.17)  7.2 (1.07) 4q CH₃ H 1-napthyl  5.2(1.15)  9.0 (1.07) 13 (1.10)  6.6 (1.10) 4r CH₃ H 2-napthyl  2.0 (1.05) 6.5 (1.07) 11 (1.10) 11 (1.12) 4s C₂H₅ H Cl H H  4.3 (1.12)  2.9 (1.10)16 (1.05) 14 (1.10) 4t C₃H₇ H Cl H H  4.8 (1.10)  7.5 (1.05) 18 (1.07)10 (1.07) 4u CH₃ CH₃ Cl H H  6.5 (1.05)  7.1 (1.07) 43 (1.20) 57 (1.05)4v CH₃ CH₃ H Cl H  4.6 (1.15) 42 (1.17) 91 (1.12) 43 (1.05) 5^(c) IA IAIA IA 6^(c) IA IA IA IA ^(a)Values for mean ± standard error of threeindependent experiments, each conducted with triplicate determination.^(b)Mean micromolar IC₅₀ values (to two significant digits) forbupropion and the indicated analogs from three independent experimentsfor inhibition of functional responses to an EC₈₀-EC₉₀ concentration ofcarbamylcholine mediated by nAChR subtypes composed of the indicatedsubunits (where * indicates that additional subunits are or may beadditional assembly partners with the subunits specified; see Methodsand Materials). Numbers in parentheses indicate S.E.M. as amultiplication/division factor of the mean micromolar IC₅₀ values shown[i.e., the value 1.8 (1.15) reflects a mean IC₅₀ value of 1.8 μM with anS.E.M. range of 1.8 x 1.15 μM to 1.8/1.15 μM or 1.6-2.1 μM]. The value11 (1.48) reflects a mean IC₅₀ value of 11 μM with an S.E.M. range of 11x 1.40 μM to 11/1.48 μM or 7.4-16 μM. IA: IC₅₀ >100 μM. ^(c)Compounds4b-4m, and 4o-4v are all (2S,3S)-isomers. Compounds 4n, 4p, 5, and 6 areracemic materials.

⁸⁶Rb⁺ efflux assays also were used to assess whether ligands hadactivity as antagonists at human nAChR. Representativeconcentration-response curves for selected ligands (2S,3S)-4a, 4d, 4c,and 4g (FIG. 1) and (2R,3R)-4a, 4s, 4u, and 4t (FIG. 2) illustrate nAChRin vitro inhibitory profiles (see also Table 4).

FIG. 1 shows specific ⁸⁶Rb⁺ efflux (ordinate; percentage of control)determined for functional, human muscle-type α1β1γδ-nAChR (),ganglionic α3β4*-nAChR (◯), α4β2-nAChR (▴) or a4β4-nAChR (∇) naturallyor heterologously expressed in human cell lines in the presence of areceptor subtype-specific, EC₈₀-EC₉₀ concentration of the full agonist,carbamylcholine, either alone or in the presence of the indicatedconcentrations (abscissa, log molar) of (2S,3S)-hydroxybupropion[(2S,3S)-4a] or its analogues (compounds 4d, 4c, and 4g) as indicated.Mean micromolar IC₅₀ values and SEM as a multiplication/division factorof the mean micromolar IC₅₀ value are provided in Table 4. FIG. 2 showsSpecific ⁸⁶Rb⁺ efflux (ordinate; percentage of control) determined forfunctional, human muscle-type α1β1γδ-nAChR (), ganglionic α3β4*-nAChR(◯), α4β2-nAChR (▴) or a4β4-nAChR (∇) naturally or heterologouslyexpressed in human cell lines in the presence of a receptorsubtype-specific, EC₈₀-EC₉₀ concentration of the full agonist,carbamylcholine, either alone or in the presence of the indicatedconcentrations (abscissa, log molar) of (2R,3R)-hydroxybupropion[(2R,3R)-4a] or analogues (compounds 4s, 4u, and 4t) as indicated. Meanmicromolar IC₅₀ values and SEM as a multiplication/division factor ofthe mean micromolar IC₅₀ value are provided in Table 4.

Not shown here are other studies demonstrating that antagonism in allcases was mediated non-competitively, in that agonist concentration-ionflux response curves in the presence of ˜IC₅₀ concentrations ofanalogues showed diminished efficacy of agonist relative to responsecurves obtained in the absence of analogues and that agonist apparentEC₅₀ values were unaffected by the presence of analogs.

b) In Vivo Studies

Compound (2S,3S)-4a analogues 4b-4v and 5 and 6 also were evaluated fortheir ability to antagonize behavioral responses to acute nicotineadministration as previously described in Damaj, M. I.; Carroll, F. I.;Eaton, J. B.; Navarro, H. A.; Blough, B. E.; Mirza, S.; Lukas, R. J.;Martin, B. R., Mol. Pharmacol. 2004, 66, (3), 675-682. The tests aredescribed below and results are given in Table 5.

Behavior:

All animal experiments were conducted in accordance with the NIH Guidefor the Care and Use of Laboratory Animals and Institutional Animal Careand Use Committee guidelines.

Animals:

Male Institute of Cancer Research (ICR) mice (weighing 20-25 g) obtainedfrom Harlan (Indianapolis, Ind.) were used throughout the study. Animalswere housed in an Association for Assessment and Accreditation ofLaboratory Animal Care-approved facility, were placed in groups of six,and had free access to food and water. Studies were approved by theInstitutional Animal Care and Use Committee of Virginia CommonwealthUniversity.

Tail-Flick Test:

Antinociception for pain mediated at the spinal level was assessed bythe tail-flick method of D'Amour, F. E.; Smith, D. L., J. Pharmacol.Exp. Ther. 1941, 72, 74-79, incorporated herein by reference in itsentirety. In brief, mice were lightly restrained while a radiant heatsource was shone onto the upper portion of the tail. To minimize tissuedamage, a maximum latency of 10 s was imposed. Latency to remove thetail from the heat source was recorded for each animal. A controlresponse (2-4 s) was determined for each mouse before treatment, and atest latency was determined after drug administration (nicotine as ananalgesic 5 min after subcutaneous administration at 2.5 mg/kg; nicotineadministration 15 min after exposure to saline of bupropion analogue toassess the latter drug's ability to block nicotine-mediatedantinociception). Antinociceptive response was calculated as thepercentage of maximum possible effect (% MPE), where % MPE=[(testcontrol)/(10 control)]×100.

Hot-Plate Test:

Mice were placed into a 10-cm wide glass cylinder on a hot plate(Thermojust Apparatus) maintained at 55° C. for assessment of painresponses mediated at supraspinal levels. To minimize tissue damage, amaximum exposure to the hot plate 40 s was imposed. Measures of controllatencies (time until the animal jumped or licked its paws; typically8-12 s) were done twice for stimuli applied at least 10 min apart foreach mouse. Antinociceptive responses after test drug administrationswere determined and calculated as the % MPE, where % MPE=[(test latencyin s−control latency in s)/(40 s−control latency in s)×100]. Groups of 8to 12 animals were used for each drug condition. Antagonism studies werecarried in mice pretreated with either saline or bupropion metabolites15 min before nicotine administration. The animals were then tested 5min after administration of a subcutaneous dose of 2.5 mg/kg nicotine.

Locomotor Activity:

Mice were placed into individual Omnitech photocell activity cages(28×16.5 cm; Omnitech Electronics, Columbus, Ohio) 5 min aftersubcutaneous administration of either 0.9% saline or nicotine (1.5mg/kg). Interruptions of the photocell beams (two banks of eight cellseach) were then recorded for the next 10 min. Data were expressed as thenumber of photocell interruptions. Antagonism studies were carried outby pretreating the mice with either saline or bupropion metabolites 15min before nicotine administration.

Body Temperature:

Rectal temperature was measured by a thermistor probe (inserted 24 mm)and digital thermometer (YSI Inc., Yellow Springs, Ohio). Readings weretaken just before and 30 min after subcutaneous injection of eithersaline or 2.5 mg/kg nicotine. The difference in rectal temperaturebefore and after treatment was calculated for each mouse. The ambienttemperature of the laboratory varied from 21 to 24° C. from day to day.Antagonism studies were carried out by pretreating the mice with eithersaline or bupropion metabolites 15 min before nicotine administration.The animals were then tested 30 min after administration of asubcutaneous dose of 2.5 mg/kg nicotine.

Results:

Compound 2 blocks nicotine-induced increases in locomotor activity withan AD₅₀ value of 4.9 mg/kg, while (2S,3S)-4a has a lower AD₅₀ value of0.9 mg/kg in the same assay, but none of the analogues is better than(2S,3S)-4a, although 4d and 4p (2.6 and 1.9 mg/kg AD₅₀, respectively)have slightly higher potency than 2.

The ability of (2S,3S)-4a to block the nicotine-induced decrease in bodytemperature is lower than that for 2 AD₅₀=1.5 and 9.2 mg/kg,respectively. Compound 4d (AD₅₀=1.7 mg/kg) also rivals (2S,3S)-4a inthis assay, analogues 4c, 4e, 4g, 4h, and 4s have intermediate potencies(2.3-7 mg/kg AD₅₀ values).

In the hot-plate assay, 2 blocks nicotine-induced,supraspinally-mediated analgesia with an AD₅₀ value of 15 mg/kg.Compound (2S,3S)-4a is 15-fold more potent (AD₅₀ value of 1 mg/kg), butblockade of nicotine-induced hot-plate analgesia is no better for any ofthe new analogues tested. However, 4c, 4d, 4e, and 4s (3.7-8.6 mg/kgAD₅₀ values) are more potent than 2.

Nicotine-induced analgesia in the tail flick assay, which assessesspinal processes involved in nicotine antinociception,²⁷ is blocked by 2with an AD₅₀ of 1.2 mg/kg. Compound (2S,3S)-4a with an AD₅₀=0.2 mg/kghas a 6-fold increase in effectiveness in this assay. Fifteen of the newanalogues have even higher potency. AD₅₀ values (in mg/kg) are 0.004 for4j, 4s, and 4t; ˜0.006 for 4m and 4o; 0.012-0.013 for 4c and 4h; 0.016for 4u; 0.019 for 4i and 4k; 0.021 for 4l; between 0.034 and 0.054 for4q, 4r, and 4e; and 0.16 for 4d.

Thus, in four assays of the ability of analogues to block acute actionsof nicotine, 3′-bromophenyl analogue 4d was more effective than 2 ineach and rivaled effects of (2S,3S)-4a in tail-flick and hypothermiaassessments. The 3′-fluorophenyl analogue 4c, 3′-methylphenyl analogue4e, and ethyl extended chain analogue 4s exceeded 2's potency in threeassays and had higher potency than (2S,3S)-4a in the tail-flick assay.Compounds 4c, 4d, and 4s also are remarkable for their higher inhibitoryeffectiveness at α4β2-nAChR than (2S,3S)-4a. Eleven of the other ligandshad better effectiveness than 2 in one of the acute assays, with potencyin the tail-flick assay correlating with IC₅₀ values <10 μM forinhibition of α4β2-nAChR function for 4c-4e, 4l, 4o, and 4q-4u, but notfor 4 h-4k, 4m and 4v, which were potent in the tail-flick assay but notas α4β2-nAChR antagonists, or for 4b, 4f and 4g, which lackedeffectiveness relative to (2S,3S)-4a in the tail-flick assay but havesub-10 μM IC₅₀ values at α4β2-nAChR. Lacking potency in tail-flick orinhibition of α4β2-nAChR function, but having activity as antagonists ofa3β4*-nAChR, are 4n and 4p. Increased in vitro inhibition of DA and NEuptake did not necessarily correlate with increased in vivo inhibitorypotency in nicotine-sensitive assays if there also was no increase ineffectiveness at α4β2-nAChR or selectivity for that target (e.g., 4n).On the other hand, the ligands with the highest inhibitory potency forNE uptake inhibition (and highest or higher effectiveness than(2S,3S)-4a at DA uptake inhibition) were among the most potentinhibitors of nicotine-induced analgesia in the tail-flick assay (4s and4t). Improvement over (2S,3S)-4a in the ability to blocknicotine-induced analgesia in the tail-flick assay as seen for 4j, 4m,and 4o has no obvious basis as judged from in vitro assays.

TABLE 5 Pharmacological evaluation of hydroxybupropion analogs asnon-competitive nicotinic antagonists^(a) AD₅₀ (mg/kg) Hot- Compound^(b)Tail-flick^(c) plate^(c) Locomotion^(c) Hypothermia^(c) 2 1.2 15 4.9 9.2(1-1.8) (6-19) (0.9-46) (4-23) (2S,3S)-4a 0.2 1.0 0.9 1.5 (0.1-1.1)(0.5-4.5) (0.38-3.7) (0.95-2.6) (2R,3R)-4a 2.5 10.3 IA IA (1.7-3.5)(8.9-15) 4b IA IA IA IA 4c 0.012 8.6 IA 4.4 (0.002-0.16) (0.7-10.5)(1.3-14.5) 4d 0.16 4.3 2.6 1.7 (0.05-0.6) (1.8-9.8) (0.7-10.1) (0.5-6.8)4e 0.054 7.6 IA 2.3 (0.04-0.066) (2-29) (0.4-11) 4f 5.85 IA IA IA(3.8-8.8) 4g 4.9 IA IA 4.7 (1.6-15) (3.5-6.2) 4h 0.013 IA IA 5.67(0.005-0.03) (2.5-12.8) 4i 0.019 IA IA IA (0.063-0.1) 4j 0.004 IA IA IA(0.002-0.012) 4k 0.019 IA IA IA (0.06-0.064) 4l 0.021 IA IA IA(0.005-0.1) 4m 0.006 IA IA IA (0.004-0.01) 4n 8.8 IA IA IA (4.3-18) 4o0.0056 IA IA IA (0.004-0.009) 4p IA IA 1.9 IA 4q 0.034 IA IA IA(0.001-0.1) 4r 0.04 IA IA IA (0.001-0.6) 4s 0.004 3.7 10.3 7(0.001-0.03) (0.8-17) (1.4-75) (4.5-10.8) 4t 0.004 IA 4.7 IA(0.001-0.03) 4u 0.016 IA IA IA (0.004-0.06) 4v 0.32 IA IA IA (0.04-2.5)5 n/a n/a n/a n/a 6 n/a n/a n/a n/a ^(a)Results were expressed as AD₅₀(mg/kg) ± confidence limits (CL) or % effect at the highest dose tested.Dose-response curves were determined using a minimum of four differentdoses of test compound, and at least eight mice were used per dosegroup. ^(b)Compounds 4b-4m, and 4o-4v are all (2S,3S)-isomers. Compounds4n, 4p, 5, and 6 are racemic materials. ^(c)n/a: not assayed; IA: AD₅₀ >15 mg/kg; NFT = no further testing.

c) Overview of Biological Studies

Analogues were generated with higher inhibitory potency than 2(bupropion) or either of its hydroxymetabolite isomers (2R,3R)-4a and(2S,3S)-4a for DA uptake inhibition (4i, 4n, 4r, 4s, and 4t), NE uptakeinhibition [(±)-4n, 4o, 4s, and 4t], or 5HT uptake inhibition [(±)-4nand 4r], of for functional inhibition of a3β4*-nAChR (4l) or α4β2-nAChR(4c, 4d, 4l and 4s). Selectivity for inhibition of DA uptake over nAChRfunctional blockade or NE uptake inhibition like that of 2 was achievedfor 4r (except that this ligand is a slightly selective inhibitor of 5HTover DA uptake). Selectivity for inhibition of DA uptake over nAChR orNE uptake inhibition better than that of 2 was achieved with retentionof reasonable potency at DAT for 4i. As predicted based on our previousstudies of hydroxymetabolites, many of the compounds evaluated haveselectivity for inhibition of NE over DA uptake. This was improvedrelative to (2S,3S)-4a for 4f-4g, 4s, 4v, 4o, 4u and 4q, but only 4s and4o have improved potency at NE uptake inhibition. Compounds (±)-4n, 4t,and 4s are more selective than (2S,3S)-4a for inhibition of NE uptakeinhibition over nAChR function. Only (±)-4n and 4v have increasedselectivity for α3β4*-nAChR over other nAChR subtypes relative to 2 or(2R,3R)-4a. Compounds 4l and 4k have improved selectivity fora3β4*-nAChR functional inhibition over DA and NE uptake inhibitionrelative to that of (2R,3R)-4a. Compound 4d has absolute selectivity forinhibition of α4β2-nAChRs over inhibition of α3β4*-nAChR as well as overNE, 5HT or DA uptake inhibition, and 4l's similar potency at α4β2- andα3β4*-nAChR also means that it is selective for inhibition ofα4β2-nAChRs over monoamine transporters. Selectivity for α4β2-nAChR overα3β4*- and other nAChR subtypes was increased for 4c and 4d relative tothat for 2 and (2S,3S)-4a. Selectivity for inhibition of NE uptakeinhibition over α4β2-nAChRs was reduced relative to that of (2S,3S)-4afor 4b, 4c, 4e, 4f, 4g, 4p, and 4r, with 4d actually being absolutelyselective for inhibition of α4β2-nAChRs function over other nAChRsubtypes and over inhibition of DA and NE uptake.

From a chemical structure perspective, changes in the 3′-chlorophenylgroup in (2S,3S)-4a to 3′-bromophenyl 4d or 3′-fluorophenyl 4c affordedligands with improved affinity and selectivity for α4β2-nAChRs.Selectivity for monoamine transporter uptake over α4β2-nAChRs functionalblock was decreased while selectivity for α4β2-nAChRs over other nAChRsubtypes was preserved by other changes in the phenyl substitution(nitro 4g, methyl 4e) or lack of chloro group (4b) but not for3′-methoxyphenyl substitution (4f). The dichlorophenyl analogues (±)-4nand 4p have increased selectivity for a3β4*-nAChR over other nAChRsubtypes. In addition, the (±)-3′,4′-dichlorophenyl analogue [(±)-4n]also has a marked increase in affinity for inhibition of DA uptake.Replacement of the 3-methyl group on the morpholinol ring with an ethylor propyl group (4s and 4t) affords ligands with notable improvements inselectivity for inhibition of NE uptake over nAChR and increases inpotencies for inhibition of DA and NE uptake. Changing the3-chlorophenyl ring to a pyridine ring leads to ligands 5 and 6, whichare without activity. Naphthyl analogues 4q and 4r have modestly alteredactivities compared to (2S,3S)-4a. Interestingly, moving the3-substituent of the phenyl group of (2S,3S)-4a and 4e to the 4′position affords ligands (4i-4j) that are selective for DA over NEuptake and nAChR functional inhibition and for inhibition of α3β4*- overα4β2-nAChRs. However, the biphenyl analogue (4l) has almost no activityat monoamine transporters yet is very potent as an inhibitor of α4β2 andα3β4*-nAChR. Moving the 3′-substituent of the phenyl group of theN-methyl analogue 4u to the 4′ position (4v) has little effect oninhibition or DA or NE uptake but increases selectivity for functionalblockage of α3β4*- over α4β2-nAChRs from negligible to ˜9-fold.

In silico predictions that all of the compounds synthesized would havedrug-like character and activity in the central nervous system wereconsistent with the results of behavioral studies. We obtained severalanalogues with higher potency than (2S,3S)-4a or 2 as antagonists ofnicotine-mediated antinociception in the tail-flick assay. The ethyl andpropyl extended chain ligands 4s and 4t with high affinity forinhibition of DA and NE uptake, 3′-fluoro and 3′-bromo phenylsubstituted analogues 4c and 4d with high affinity and good selectivityfor α4β2-nAChRs, and to a lesser extent the 3′-methylphenyl analogue 4ealso with good activity at α4β2-nAChRs, also had better potency in thetail-flick assay than 2 or (2S,3S)-4a. The naphthyl analogues 4q and 4rwith selectivity for inhibition of NE over DA uptake and for inhibitionof DA over NE uptake, respectively, but having comparable effects onnAChR function, had ˜5-fold higher activity in the tail-flick assay than(2S,3S)-4a. However, the other in vivo assays mostly did not revealstriking inhibition by analogues of acute nicotine action. Moreover, thetail-flick assay could reflect CNS actions of ligands at higher levelthan the presumed spinal level of nicotine-mediated antinociception inthe test.

Extensions of the R₁ methyl group in (2S,3S)-4a to an ethyl or propylgroup (4s and 4t) preferentially improve activities for inhibition of DAand NE uptake. The naphthyl analogues (4q and 4r) afford ligands withbetter potency for 5HT uptake inhibition, and changing the3′-chlorophenyl moiety of (2S,3S)-4a to a 3′-fluoro or 3′-bromophenylgroup leads to ligands with better activity at α4β2-nAChRs (4c and 4d).

Even for assays that are done soon after delivery, the chemicalmodifications that selectively increase in vitro activity attransporters or at α4β2-nAChR afford ligands with potential as nicotineantagonists in vivo. That is, increased activity at either α4β2-nAChRsor for inhibition of DA or NE uptake (or for one ligand, at 5HT uptakeinhibition) correlates well with improvement in ligand antagonistpotency in the tail-flick assay. Thus, the behavioral results suggestthat effects of nicotine dependence and/or depression could be counteredby ligands acting at DAT, NET, or α4β2-nAChR or any combination of thethree.

Many modifications and other embodiments of the inventions set forthherein will come to mind to one skilled in the art to which theseinventions pertain having the benefit of the teachings presented in theforegoing descriptions and the associated drawings. Therefore, it is tobe understood that the inventions are not to be limited to the specificembodiments disclosed and that modifications and other embodiments areintended to be included within the scope of the appended claims.Although specific terms are employed herein, they are used in a genericand descriptive sense only and not for purposes of limitation.

That which is claimed:
 1. A compound according to the structure:

wherein: R₁ is optionally substituted C1-10 alkyl; R₂ is H or optionallysubstituted C1-10 alkyl; R₃ and R₄ are each independently selected fromoptionally substituted C1-10 alkyl; X, Y, and Z are each independentlyselected from H; optionally substituted C1-10 alkyl; optionallysubstituted C1-10 alkoxy; optionally substituted C2-10 alkenyl;optionally substituted C2-10 alkynyl; optionally substituted C6-C12aryl; alkaryl; arylalkyl; aryloxy; optionally substituted heteroaryl;optionally substituted heterocycle; halo; hydroxyl; halogenated alkyl;an amino group of formula NH₂, NR₁₂H, or NR₁₂R₁₃; alkylamino; arylamino;acyl; CN; NO₂; N₃; CH₂OH; CONH₂; CONR₁₂R₁₃; CO₂R₁₂; CH₂OR₁₂; NHCOR₁₂;NHCO₂R₁₂; C1-3 alkylthio; sulfate; sulfonic acid; sulfonate ester;phosphonic acid; phosphate; phosphonate; mono-, di-, or triphosphateester; trityl or monomethoxytrityl; R₁₂SO; R₁₂SO₂; CF₃S; CF₃SO₂;trialkylsilyl; and diphenylmethylsilyl; or wherein X and Y or Y and Zform a fused aryl ring together with the phenyl ring to which X, Y, andZ are attached; and R₁₂ and R₁₃ are each independently selected from Hor optionally substituted C1-10 alkyl; with the proviso that either (a)X is a halo substituent other than chloro; (b) two or more of X, Y, andZ are halo substituents; (c) one or more of X, Y, and Z are optionallysubstituted C6-C12 aryl; (d) X and Y or Y and Z form a fused aryl ringtogether with the phenyl ring to which X, Y, and Z are attached; (e) R₁is an optionally substituted C2-C10 alkyl; or any combination of two ormore of (a) through (e), or a pharmaceutically acceptable ester, amide,salt, solvate, prodrug, or isomer thereof.
 2. The compound according toclaim 1, having the structure:

or a pharmaceutically acceptable ester, amide, salt, solvate, prodrug,or isomer thereof.
 3. The compound according to claim 1, having thestructure:

or a pharmaceutically acceptable ester, amide, salt, solvate, prodrug,or isomer thereof.
 4. The compound according to claim 1, wherein R₁ isselected from the group consisting of CH₃, CH₂CH₃, and C₃H₇.
 5. Thecompound according to claim 2, wherein R₁ is selected from the groupconsisting of CH₃, CH₂CH₃, and C₃H₇.
 6. The compound according to claim3, wherein R₁ is selected from the group consisting of CH₃, CH₂CH₃, andC₃H₇.
 7. The compound according to claim 1, wherein X, Y, and Z areindependently selected from the group consisting of H, Cl, Br, F,optionally substituted C1-10 alkyl, and phenyl.
 8. The compoundaccording to claim 2, wherein X, Y, and Z are independently selectedfrom the group consisting of H, Cl, Br, F, optionally substituted C1-10alkyl, and phenyl.
 9. The compound according to claim 3, wherein X, Y,and Z are independently selected from the group consisting of H, Cl, Br,F, optionally substituted C1-10 alkyl, and phenyl.
 10. The compoundaccording to claim 1, wherein X and Y or Y and Z Rum a fused aryl ringtogether with the phenyl ring to which X, Y, and Z are attached.
 11. Thecompound according to claim 2, wherein X and Y or Y and Z form a fusedaryl ring together with the phenyl ring to which X, Y, and Z areattached.
 12. The compound according to claim 3, wherein X and Y or Yand Z faun a fused aryl ring together with the phenyl ring to which X,Y, and Z are attached.
 13. The compound according to claim 1, wherein R₁is optionally substituted methyl, ethyl, propyl, or butyl, and at leastone of X, Y, and Z is optionally substituted C6-C12 aryl or X and Y or Yand Z form a fused aryl ring together with the phenyl ring to which X,Y, and Z are attached.
 14. The compound according to claim 2, wherein R₁is optionally substituted methyl, ethyl, propyl, or butyl, and at leastone of X, Y, and Z is optionally substituted C6-C12 aryl or X and Y or Yand Z form a fused aryl ring together with the phenyl ring to which X,Y, and Z are attached.
 15. The compound according to claim 3, wherein R₁is optionally substituted methyl, ethyl, propyl, or butyl, and at leastone of X, Y, and Z is optionally substituted C6-C12 aryl or X and Y or Yand Z form a fused aryl ring together with the phenyl ring to which X,Y, and Z are attached.
 16. The compound according to claim 1, wherein R₁is optionally substituted C2-C10 alkyl, and at least one of X, Y, and Zis optionally substituted C6-C12 aryl or halo, or X and Y or Y and Zform a fused aryl ring together with the phenyl ring to which X, Y, andZ are attached.
 17. The compound according to claim 2, wherein R₁ isoptionally substituted C2-C10 alkyl, and at least one of X, Y, and Z isoptionally substituted C6-C12 aryl or halo, or X and Y or Y and Z form afused aryl ring together with the phenyl ring to which X, Y, and Z areattached.
 18. The compound according to claim 3, wherein R₁ isoptionally substituted C2-C10 alkyl, and at least one of X, Y, and Z isoptionally substituted C6-C12 aryl or halo, or X and Y or Y and Z form afused aryl ring together with the phenyl ring to which X, Y, and Z areattached.
 19. The compound according to claim 1, selected from the groupconsisting of: 2-(3-Fluorophenyl)-3,5,5-trimethylmorpholin-2-ol;2-(3-Bromophenyl)-3,5,5-trimethylmorpholin-2-ol;2-Biphenyl-4-yl-3,5,5-trimethylmorpholin-2-ol;2-(3,4-Dichlorophenyl)-3,5,5-trimethylmorpholin-2-ol;2-(Naphthalen-2-yl)-3,5,5-trimethylmorpholin-2-ol;2-(3-Chlorophenyl)-3-ethyl-5,5-dimethylmorpholin-2-ol;2-(3-Chlorophenyl)-5,5-dimethyl-3-propyl-morpholin-2-ol, or apharmaceutically acceptable ester, amide, salt, solvate, prodrug, orisomer thereof.
 20. The compound according to claim 1, selected from thegroup consisting of: 2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol;2-(3-Methoxyphenyl)-3,5,5-trimethylmorpholin-2-ol;2-(4-Fluorophenyl)-3,5,5-trimethylmorpholin-2-ol;2-(4-Chlorophenyl)-3,5,5-trimethylmorpholin-2-ol;3,5,5-Trimethyl-2-(4-methylphenyl)morpholin-2-ol;2-(4-Methoxyphenyl)-3,5,5-trimethylmorpholin-2-ol;2-(3,4-Difluorophenyl)-3,5,5-trimethylmorpholin-2-ol;2-(3,5-Difluorophenyl)-3,5,5-trimethylmorpholin-2-ol;2-(3,5-Dichlorophenyl)-3,5,5-trimethylmorpholin-2-ol;2-(Naphthalen-1-yl)-3,5,5-trimethylmorpholin-2-ol;2-(3-Chlorophenyl)-3,4,5,5-tetramethylmorpholin-2-ol;2-(4-Chlorophenyl)-3,4,5,5-tetramethylmorpholin-2-ol, or apharmaceutically acceptable ester, amide, salt, solvate, prodrug, orisomer thereof.
 21. The compound according to claim 1, wherein thecompound comprises an enantiomeric excess of at least 95% of the (2S-3S)enantiomer.
 22. The compound according to claim 2, wherein the compoundcomprises an enantiomeric excess of at least 95% of the (2S-3S)enantiomer.
 23. A pharmaceutical composition comprising a compoundaccording to claim 1 and one or more pharmaceutically acceptablecarriers.
 24. A method for treating or delaying the progression ofdisorders that are alleviated by inhibiting monoamine reuptake in apatient or antagonizing the nicotinic acetylcholine receptors, themethod comprising administering a therapeutically effective amount of atleast one compound according to claim
 1. 25. The method of claim 24,wherein the disorder is selected from the group consisting of addiction,depression, obesity, bipolar disorder, attention deficit disorder (ADD),attention deficit/hyperactivity disorder (ADHD), hypoactive sexualdesire disorder, antidepressant-induced sexual dysfunction, orgasmicdysfunction, seasonal affective disorder/winter depression, mania,bulimia and other eating disorders, panic disorders, obsessivecompulsive disorder, schizophrenia, schizo-affective disorder,Parkinson's disease, narcolepsy, anxiety disorders, insomnia, chronicpain, migraine headaches, and restless legs syndrome.
 26. The method ofclaim 25, wherein the addiction comprises nicotine addiction.